UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________

 

FORM 10-K

ANNUAL REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

(Mark One)

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscalfiscal year ended December 31, 20182019

OR

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________to_________

 

Commission File Number

000-19932

RELIV’ INTERNATIONAL, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware 371172197

(State or other jurisdiction of

incorporation or organization)

 (I.R.S. Employer Identification Number)
incorporation or organization)  

136 Chesterfield Industrial Boulevard

              Chesterfield, Missouri                  

63005

(Address

 (Address of principal executive offices)

(Zip Code)

 

(636) 537-9715

Registrant’s telephone number, including area code

 

Securities registered pursuant to Sections 12(b) of the Act:

 

Title of Each Classeach class

Trading Symbol(s)

Name of Each Exchangeeach exchange on Which Registeredwhich registered

Common Stock, par value $0.001

RELV

NASDAQ Global SelectCapital Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ☐     No ☑

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes ☐     No ☑

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☑     No ☐

 


 

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑     No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ☑

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐     Accelerated filer ☐      Non-accelerated filer ☐

Smaller reporting company ☑     Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐     No ☑

 

Based upon the closing price of $4.83$4.22 per share of the registrant’s common stock as reported on the NASDAQ Global Select Market on June 29, 2018,28, 2019, the aggregate market value of the common stock held by non-affiliates of the registrant was approximately $5.4$4.5 million. (The determination of stock ownership by non-affiliates was made solely for the purpose of responding to the requirements of the Form and the registrant is not bound by this determination for any other purpose.)

 

The number of shares outstanding of the registrant’s common stock as of March 18, 201923, 2020 was 1,746,499 (excluding treasury shares).

 

Documents Incorporated by Reference

 

NONE

Document

Part of Form 10-K into Which

Document Is Incorporated

Sections of the registrant’s definitive Proxy Statement for the Annual Meeting of Stockholders to be held on May 23, 2019, which is expected to be filed no later than 120 days after December 31, 2018

Part III

 


 

 

INDEX

 

 

Part I

Item No. 1

Business

1

Item No. 2

Properties

164

Item No. 3

Legal Proceedings

164

Part II

Item No. 5

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

17

5

Item No. 7

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

6

Item No. 8

Financial Statements and Supplementary Data

2817

Item No. 9

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

28

17

Item No. 9A

Controls and Procedures

2817

Item No. 9B

Other Information

2817

Part III

Item No. 10

Directors, Executive Officers and Corporate Governance

2918

Item No. 11

Executive Compensation

2923

Item No. 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

29

27

Item No. 13

Certain Relationships and Related Transactions, and Director Independence

2928

Item No. 14

Principal Accounting Fees and Services

2928

Part IV

Item No. 15

Exhibits and Financial Statement Schedules

29

Item No. 16

Form 10-K Summary

29

 


 

FORWARD-LOOKING STATEMENTS

 

This annual report includes both historical and “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements on our current expectations and projections about future results. Words such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this annual report. We disclaim any intent or obligation to update any forward-looking statements after the date of this annual report to conform such statements to actual results or to changes in our opinions or expectations.

 

PART I

 

Item No. 1 - Business

 

Overview

 

We are a developer and marketer of a proprietary line of nutritional supplements addressing basic nutrition, specific wellness needs, weight management and sports nutrition. We sell our products through an international network marketingdirect selling system using independent distributors. We have sold products in the United States since 1988 and in selected international markets since 1991.

 

  We currently offer 19 nutritional supplements, and our product offering has selectively evolved over our history. Our core line of nutritional supplements, which represented 58.9% of net sales for the year ended December 31, 2018, included the following five products:

Reliv Classic and Reliv Now — two basic nutritional supplements containing a full and balanced blend of vitamins, minerals, protein and herbs, including a whey-based version of Now.

Innergize! — an isotonic sports supplement in two flavors

FibRestore — a high-fiber and antioxidant supplement

LunaRich X — a soy concentrate with elevated levels of lunasin, in capsule form

In February 2017, we launched our Fit3 fitness and weight loss program in the United States to broaden and bolster our weight management offering, and to appeal to a broader demographic than our essential nutrition. The Fit3 program consists of three principal components: (1) nutrition coaching, (2) exercise coaching and videos, and (3) three fitness products: Active, Burn and Purify. The Fit3 program involves our most interactive offering for distributors and customers, including a separate website with independent content and a focused social media outreach and support initiative. We offer a Fit Kit that includes a 90-day supply of the Fit3 products and access to the information, tools and videos we offer through the program. We believe the Fit3 program provides an attractive alternate entry point for new distributors or customers who are more interested in weight loss and fitness than our essential nutrition or targeted solutions.

We periodically refine our products and introduce related new products and product categories. Our internal research and development team has developed most of our products, and we hold U.S. patents on five of these products —ReversAge, GlucAffect, ProVantage, 24K and CardioSentials. We also own several U.S. and international patents and patent applications related to lunasin through our acquisition of the lunasin technology in September 2016.

We believe that our network marketing model is the best method for the marketing and sale of our products because it utilizes ongoing personal contact among our distributors and their retail customers. This enables our distributors to communicate directly regarding the products, the business opportunity we offer and their personal experiences with both. We provide our distributors with a financially rewarding and entrepreneurial business opportunity, affording them the ability to earn compensation both from the direct sale of products and from sales volume generated by distributors they sponsor. We actively support our distributors by providing marketing materials, a dependable product fulfillment system and frequent educational, training and motivational programs.


The majority of our sales traditionally has been, and is expected to continue to be, made through our distributors in the United States. We also currently generate sales through distributor networks in Australia, Austria, Canada, France, Germany, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, Singapore and the United Kingdom. In each country in which we conduct business, our distributors operate under a business and compensation model that maintains consistent marketing, sales, fulfillment, and compliance procedures. As of December 31, 2018, our network consisted of approximately 30,370 distributors and preferred customers —19,810 in the United States and 10,560 across our international markets.

Industry Overview

Nutritional Supplement Market

We operate primarily in the $44 billion U.S. nutritional supplement market which is up 6.1% from the prior year. This is part of the broader $140 billion U.S. nutrition industry according to data published by the Nutrition Business Journal, or NBJ, and an estimated $320.0 billion global nutrition industry, also according to the NBJ. Additionally, more than 185 million Americans, or 75% of all U.S. adults, take dietary supplements annually according to the Council for Responsible Nutrition, an increase of 5 percentage points from 2016.

A combination of demographic, healthcare and lifestyle trends are expected to drive continued growth in the nutritional supplement market. These trends include:

Aging Population: The older population (persons 65 years or older) numbered 50 million in 2017 according to latest information from the Department of Health and Human Services. This population segment grew 1.6 million from 2014 and they represented 16.03% of the U.S. population, or about one in every seven Americans. By 2060, there will be approximately 98.2 million older persons, nearly one in four U.S. residents. Recent data from the Council for Responsible Nutrition shows that 78% of adults aged 55 and over take dietary supplements. This is up from 74% in 2016. We believe this ever-growing population, living longer lives than in previous decades, will continue to focus on their nutritional needs as they age.

Rising Healthcare Costs and Commitment to Health: The cost of healthcare in the United States is projected to have grown 5.5% in 2018, up slightly from 4.6% growth in 2017, according to the Centers for Medicare and Medicaid Services (CMS). In 2017, U.S. healthcare spending reached $3.5 trillion or $10,739 per person. As reported from Frost and Sullivan, approximately 75% of total U.S. health care expenditures are spent on preventable health issues. Many studies have demonstrated that dietary supplements have a positive effect on reducing the potential for health issues and consumers are reacting to this by taking charge of their personal health. In a recent survey conducted by Harris Poll, taking vitamins was one of the top five responses from participants wanting to improve health and wellness habits. We believe more consumers will seek the use of nutritional supplements to maintain quality of life as well as reduce medical costs.

Continued Focus on Weight Management: According to a report published by The State of Obesity in September 2016, nearly 38%, or more than one-third of U.S. men and women were obese, as were almost 17% of U.S. children. It is estimated that 86.3% of Americans will be overweight or obese by 2030. Health care costs related to obesity currently account for almost 21% of U.S. health care costs according to a report by Cornell University and are expected to grow to as much as $956.9 billion by 2030. Being overweight is linked to more than 90 chronic diseases and can lead to more serious health concerns such as diabetes, heart disease and other chronic illnesses. According to a May 2016 report from Technavio, the global weight loss supplement market via direct selling was valued at $624.9 million in 2015 and North America accounted for more than one-third of those sales. Bearing these facts in mind, we believe that there will be a continual need not only for weight loss products but also for wellness products.


Direct Selling Market

Health and nutrition products are distributed through various market means, including retailers such as supermarkets, drugstores, mass merchants and specialty retailers; direct marketers such as mail order companies and Internet retailers; and direct sellers such as network marketers and healthcare practitioners. We distribute our products through the direct selling channel via our network marketers.

Direct selling involves the marketing of products and services directly to consumers in a person-to-person manner. Direct selling is a significant global industry largely utilized for the sale of a wide range of consumer products from companies such as Avon Products Inc., Alticor Global Holdings, Inc. (Amway Corp.) and Tupperware Brands Corporation. According to the World Federation of Direct Selling Associations, or WFDSA, the 2017 global direct selling market (for all product categories) was estimated to be $189.4 billion, an increase from $182.6 billion in 2016. The WFDSA estimates that the number of individuals engaged in direct selling has nearly tripled between 1999 and 2017, from 35.9 million sellers to 116.7 million in 2017. The United States had 18.6 million direct sellers in 2017, the most of any country. Globally, wellness products came in as the top selling category, the third year in a row that it has come in ahead of cosmetics and personal care.

While the United States is currently the largest direct selling market with $34.9 billion in annual sales in 2017, international markets account for 81% of the entire industry, according to the WFDSA. Twenty-four countries (including the United States) have annual direct sales revenue of at least $1 billion and another twenty-six have annual direct sales revenue of at least $100 million, according to the WFDSA.

  We believe that we are well positioned to capitalize on the world-wide growth trends in direct sales, as both a developer of proprietary nutritional products, utilizing our network marketing distribution system.

Our Competitive Strengths

We believe that we possess a number of competitive strengths that are the keys to our growth and profitability in the future.

Leading Marketer of Bioavailable Lunasin-Containing Products. We own certain technology and proprietary testing and manufacturing processes that allow us to produce LunaRich X, to our knowledge, the only commercial source of soy concentrate with elevated levels of bioactive lunasin. One 310 mg capsule of LunaRich X contains an amount of lunasin equivalent to 25 grams of high quality soy protein. In addition to our LunaRich X capsules, we fortified six other nutritional supplements with LunaRich X so that a serving of those products yields an amount of bioactive lunasin equivalent to consuming 25 grams of soy protein. The products fortified with LunaRich X are Reliv Now with Soy, Reliv Now for Kids, ProVantage, GlucAffect, SoySentials and Fit3 Active.

Complete, Simple Nutrition. We focus on the completeness, balance and simplicity of our basic nutritional supplements — Reliv Classic or Reliv Now — combined with LunaRich X. Our recommended daily regimen of essential nutrition for any new distributor or customer is one shake of either Reliv Now or Reliv Classic and two capsules of LunaRich X. Our two basic nutritional supplements each contain a full and balanced blend of vitamins, minerals, proteins and herbs supporting an individual’s daily nutritional needs and our LunaRich X capsules support an individual’s wellness at the epigenetic level. The combination of Reliv Now or Reliv Classic and LunaRich X makes supplementation simple and effective for the consumer. For more specific individual needs, we provide 16 additional supplements. We believe that our two basic nutritional supplements, together with LunaRich X and our additional supplements, enhance the ability of our distributors to build their businesses by providing a comprehensive, simple product offering.

In-House Development. We utilize nutrition science as the basis for product formulation. We maintain an ongoing research and development effort. We believe our ability to formulate nearly all of our nutritional supplement products enables us to maintain our high standards of quality assurance and proprietary product composition.


Experienced Ambassador Team. Our Ambassador corps consists of distributors who have achieved the level of Master Director, have earned royalty payments of at least $4,000 in consecutive months and meet our leadership and character criteria necessary to garner our invitation to be an Ambassador. Our Ambassadors generally are our most productive distributors and are essential in recruiting, motivating and training our entire distributor network. We, and our Ambassadors, lead hundreds of annual events throughout all of our markets to motivate and train distributors, including regular recruiting meetings, trainings, conference calls, training schools for Master Affiliates and higher levels and regional, national and international distributor conferences.

Experienced and Incentivized Management Team. Our management team is led by Robert L. Montgomery, who founded our company in 1985. Our executive officers have been employed by our company for an average of 22 years and are experienced in their areas of focus, which include manufacturing, sales, finance, marketing and operations. As of March 18, 2019, our directors and executive officers beneficially own approximately 36.0% of our common stock.

Our Business Strategy

Our basic objective is to increase our net sales by adding customers and distributors, increasing the productivity of our distributors, and by periodically improving our existing products and introducing new products. We also intend to invest in our infrastructure to improve our operating efficiencies, provide better service to our customers and distributors and leverage our current operating facilities to improve our profitability. We seek to accomplish these objectives by employing the following strategic initiatives:

Leverage and Expand our Existing Distributor Base Throughout the United States. The United States has been and will continue to be our largest market. Our growth strategy in the United States involves multiple initiatives, such as the launch in early 2017 of our Fit3 product line and fitness program, continued investment in company-sponsored events and distributor training and better utilization of our upper-level distributors across different geographical areas to increase our distributor base.

Increase Appeal to Broader Demographic. Traditionally, our customer and distributor demographic has skewed towards baby boomers and older individuals searching for nutritional solutions to supplement their diet and support overall wellness.  While continuing to maintain our focus on the needs of this important segment, we believe there is an opportunity to expand our sales and distributor base by increasing our appeal to younger generations interested in nutrition and an active healthy lifestyle.  In February 2017, we launched our Fit3 product line and fitness program aimed at individuals seeking to improve their fitness levels and incorporate healthier options into their daily routines. We believe the nutritional and fitness aspects of Fit3 will attract health conscious on-the-go individuals, many of whom fall within the under-40 demographic.  Further, we maintain an active presence on popular social media sites including Facebook, Twitter, YouTube and several other social networks that are popular with younger generations.  Our internal social media team is comprised of Gen X and Gen Y staffers who regularly interact with distributors, customers and prospects. We plan to continue to develop products and programs and expand our technology offerings in an effort to further appeal to younger generations interested in healthy active lifestyles and a vibrant evolving business opportunity.

Expand in Existing and New International Markets. We believe there is a significant opportunity to increase our net sales in international markets. We have a business model that is compatible across all of our markets and encourages our distributors to pursue their business in multiple markets. We believe this business model supports expansion of our distributor network in our existing international markets and will provide a framework that facilitates our entry into new international markets. To that end, we continue to monitor business conditions in potential new markets and will selectively expand as timing and conditions are appropriate.

Invest in Improved and New Products. As a developer of nutritional supplements, it is vital to continue to invest in the research and development of new and innovative products. For example, in January 2017, we introduced our Fit3 line of products and in January 2013 we launched LunaRich X to support heart health and overall wellness. Additionally, we will continue to improve and validate the efficacy of our existing product line. These types of investments should facilitate customer and distributor retention, as well as the recruitment of new distributors.


Our Products

Product Overview

Our product line includes nutritional supplements that address basic nutrition, specific wellness needs, weight management and sports nutrition. We combine ingredients from science and nature in targeted, well-balanced, easy-to-use formulas that are specifically designed to enhance wellness and increase performance and energy in specific applications. All but three of our supplements are in powdered form that the consumer mixes with water, juice or other liquid. LunaRich X, Burn and Purify are available in capsule form.   

 

We currently offer 19 nutritional supplements. Our basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. For more specific needs, we provide other focused product formulations. Most of our supplements are in powdered form that the consumer mixes with water, juice or other liquid and others are available in capsule form.   We have purposely been selective in the number and types of products that we offer. By providing a line of targeted products, we make it simple for our distributors and consumers to choose products appropriate for their objectives. We consider four of our oldest and best selling products — Reliv Classic, Reliv Now, Innergize!, and FibRestore — along with LunaRich X capsules to be our primary or “core” products.

The following table summarizes Sales of these products represented approximately 53.5% of total product sales in 2019. In June 2019 we launched our product categories asRLV line of December 31, 2018. The net sales figures are for the year ended December 31, 2018:    


Product Category

 


Product Name

 

% of 2018
Net Sales(1)

 

Year
Introduced

 

Basic Nutrition

 

Reliv Now

  17.3   1988 
  

Reliv Now with Whey

  1.5   2018 
  

Reliv Classic

  10.5   1988 
  

Now for Kids

  6.3   2000 
           

Specific Wellness

 

FibRestore

  9.5   1993 
  

Arthaffect

  6.9   1996 
  

ReversAge

  3.6   2000 
  

SoySentials

  1.5   1998 
  

CardioSentials

  1.7   2005 
  

GlucAffect

  1.0   2008 
  

24K

  1.2   2011 
  

LunaRich X capsules

  12.6   2013 
           

Weight Management

 

Fit3 product line

  2.5   2017 
  

Meal replacements

  0.1  

 

Various 
           

Sports Nutrition

 

Innergize!

  7.6   1991 
  

ProVantage

  2.9   1997 

______________________

(1)

This table does not include net sales for the year ended December 31, 2018 related to freight and handling, sales of marketing materials, membership fees, and other manufacturing revenue, which represented approximately 13.3% of net sales for the year ended December 31, 2018.

Basic Nutrition Supplements

Our three basic nutrition supplements provide consumers with a broad spectrum of essential nutrients. Every formulation is specifically designed to optimize and enhance the benefits of the nutrients it contains.

Reliv Now with Soy is a nutritional supplement containing a variety of vitamins and minerals, soy and various herbs. Reliv Now is available in every country where we operate. In Australia, the product is marketed as Nourish. In 2018, we introduced a soy-free option, Now with Whey. This product has a nearly identical vitamin/mineral profile as Reliv Now with Soy. It is only available in the United States.


Reliv Classic is a nutritional supplement containing a variety of vitamins and minerals, soy and various herbs. It is a vegetarian product that contains no animal compounds, artificial preservatives, artificial flavors or added simple sugars. Reliv Classic is availablehemp-extract products in the United States Canada, France, Germany, Austria, the Netherlands, the United Kingdomwhich now include ingestible and Ireland.

Now for Kids is a product designed to provide a balanced nutritional supplement for a child’s diet and contains a varietytopical products. The RLV line represented approximately 4.9% of vitamins and minerals. Now for Kids is available in Australia, New Zealand, the United States, the United Kingdom, France, Germany, Ireland, Austria, the Netherlands, Mexico, Malaysia and the Philippines. In Australia, the product is marketed as Nourish for Kids.

Specific Wellness Supplements

Our line of eight specific wellness supplements contains specific compounds that target certain nutritional needs. Each product is intended to work in conjunction with our basic nutritional supplement formulas to provide an effective and balanced method for sustaining health and well-being.

ReversAge is a patented youth-promoting nutritional supplement designed to slow down the effects of the aging process. Three proprietary complexes form the foundation of the supplement: longevity complex, antioxidant complex and herbal complex. The longevity complex is restorative and designed to replenish key hormones while creating balance within the body’s major systems; the antioxidant complex is designed to slow aging at the cellular level; and the herbal complex delivers a variety of herbs, including Ginkgo Biloba and Maca. ReversAge is available in every country where we operate except Germany, the United Kingdom, France, the Netherlands and Ireland. In Canada and Mexico, the product is marketed as Nutriversal.

SoySentials is a nutritional supplement containing soy as well as other vitamins, minerals and herbs designed for use by women. SoySentials provides a woman with key nutrients targeted to promote women’s health and ease the symptoms of menopause and PMS. SoySentials is availablenet sales in the United States and Mexico.in 2019. We have not experienced any significant difficulty in obtaining supplies of raw materials for our nutritional supplements or finished products.

 

CardioSentialsOn January 1, 2019, we sold substantially all of the machinery, equipment, inventory, tools and other assets and materials used in manufacturing operations to Nutracom, LLC, (“Nutracom”). Nutracom is substantially owned and is controlled by former officers/employees of Reliv. Nutracom is leasing the manufacturing space in our facility for a patented berry-flavored nutritional supplement that promotes heart health. The product contains 1,500 mgperiod of phytosterols per serving, policosanol and several powerful antioxidants. Inseven years, with an option to renew for a clinical studyfive-year term. We also entered into agreements whereby Nutracom will continue to manufacture our core products on our premises for a period of this product, participants experienced meaningful reductions in cholesterol as well as improvement in their high-density lipoprotein, or HDL, and low-density lipoprotein, or LDL, ratios. CardioSentials is available only inseven years.

Markets

We currently sell our products throughout the United States.

Arthaffect is a nutritional supplement containing Arthred, a form of hydrolyzed collagen protein, which is clinically reported to support healthy joint function. The product is availableStates and in 12 other countries around the world. We have sold products in the United States Australia, New Zealand, Mexico, the Philippines, Malaysia, Singapore,since 1988 and Canada. Theour first product is marketed as A-Affect in Australia, New Zealand and Canada due to local product regulations.

FibRestore is a nutritional supplement containing fiber, vitamins, minerals and herbs. A modified versionoutside of the FibRestore formula is marketed in Canada under the name Herbal Harmony to comply with Canada’s nutritional regulations. FibRestore is available in all of the countries in which we operate.

GlucAffect is a patented cinnamon cream flavored nutritional supplement designed to support healthy blood sugar levels. GlucAffect contains Pycnogenol® and other clinically supported active ingredients. GlucAffect has been clinically proven to assist in healthy blood sugar management and support weight loss. GlucAffect is available in the United States.


24K is a patented healthy energy product. 24K is formulated with a synergistic blend of 24 active ingredients designed to enhance the body’s natural vitality and provide energy, focus and stress relief. It contains no caffeine and only 20 calories per serving. 24K is available only in the United States.

LunaRich X is a nutritional supplement available in capsule form and comes in a bottle of 30, 60 or 120 capsules. LunaRich X is a soy concentrate with elevated levels of bioactive lunasin, a soy peptide shown to have heart health and wellness benefits. LunaRich X is currently available in the United States Canada, Mexico,in 1991 when we entered Australia. In 2019, approximately 26.6% of our net sales were generated outside of the United Kingdom, France, Germany, Ireland, Austria, the Netherlands, the Philippines, Singapore and New Zealand. The product is marketed as LunaRich C in Germany, Austria, the United Kingdom, France, the Netherlands and Ireland due to local regulations.

Weight Management SupplementsStates

 

Our five weight management supplements combine advanced weight loss promoting complexes with scientifically balanced nutrition and protein for muscle development and toning. Our ingredients are designed to work together, along with proper diet and exercise, to turn unwanted fat into energy without sacrificing muscle mass.

Active is a nutritional supplement designed as the protein, energy and recovery product for use in our Fit3 program introduced in February 2017. Active combines a three-protein blend of whey, casein and non-GMO soy with active ingredients to support weight loss, physical performance and energy when combined with healthy eating and exercise. Active is currently available in the United States.

Burn is a nutritional supplement in our Fit 3 program that promotes weight loss when combined with healthy eating and exercise through a targeted fat-burning formula. Burn is available in the United States.

Purify is a nutritional supplement in our Fit3 program that contains probiotics and liver and metabolic supporting ingredients intended to cleanse the digestive system and allow maximum absorption and metabolic efficiency. Purify is available in the United States.

Reliv ReShape is designed as a meal replacement or a nutritious snack delivering 12 grams of protein. Reliv ReShape is only sold in Australia and New Zealand.

Reliv Ultrim-Plus is designed as a meal replacement (for a maximum of two meals per day) for use in a weight loss program. Reliv Ultrim-Plus is sold only in Mexico.

Sports Nutrition Supplements

Our two sports nutrition supplements contain a balance of nutrients scientifically designed to improve athletic performance and endurance, as well as muscle recovery and repair.

Innergize! is a sports supplement, containing vitamins and minerals designed for performance enhancement. Innergize! is available in every country where we operate. In Canada, the product is marketed as Optain due to local product regulations.

ProVantage is a patented nutritional supplement containing soy designed to enhance athletic performance with a balance of nutrients needed to improve endurance, muscle recovery and repair. The product also benefits those seeking to increase their soy intake. ProVantage is available inWithin the United States, we sell our products to distributors in all 50 states. We derived 43.2% of our domestic net sales in 2019 in California, Pennsylvania, Illinois, Michigan, Texas, Ohio, and Canada.

Research and Development

Florida, with each state contributing at least 4% of net sales. We maintain an ongoing research and development effort and consult with other industry professionals with respectbelieve that there is the opportunity to developmentsincrease the number of our distributors in nutritional science, product enhancements and new products. Since 2011,all markets where we have introduced six nutritional supplement products, including 24K, LunaRich X, Active, Burn, Purify and Now with Whey. From time to time, we reformulate and enhancesell our products. Our research and development team consistently evaluates product advancements in the marketplace and advancements in raw materials and ingredients available for new product ideas and developments.

 


1

 

For the years ended December 31, 2018 and 2017, our research and development expenses were $473,000 and $488,000 respectively.

SL Technology, Inc.

In mid-2013, we formed a wholly-owned subsidiary, SL Technology, Inc. (“SLTI”) for the purpose of entering into a Technology License Agreement (the “License Agreement”) with Soy Labs, LLC (“Soy Labs”). Pursuant to this License Agreement, Soy Labs granted SLTI an exclusive license for its intellectual property related to its soy concentrate with elevated levels of bioactive lunasin and other soy-related ingredients. The license covered an issued patent and several patent applications related to lunasin and soy-related peptides, proprietary information and manufacturing processes of Soy Labs.

In September 2016, we entered into a letter agreement with Soy Labs to acquire sole ownership of intellectual property subject to the License Agreement.  In consideration for acceleration of the final payment under the License Agreement, Soy Labs transferred all rights, title and interest in the technology to us and terminated any of our future royalty obligations under the License Agreement.

Network MarketingDirect Selling Program

General Overview

 

We market and sell our products through a network marketingdirect selling system of independent distributors, who purchase our products from us, or from other distributors, and who then sell our products directly to consumers. In addition to selling our products, our distributors also recruit others to distribute our products. Distributors receive compensation from both the sale of the products they have purchased at wholesale and, in the case of Master Affiliates and above,distributors reaching a certain rank, commissions on the volume of products sold by their downline organization. We believe network marketingdirect selling is an effective way to distribute our products because it allows and relies on personal contact, education and endorsement of products which are not as readily available through other distribution channels. Due to our distribution method we are not dependent on any one or a few customers.

 

We recognize that our sales growthCompetition

The business of developing and distributing nutritional products such as those we offer is basedhighly competitive. Numerous manufacturers, distributors and retailers compete for consumers and, in the case of other direct selling companies, for distributors. Our competitors include both direct selling companies, many of which are much larger and have far greater resources than we have, such as Alticor Global Holdings, Inc. (Amway Corp.), Avon Products Inc., Herbalife Ltd., Mary Kay Inc., Melaleuca, Inc., Mannatech, Inc., Nature’s Sunshine Products Inc., NuSkin Enterprises Inc. and USANA Health Sciences Inc., as well as specialty and mass retail establishments. Our ability to remain competitive depends on the continued developmentunderlying science and growthhigh quality of our independent distributor force and we strive to maintain an active and motivated distributor network through a combination of quality products and our success in recruiting and retaining distributors. The pool of individuals interested in direct selling tends to be limited in each market and may be reduced to the extent other direct selling companies successfully recruit these individuals into their businesses. We believe that we offer a business opportunityrewarding compensation plan with distributor discounts, commissionsattractive financial benefits to compete for the time, attention and bonus payments, sales conventions, training, personal recognition and a varietycommitment of publications and promotional materials.distributors.

 

Program Structure

IndividualsReliv Now and Reliv Classic compete with numerous supplements that do not wish to become distributors, but want to purchaseoffer multi-vitamin benefits. Our fitness and weight management products directly from the company may enroll as retail or preferred customers, so long as they are sponsored by an existing distributor. We created a Preferred Customer programcompete with other products in the United Statesweight loss market, including nationally advertised products such as SlimFast. Many companies have entered, or have plans to enter, the sports drink market in which Innergize! competes, a market led by Gatorade. 24K competes with 5-Hour Energy and Canada, effective February 1, 2016. Those wishingnumerous other liquid energy shots and drinks. Our competitive advantages include the uniqueness of our products, our ability to join as a preferred customer may enroll for an annual fee of $10, for which they receive a 10% discount fromformulate new products in-house, and the retail pricesintellectual property rights we possess in many of our products.

 

Individuals who desire to market and sell our products may become distributors by being sponsored into the program by an existing distributor, and becoming part of that distributor’s “downline.” We offer a tiered discount and commission, or royalty, format that consists of four principal levels and several sub-levels, which are designed to compensate and motivate distributors to increase their networks and sales volumes.

Our distributors consist principally of individuals, although we also permit entities such as corporations, partnerships, limited liability companies and trusts to become distributors. A new distributor is required to complete a distributor application and, in most areas, to purchase a package of distributor materials (for $40 plus sales tax in the United States) consisting of a Distributor Guide and CD, business forms and promotional materials. The Distributor Agreement, when accepted by us, becomes the contract between us and the distributor and obligates the distributor to the terms of the agreement, which includes our Policies and Procedures for conduct of their business. All distributors are independent contractors and are not our employees.


In each country in which we conduct business, distributors operate under a compensation system pursuant to which distributors generally are compensated based on their sales volumes. On the basis of sales volume or commission volume, distributors may achieve the following successive levels of achievement and compensation:

Designation

Discount

Retail Distributor(1)

20%

Affiliate

25%

Key Affiliate

30%

Senior Affiliate

35%

Master Affiliate

40%(1)

Director

40%(1)

Key Director

40%(1)

Senior Director

40%(1)

Master Director/Ambassador

40%(1)

Presidential Director/Ambassador

40%(1)

______________________

(1)

In addition to discounts, these levels also receive commissions based on sales in their downline organization.

Distributors purchase products from us at a discount from the suggested retail price for the products and then may sell the product at retail to customers, sell the product to other distributors at wholesale or consume the product. The amount of the discount varies depending on the distributor’s level of achievement, as indicated above.

Distributors generate income equal to the difference between the price at which they sell the product to customers and the discounted price they pay for the product. Distributors also earn wholesale commissions on products purchased by downline distributors in the distributor’s sponsored group equal to the difference between the price at which the distributor is entitled to purchase product and the price at which downline distributors purchase product. We calculate payments and issue a payment directly to the qualified distributor on a weekly basis. For example, assume Distributor A is a 40% discount Master Affiliate who signs up Distributor B, a 30% discount Key Affiliate, who signs up Distributor C, a 20% discount Retail Distributor. If Distributor C purchases directly from us, a 10% wholesale profit check will be sent to Distributor A and a 10% wholesale profit check will be sent to Distributor B.

Upon achieving the level of Master Affiliate, distributors begin to receive additional compensation — “generation royalty” — payments of 8%, 6%, 4%, 3% and 2% of the retail volume of product purchased from us by Master Affiliates and above (and their personal groups) whom they have sponsored, and for each of five downline levels of sponsorship. To qualify for these additional compensation payments, Master Affiliates and above are required to maintain certain monthly sales volumes.

Master Affiliates who sponsor other distributors that achieve the level of Master Affiliate are entitled to become part of the Director Program. Advancement at the Director level is based upon achieving increasing levels of royalties based on sales generated by other distributors in the Director’s downline organization. Distributors achieving each level receive recognition for their achievements at our company-sponsored events and in our publications. We also have a Star Director Program under which distributors achieving the level of Director and above receive additional compensation based on the number of Master Affiliates they have sponsored into the program. Directors receive an additional 1% to 3% royalty on the retail sales volume of Master Affiliates in their downline organization for an unlimited number of levels of sponsorship, until reaching a level that includes a Master Affiliate who also has achieved Star Director status.

Master Directors and Presidential Directors may also be invited to participate in the Ambassador Program. Qualifications to be invited by us to participate in the Ambassador Program include demonstrated competence and leadership qualities. Ambassadors receive recognition and awards for achieving Ambassador status and can then achieve additional levels of accomplishment. We utilize our Ambassadors to lead meetings and conferences, and to provide training and education to our distributors. Ambassadors achieving the level of Silver and higher also participate in the “Reliv Inner Circle,” which may entitle them to receive additional compensation, paid participation in our sponsored events, health insurance and car allowances.


In addition to the levels of compensation described, we also provide a variety of incentives, bonuses, awards and trips to distributors who achieve high sales volumes and who advance in the distributor ranks.

Distributor Training, Motivation and Management

Our marketing efforts are focused on the development, training, motivation and support of our independent distributors. We support an active training program for our distributors in which our representatives and experienced distributors, usually Ambassadors, lead group training sessions. We provide distributors with manuals, brochures and other promotional, training and informational publications. We encourage distributors to hold regular weekly recruiting meetings and training sessions. We sponsor weekly training conference calls in which a significant number of distributors participate.

Our sponsorship generally includes the following: 

During 2018, we sponsored numerous special events in cities across all of our markets led by corporate executives and/or experienced Ambassadors;

For the key markets in which we operate, we sponsor our annual conference for distributors; and

In the United States during 2018, we sponsored two regional conferences for U.S. distributors.

During 2018, we invested approximately $1.03 million in training, conferences and promotional events for our distributors worldwide compared with $1.25 million in 2017.

Distributor Compliance

Our distributor organization and business model are designed and intended to promote the sale of our products to consumers by distributors. Sales training and promotional efforts emphasize that intention. To that end, we monitor purchases by distributors to identify potentially excessive individual purchases and keep detailed information regarding customer purchases through our corporate shopping cart and as part of our autoship program. Distributors are not required at any time to purchase product, although Master Affiliates and above are required to maintain certain minimum sales levels in their personal groups to continue receiving generation royalty compensation payments.

Distributors may create their own advertising provided that it is within our advertising rules. Unless a distributor is using our designed and approved advertisements, the distributor must submit for approval in writing all advertising (e.g. brochures, flyers, audio tapes, classified or display ads, radio scripts) to our Compliance Department before placing it or arranging for placement.

Pursuant to our Policies and Procedures, which are incorporated by reference into our Distributor Agreement, distributors are permitted to make only those claims about our products that have been approved by us and/or provided in sales and training materials. Distributors acknowledge that our products are not represented as drugs and they are not authorized to make any diagnosis of any medical condition, make drug-type claims for, or prescribe our products to treat or cure, any disease or condition. We do not authorize or permit our distributors to make any express or implied references with regard to our products that they cure, prevent or relieve disease, replace or augment medication, provide therapy, promote healing, alleviate illnesses or symptoms of illnesses, or make any other medical claims for specific ailments.

In order to comply with regulations that apply to both us and our distributors, we conduct considerable research into the applicable regulatory framework prior to entering any new market to identify all necessary licenses and approvals and applicable limitations on operations in that market. We devote substantial resources to obtaining the necessary licenses and approvals and maintaining operations that are in compliance with the applicable limitations. We also research laws applicable to distributor operations and revise or alter distributor materials and products, as required by applicable regulations in each market.


Regulations in existing and new markets often are ambiguous and subject to considerable interpretive and enforcement discretion by the responsible regulators. In addition, regulations affecting our business often change and are subject to varying interpretation and application. We make every effort to monitor and comply with changes in laws and regulations as they occur.

We have a Compliance Department that receives and reviews allegations of distributor misconduct. If we determine that a distributor has violated our Policies and Procedures, we may take a number of disciplinary actions. For example, we may impose sanctions such as warnings or suspensions until specific conditions are satisfied, or take other appropriate actions at our discretion, including termination of the distributor’s agreement.

Geographic Presence

Markets

We currently sell our products throughout the United States and in 13 other countries around the world. We have sold products in the United States since 1988 and our first product outside of the United States in 1991 when we entered Australia. In 2018, approximately 23.4% of our net sales were generated outside of the United States.

The table below shows the countries in which we operate and the year we commenced selling products:  

Country

Year Entered

Country

Year Entered

United States

1988

Malaysia

2003

Australia

1991

Ireland

2003

New Zealand

1992

Singapore

2004

Canada

1992

Germany

2005

Mexico

1993

Austria

2006

United Kingdom(1)

1995

Netherlands

2006

Philippines

2000

France

2013

    

______________________

(1)

Includes Great Britain, Scotland, Wales and Northern Ireland.

Within the United States, we sell our products to distributors in all 50 states. We derived 42.5% of our domestic net sales in 2018 in California, Pennsylvania, Illinois, Michigan, Texas, Ohio, and Florida, with each state contributing at least 4% of net sales. We believe that there is the opportunity to increase the number of our distributors in all markets where we sell our products.

We organize all of our international operations under our wholly owned subsidiary, Reliv’ World. As of December 31, 2018, Reliv’ World consisted of the following market-specific entities: Reliv’ Australia, Reliv’ New Zealand, Reliv’ Canada, Reliv’ Mexico, Reliv’ Europe, Reliv’ Philippines, Reliv’ Malaysia, and Reliv’ Singapore. We have utilized this method of separate corporations in most of our markets, as local business licensing and product approvals require a local legal entity.

We believe that there is a significant opportunity to increase sales in our current international markets, as a whole. We have established a substantially consistent business model and compensation plan across all of our markets, and we continue to support our international markets with additional marketing programs and materials.

In addition to increasing sales in current international markets, our expansion strategy targets selected new foreign markets, when appropriate.


New Market Entry Process

When conditions warrant, we evaluate new markets for our products. In order to do so, we perform an analysis of synergies between new and existing countries and distributor presence or interest in new markets, market conditions, regulatory conditions, product approval procedures and competition before selecting markets to enter. Once we decide to enter a new market, we first hire local legal counsel and/or a consultant with appropriate expertise to:

help ensure that our network marketing system and products comply with all applicable regulations;

help establish favorable public relations in the new market by acting as an intermediary between us and local regulatory authorities, public officials and business people; and

explain our products and product ingredients to appropriate regulators and, when necessary, to arrange for local technicians to conduct required ingredient analysis tests of the products.

Where regulatory approval in a foreign market is required, we utilize local counsel and/or consultants to work with regulatory agencies to confirm that all of the ingredients in our products are permissible within the new market. Where reformulation of one or more of our products is required, we attempt to obtain substitute or replacement ingredients. During the regulatory compliance process, we may alter the formulation, packaging, branding or labeling of our products to conform to applicable regulations as well as local variations in customs and consumer habits, and we may modify some aspects of our network marketing system as necessary to comply with applicable regulations.

Following completion of the regulatory compliance phase, we undertake the steps necessary to meet the operations requirements of the new market. In the majority of our new markets, we establish a sales center in a major city and provide for product purchases by telephone and/or pick up. Product is shipped to the purchaser from a warehouse located in the general geographic market or the distributor may walk in to the local office and purchase products, if a pick up center is available. In addition, we initiate plans to satisfy inventory, personnel and transportation requirements of the new market, and we modify our distributor materials, recordings, videos and other training materials as necessary to be suitable for the new market.

In some countries, regulations applicable to the activities of our distributors also may affect our business because in some countries we are, or regulators may assert that we are, responsible for our distributors’ conduct. In these countries, regulators may request or require that we take steps to ensure that our distributors comply with local regulations.

Manufacturing

We established a manufacturing line at our headquarters facility in Chesterfield, Missouri and began to manufacture all of our nutritional supplements in early 1993. We expanded our Chesterfield facility in 1997 to 126,000 square feet of total space. On January 1, 2019, we sold substantially all of the machinery, equipment, inventory, tools and other assets and materials used in manufacturing operations to Nutracom, LLC, (“Nutracom”). Nutracom is owned substantially and is controlled by Dr. Carl W. Hastings and his family. Nutracom is leasing the manufacturing space in our facility for a period of seven years, with an option to renew for a five-year term. We also entered into agreements whereby Nutracom will continue to manufacture our core products on our premises for a period of seven years.   

The substantial overhead and cash flow required to operate the production facility had become a significant detriment to our financial performance, financing strategies and focus.  We sold the manufacturing operations in an effort to reduce operating losses and improve cash flow, provide additional sources of lease and financing revenue and to potentially reduce our cost of goods sold as Nutracom increases its production. The sale to Nutracom also allows us to retain a level of involvement over the production and cost of our products and grants us an equity interest in Nutracom.  The sale will also allow our management to focus on our core business. 

At this facility, all of our powdered nutritional supplements and encapsulated products are manufactured for distribution both domestically and internationally.

Historically, our ability to closely monitor the manufacture of nearly all of our nutritional supplements is a competitive advantage over competitors and contributes to our ability to provide high-quality products. We have not experienced any significant difficulty in obtaining supplies of raw materials for our nutritional supplements or finished product.


Fulfillment

Distributors and their customers order product in either case lots or individual units of each product and pay for the goods prior to shipment. We also have a preferred customer plan that allows these customers to purchase product at a 10% discount for an annual enrollment fee of $10. We also offer a monthly or quarterly autoship program for distributors and customers. Product is shipped directly to the distributor or customer and upline distributors earn wholesale profits or, if applicable, a commission on all sales.    

In the United States, our products are warehoused at our Chesterfield facility and shipped by common carrier to distributors and customers upon order. Our facility in Chesterfield, Missouri serves all parts of the country. Our products are also warehoused in, and shipped to local distributors from: Sydney, Australia; Auckland, New Zealand; Oakville, Canada; Guadalajara, Mexico; Redditch (Birmingham), England; Makati (Manila), Philippines; and Subang Jaya (Kuala Lumpur), Malaysia. With the exception of our Canada, New Zealand, and Singapore subsidiaries, each of our subsidiaries maintains an office and personnel to receive, record, and fill orders from distributors. Distributors in Ireland, France, Germany, Austria, and the Netherlands order and receive product from our UK-based subsidiary.

We maintain a policy that unused product may be returned by a customer to the selling distributor for a full refund or exchange within 30 days after purchase. We also maintain a policy that any distributor who terminates his or her distributorship may return saleable product which was purchased from us within twelve months of the termination for a refund of 100% of the purchase price less any compensation received relating to the purchase of the products. We believe this buyback policy addresses and satisfies a number of regulatory compliance issues pertaining to network marketing systems.

Historically, product returns and buy backs have not been significant. Product returns and buy backs have been approximately 0.17% and 0.25% of net sales in 2018 and 2017, respectively.

IntellectualIntellectual Property

 

Our formulas are protected as trade secrets and, to the extent necessary, by confidentiality agreements. In addition, we have obtained U.S. patents on five products as set forth below:

 

Product

Patent Expiration Date

  

ReversAge

May 2021

ProVantage 

December 2030

GlucAffect

November 2029

24K

February 2032

CardioSentials

January 2029

 

In addition to our patented formulas, we own four U.S. patents, 12 international patents and twothree patent applications related to our soy concentrate ingredient with elevated levels of bioactive lunasin, the key ingredient in our LunaRich X product. Further, we utilize a proprietary production process to produce our soy concentrate that we protect as a trade secret, along with the bioassay to determine the bioavailability of lunasin in our products.

 

Currently, we have 14 trademarks registered with the U.S. Patent and Trademark Office, or USPTO, including Reliv and the names of 12 of our 18 nutritional products. Reliv Now for Kids, LunaRich X, ReShape, Active, Burn and Purify are not registered with the USPTO. Trademark registrations for selected marks have been issued or applied for in Australia, New Zealand, Canada, Mexico, the United Kingdom, Ireland, the Philippines, Malaysia, Singapore, Germany and several other foreign countries that offer network marketingdirect selling opportunities. We consider our trademarks to be an important asset of our business.

 


2

 

Regulation

 

Product Regulation

 

The formulation, manufacturing, labeling and advertising or promotion of our products are subject to regulation by the Food and Drug Administration, or FDA, which regulates our products under the federal Food, Drug and Cosmetic Act, or FDCA, the Federal Trade Commission, or FTC, and various agencies of the states or countries into which our products are shipped or sold. FDA regulations include requirements and limitations with respect to the labeling of our food products and also with respect to the formulation of those products. FDA regulations also limit and control the extent to which health or other claims can be made with respect to the efficacy of any food or cosmetic.      The FDCA has been amended several times with respect to dietary supplements, most recently by the Nutrition Labeling and Education Act of 1990, or NLEA, and the Dietary Supplement Health and Education Act of 1994, or DSHEA, and related regulations. Such legislation governs the formulation, manufacturing, marketing and sale of nutritional supplements, including the content and presentation of health-related information included on the labels or labeling of nutritional supplements.

AllMost of the products we market are classified as dietary supplements under the FDCA. Dietary supplements, such as those we sell, for which no “drug” claim is made, are not subject to FDA approval prior to their sale.      However, DSHEA established a pre-market notification process for dietary supplements that contain a “new dietary ingredient,” or NDI, a term that is defined as “a dietary ingredient that was not marketed in the United States before October 15, 1994,” the date on which DSHEA was signed into law. Certain NDIs that have been “present in the food supply” are exempt from the notification requirement. For those NDIs that are not exempt, DSHEA requires the manufacturer or distributor of a dietary supplement containing an NDI to submit to the FDA, at least 75 days prior to marketing, a notification containing the basis for concluding that the dietary supplement containing the NDI will “reasonably be expected to be safe.” Dietary supplement products can be removed from the market if shown to be unsafe, or if the FDA determines, based on the labeling of products, that the intended use of the product is for the diagnosis, cure, mitigation, treatment or prevention of disease. The FDA can regulate those products as “drugs” and require premarket approval of a “new drug application.” Distributors of dietary supplements that make any claims for dietary supplements, including product performance and health benefit claims must have substantiation that the statements are truthful and not misleading.

In January 2000, the FDA published a final rule that defines the types of statements that can be made concerning the effect of a dietary supplement on the structure or function of the body pursuant to DSHEA. Under DSHEA, dietary supplement labeling may bear “structure/function” claims, which are claims that the products affect the structure or function of the body, without prior FDA approval. They may not, without prior FDA approval, bear a claim that they can prevent, treat, cure, mitigate or diagnose disease, otherwise known as a “drug claim.” The final rule describes how the FDA will distinguish drug claims from structure/function claims. Dietary supplements, like conventional foods, are also permitted to make “health claims,” which are claims that are exempt from regulation as “drug” claims pursuant to the amendments to the FDCA established by the NLEA in 1990. A “health claim” is a claim, ordinarily approved by FDA regulation, on a food or dietary supplement product’s labeling that “characterizes the relationship of any substance to a disease or health-related condition.” To help assure that foods, dietary supplements and cosmetics comply with the provisions of the FDCA and FDA’s regulations, the FDA has numerous enforcement tools, including the ability to issue warning letters, initiate product seizures and injunctions and pursue criminal penalties.

In July 2016, the FDA put into effect new labeling regulations in which manufacturers must comply by January 1, 2020. We are currently implementing these label changes and will be in full compliance prior to the deadline. The changes will affect the Supplement Facts panel and how macro and micronutrients are claimed.

The manufacture of dietary supplements is subject to existing FDA current good manufacturing practice, or cGMP, regulations for food. In June 2007, the FDA issued regulations relating to more detailed cGMP specifically for dietary supplements. The facilities in Chesterfield are periodically audited by the FDA and we believe they are in full compliance with cGMP.


 

Advertisements for our products are subject to regulation by the FTC. The FTC prohibits unfair methods of competition and unfair or deceptive acts or practices in or affecting commerce and provides that the dissemination of any false advertisement pertaining to drugs, cosmetics or foods, including dietary supplements, is an unfair or deceptive practice. Under the FTC’s substantiation doctrine, an advertiser must have a “reasonable basis” for all claims made about a product. The failure to be able to adequately substantiate claims may be considered either deceptive or unfair practices. In order to avoid a violation of the FTC standards, we endeavor to assure that we have adequate substantiation for all advertising claims made for our products. In addition, the FTC has increased its scrutiny of the use of distributor testimonials. Although it is impossible for us to monitor all the product claims made by our independent distributors, we make efforts to monitor distributor testimonials and restrict inappropriate distributor claims. The FTC has been more aggressive recently in pursuing enforcement against dietary supplement products, since the passage of DSHEA in 1994, and has brought numerous actions against dietary supplement companies, some resulting in several million dollar civil penalties and/or restitution as well as court-ordered injunctions.

 

We are aware that there is adverse publicityWhile the sale of hemp-based CBD products in many markets, including the United States concerning foodshas increased dramatically throughout almost all sales channels in 2019, the FDA has not issued regulations governing the sale of ingestible Hemp-extract products containing CBD and has not approved the sale of such products. The FDA has indicated that it is currently pursuing actions against companies selling such products that are grown from genetically modified organisms,making deceptive health claims, mis-labelling their products or GMOs. In some markets,engaging in improper manufacturing practices. Many states have issued regulations governing the possibilitymanufacturing, labelling and sale of health risks thoughthemp-extract products in their state, which in certain cases includes registration with the state. The FDA has indicated that it intends to be associated with GMOs has prompted proposed or actual governmental regulation. Nearly all ingredients in our formulasissue regulations governing the manufacture, labelling and sale of hemp-extract products and we are non-GMO.  We use non-GMO ingredients when required by governmentalunable to predict the effect such regulations and strive to use non-GMO ingredients in every other instance when commercially feasible and available.  We believe compliance with regulatory requirements in this area should notwill have a material adverse effect on our business.RLV line nor are we able to predict the probability of future laws, regulations or interpretations which may be passed by state or federal regulatory authorities

 

Sales Program Regulation

 

Our distribution and sales program is subject to regulation by the FTC and other federal and state regulation as well as regulations in several countries in which we conduct business. Various state agencies regulate multi-level distribution services. We are required to register with, and submit information to, certain of such agencies and we believe we have complied fully with such requirements. We actively strive to comply with all applicable state and federal laws and regulations affecting our products and our sales and distribution programs. The Attorneys General of several states have taken an active role in investigating and prosecuting companies whose compensation plans they claim violate local anti-pyramid and/or consumer protection statutes. We are unable to predict the effect such increased activity will have on our business in the future nor are we able to predict the probability of future laws, regulations or interpretations which may be passed by state or federal regulatory authorities.

Federal and state laws directed at network marketingdirect selling programs have been adopted throughout the years to prevent the use of fraudulent practices often characterized as “pyramid schemes.” Illegal pyramid schemes compensate participants primarily for the introduction or enrollment of additional participants into the program. Often these schemes are characterized by large up-front entry or sign-up fees, over-priced products of low value, little or no emphasis on the sale or use of products, high-pressure recruiting tactics and claims of huge and quick financial rewards with little or no effort. Generally, these laws are directed at ensuring that product sales ultimately are made to consumers and that advancement within such sales organizations is based on sales of products.

 

The FTC has been very aggressive recently in investigating and prosecuting direct selling companies whose compensation plans they claim are illegal pyramid schemes. These actions typically include claims that the companies and/or their key distributors made deceptive statements regarding the company’s products, the compensation plan and a participant’s ability to earn income. These actions have resulted in several million dollar civil penalties and/or restitution against the companies and/or their key distributors as well as court-ordered injunctions, and in one instance the agreement of the company to discontinue the sale of its products through direct selling. We believe that our network marketing system satisfiesare unable to predict the standards and case law defining a legal marketing system. It is an ongoing part ofeffect such increased activity will have on our business in the future nor are we able to monitor and respond topredict the probability of future laws, regulations or interpretations which may be passed by state or federal regulatory and legal developments, including those that may affect our network marketing system. However, theauthorities. The regulatory and legal requirements concerning network marketingdirect selling systems do not include “bright line” rules and are inherently fact-based.

 

Competition

The business of developing and distributing nutritional products such as those we offer is highly competitive. Numerous manufacturers, distributors and retailers compete for consumers and, in the case of other network marketing companies, for distributors. Our competitors include both network marketing companies such as Alticor Global Holdings, Inc. (Amway Corp.), Avon Products Inc., Herbalife Ltd., Mary Kay Inc., Melaleuca, Inc., Mannatech, Inc., Nature’s Sunshine Products Inc., NuSkin Enterprises Inc. and USANA Health Sciences Inc., as well as specialty and mass retail establishments. Our ability to remain competitive depends on the underlying science and high quality of our products and our success in recruiting and retaining distributors. The pool of individuals interested in network marketing tends to be limited in each market and may be reduced to the extent other network marketing companies successfully recruit these individuals into their businesses. We believe that we offer a rewarding compensation plan with attractive financial benefits to compete for the time, attention and commitment of distributors. Our compensation plan is seamless, permitting international expansion.


3

Reliv Now and Reliv Classic compete with numerous supplements that offer multi-vitamin benefits. Our fitness and weight management products compete with other products in the weight loss market, including nationally advertised products such as SlimFast. Many companies have entered, or have plans to enter, the sports drink market in which Innergize! and ProVantage compete, a market led by Gatorade. 24K competes with 5-Hour Energy and numerous other liquid energy shots and drinks. With Arthaffect, FibRestore, ReversAge, GlucAffect, CardioSentials, SoySentials, and LunaRich X, we are in the specific wellness needs, food and anti-aging markets, which are extremely competitive and led by the major food companies.


 

Employees

 

As of December 31, 2018,2019, we and all of our subsidiaries had approximately 15691 full-time employees compared with 16099 such employees at the endas of 2017. After the Nutracom transaction, our full-time headcount was 99 employees.January 1, 2019.

 

Additional Available Information

 

We make available, free of charge, copies of our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to these reports as soon as reasonably practicable after such material is electronically filed with, or furnished to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act. This information is available on our corporate web site at www.reliv.com under the “Investor Relations” section. This information may also be obtained from the SEC’s on-line database located at www.sec.gov.

 

Item No. 2 Properties

 

We own approximately six acres of land and a building containing approximately 126,000 square feet of office, manufacturing and warehouse space located in Chesterfield, Missouri, where we maintain our corporate headquarters and sole manufacturing facility. We believe that our worldwide facilities are suitable and adequate in relation to our present and immediate future needs.

 

The following table summarizes information related to our worldwide facilities as of March 18, 2019:23, 2020:

 

Location

Nature of Use

 

Square Feet

 

Owned/Leased

       

Chesterfield, MO, USA

corporate headquarters/call center/manufacturing/warehouse

  126,000 

Owned

Seven Hills (Sydney), Australia

central office/call center

  1,000 

Leased

Oakville, Ontario, Canada

warehouse/distribution

  2,100 

Leased

Guadalajara, Mexico

central office/warehouse/call center

  2,300 

Leased

Makati City (Manila), Philippines

central office/ warehouse/distribution

  4,0006,300 

Leased

Redditch (Birmingham), England, UK

central office/ warehouse/distribution

  11,500 

Leased

Subang Jaya (Kuala Lumpur), Malaysia

central office/call center

  300 

Leased

 

We haveOn January 1, 2019, we sold substantially all of the machinery, equipment, inventory, tools and other assets and materials used in our manufacturing operations to Nutracom, LLC, (“Nutracom”). Effective January 1, 2019, we leased 96,450 square feet of manufacturing and office space in our Chesterfield facility to Nutracom for a period of seven years with a five-year option. We also entered into agreements whereby Nutracom will continue to manufacture our core products on our premises for a period of seven years.

 

Item No. 3 - Legal Proceedings

 

From time to time, we are involved in litigation incidental to the conduct of our business. We do not believe that any current proceedings will have a material adverse effect on our business, financial condition, results of operations or cash flows.

 


4

 

PART II

 

Item No. 5 - Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Our common stock is listed on the NASDAQ Global SelectCapital Market under the symbol: RELV. The following table sets forth the high and low sales prices of our common stock and the quarterly dividends per share paid on our common stock during the years ended December 31, 20182019 and 2017.2018.

 

 

High

  

Low

  

Dividend

  

High

  

Low

  

Dividend

 
                        

Year Ending December 31, 2018

            

Year Ending December 31, 2019

            

Fourth Quarter

 $5.06  $3.83  $-  $4.87  $3.45  $- 

Third Quarter

  5.26   4.62   -   4.66   3.95   - 

Second Quarter

  5.35   4.15   -   5.89   3.80   - 

First Quarter

  6.24   4.60   -   4.62   3.85   - 
                        

Year Ending December 31, 2017

            

Year Ending December 31, 2018

            

Fourth Quarter

 $8.44  $3.72  $-  $5.06  $3.83  $- 

Third Quarter

  13.77   6.22   -   5.26   4.62   - 

Second Quarter

  9.00   5.18   -   5.35   4.15   - 

First Quarter

  8.87   4.13   -   6.24   4.60   - 

 

As of March 18, 2019,23, 2020, there were approximately 762975 holders of record of our common stock and an additional 1,9081,762 beneficial owners, including shares of common stock held in street name.

 

We have not declared any cash dividends over the past two years.  The declaration of future dividends is subject to the discretion of our Board of Directors and will depend upon various factors, including our earnings, financial condition, restrictions imposed by any indebtedness that may be outstanding, cash requirements, and other factors deemed relevant by our Board of Directors.  Our current lending agreements contain covenants which may limit our ability to declare cash dividends.

 


5

 

Item No. 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this Annual Report on Form 10-K. The following discussion and analysis discusses the financial condition and results of our operations on a consolidated basis, unless otherwise indicated.

 

Overview

 

We are a developer and marketer of a proprietary line of nutritional supplements addressing basic nutrition, specific wellness needs, weight management and sports nutrition. In 2019, we introduced a line of hemp-extract products under the RLV brand name. We sell our products through an international network marketingdirect selling system utilizing independent distributors. Sales in the United States represented approximately 76.6%73.4% of worldwide net sales for the year ended December 31, 20182019 compared to approximately 77.7%76.6% for the year ended December 31, 2017.2018. Our international operations currently generate sales through distributor networks with facilities in Australia, Canada, Malaysia, Mexico, the Philippines, and the United Kingdom. We also operate in Ireland, France, Germany, Austria and the Netherlands from our United Kingdom distribution center, and in New Zealand from our Australia office, and in Singapore from our Malaysia office.


 

We derive our revenues principally through product sales made by our global independent distributor base, which, as of December 31, 2018,2019, consisted of approximately 30,370 distributors15,630 registered customers and preferred customers.25,730 active distributors. Our sales can be affected by several factors, including our ability to attract new distributors and retain our existing distributor base, our ability to properly train and motivate our distributor base and our ability to develop new products and successfully maintain our current product line.

 

All of our sales to distributors outside the United States are made in the respective local currency; therefore, our earnings and cash flows are subject to fluctuations due to changes in foreign currency rates as compared to the U.S. dollar. Our foreign subsidiaries primarily source their nutritional and dietary inventories in U.S. dollars from our U.S. manufacturer. As a result, exchange rate fluctuations may have an effect on sales and gross margins. Accounting practices require that our results from operations be converted to U.S. dollars for reporting purposes. Consequently, our reported earnings may be significantly affected by fluctuations in currency exchange rates, generally increasing with a weaker U.S. dollar and decreasing with a strengthening U.S. dollar. Products manufactured for sale to our foreign subsidiaries are transacted in U.S. dollars. From time to time, we enter into foreign exchange forward contracts to mitigate our foreign currency exchange risk.

 

Components of Net Sales and Expense

 

Product sales represent the actual product purchase price typically paid by our distributors, after giving effect to distributor allowances, which can range from 20% to 40% of suggested retail price, depending on the rank of a particular distributor. Handling and freightFreight income represents the amounts billed to distributors for shipping costs. We record net sales and the related commission expense when the merchandise is shipped. Other revenue included in net sales now includes the leasing revenue, plus common area expense billings, on the lease of the manufacturing portion of our building to Nutracom, LLC (“Nutracom”) as of January 1, 2019 after the adoption of ASU 2016-02.

 

Our primary expenses include cost of products sold, distributor royalties and commissions and selling, general and administrative expenses.

 

CostIn 2018, our cost of productsgoods sold primarily consistsconsisted of expenses related to raw materials, labor, quality control and overhead directly associated with production of our products and sales materials, as well as shipping costs relating to the shipment of products to distributors, and duties and taxes associated with product exports. Cost of productsgoods sold iswas impacted by the cost of the ingredients used in our products, the cost of shipping distributors’ orders, andalong with our efficiency in managing the production of our products. For 2019, we no longer manufacture our products; therefore, the costs consist of the purchase price of the products, along with shipping costs, and duties and taxes where applicable. Cost of goods sold also include the costs related to leasing income now included in net sales after the adoption of ASU 2016-02.

6

 

Distributor royalties and commissions are weekly and monthly payments made to distributors based on products sold in their downline organization. Based on our distributor agreements, these expenses have typically approximateapproximated 23% of sales at suggested retail. Wholesale pricing discounts on distributor orders are based on the retail value of the product. Distributor royalties and commissions are paid on an amount referred to as the business value (“BV”), which typically ranges between 80% and 90% of the suggested retail price of each product. Also, we include other sales leadership bonuses, such as Ambassador bonuses, within this caption. Overall, distributor royalties and commissions remain directly related to the level of our sales and should continue at comparable levels as a percentage of net sales going forward. We have implemented or are in the process of implementing similar pricing structures in all of our international markets.


 

Selling, general and administrative expenses include the compensation and benefits paid to our employees, except for those in manufacturing, all other selling expenses, marketing, promotional expenses, travel and other corporate administrative expenses. These other corporate administrative expenses include professional fees, non-manufacturing depreciation and amortization, occupancy costs, communication costs and other similar operating expenses. Selling, general and administrative expenses can be affected by a number of factors, including staffing levels and the cost of providing competitive salaries and benefits; the amount we decide to invest in distributor training and motivational initiatives; and the cost of regulatory compliance.

 

Results of Operations

 

Year Ended December 31, 20182019 Compared to Year Ended December 31, 20120187

 

Net sales decreased by 13.6%2.9% worldwide as net sales in the United States and Europe decreased, offset by an increase in Asia. Net sales in the United States decreased by 14.8%7.0% in the year ended December 31, 20182019 compared with 2017.2018. During 2018,2019, our international net sales decreasedincreased by 9.4%10.3% over the prior year with minimalan unfavorable impact of 1.6% from foreign currency fluctuations in the aggregate. Net sales in Europe our largest foreign market, decreased by 13.2%18.8% in 20182019 compared to the prior year, with a benefitan unfavorable impact of 3.0%3.7% due to the impact of foreign currency fluctuation. Net sales in Asia increased by 3.8%68.7% in 20182019 compared to the prior year. When measured in local currencies, net sales in Asia increased by 7.9%66.1% in 2018.2019.

 

          The following table summarizes net sales by geographic market for the years ended December 31, 20182019 and 2017.2018.

 

Net Sales by Market

 

Year Ended December 31,

          

Year Ended December 31,

         

(in thousands)

 

2018

  

2017

  

Change from prior year

  

2019

  

2018

  

Change from prior year

 
 

Amount

  

% of Net

Sales

  

Amount

  

% of Net

Sales

  

Amount

  

%

  

Amount

  

% of Net

Sales

  

Amount

  

% of Net

Sales

  

Amount

  

%

 
 

(dollars in thousands)

  

(dollars in thousands)

 

United States

 $27,673   76.6

%

 $32,475   77.7

%

 $(4,802

)

  (14.8

)%

 $25,747   73.4

%

 $27,673   76.6

%

 $(1,926

)

  (7.0

)%

Australia/New Zealand

  732   2.0   923   2.2   (191

)

  (20.7

)

  595   1.7   732   2.0   (137

)

  (18.7

)

Canada

  719   2.0   915   2.2   (196

)

  (21.4

)

  617   1.8   719   2.0   (102

)

  (14.2

)

Mexico

  474   1.3   445   1.0   29   6.5   577   1.6   474   1.3   103   21.7 

Europe

  3,973   11.0   4,578   11.0   (605

)

  (13.2

)

  3,225   9.2   3,973   11.0   (748

)

  (18.8

)

Asia

  2,545   7.1   2,453   5.9   92   3.8   4,294   12.3   2,545   7.1   1,749   68.7 

Consolidated total

 $36,116   100.0

%

 $41,789   100.0

%

 $(5,673

)

  (13.6

)%

 $35,055   100.0

%

 $36,116   100.0

%

 $(1,061

)

  (2.9

)%

 


7

 

The following table sets forth, as of December 31, 20182019 and 2017,2018, the number of our active distributorsRetail Customers/Preferred Customers/Active Distributors and Master Affiliates and above. The total number of active distributors includes Master Affiliates and above. We define an active retail or preferred customer as one that has placed a product order in the prior twelve months, and we define an active distributor as one that enrolls as a distributor or renews his or her distributorship during the prior twelve months. Many individuals join Reliv as distributors to obtain our products at a discount and may not participate in the Reliv business opportunity. Master Affiliates and above are distributors that have attained the highest level of discount and are eligible for royalties generated by Master Affiliate groups in their downline organization. We include Preferred Customers as part of our Active Distributor count, and Preferred Customers represent approximately 5,060 and 4,990 of the Active Distributor count as of December 31, 2018 and 2017, respectively.

 

Active Distributors/Master

 

December 31, 2018

  

December 31, 2017

  

% Change

 

Affiliates by Market

 

 

Active

Distributors

and Preferred

Customers

  

Master

Affiliates and

Above

  

Active

Distributors

and Preferred

Customers

  

Master

Affiliates and

Above

  

Active

Distributors

and Preferred

Customers

  

Master

Affiliates and

Above

 
                         

United States

  19,810   2,340   23,050   2,820   (14.1

)%

  (17.0

)%

Australia/New Zealand

  960   90   1,100   110   (12.7

)

  (18.2

)

Canada

  560   80   660   90   (15.2

)

  (11.1

)

Mexico

  970   90   710   60   36.6   50.0 

Europe

  2,980   390   3,800   450   (21.6

)

  (13.3

)

Asia

  5,090   380   4,300   380   18.4   0.0 

Consolidated total

  30,370   3,370   33,620   3,910   (9.7

)%

  (13.8

)%

Retail and Preferred Customers/Active Distributors/Master Affiliates and Above by Market

  

As of 12/31/2019

 
  

Retail

Customers

  

Preferred

Customers

  

Active

Distributors

  

Total Customers

and Distributors

  

Master

Affiliates and

Above

 
                     

United States

  3,500   1,500   17,580   22,580   2,110 

Australia/New Zealand

  50   210   660   920   80 

Canada

  90   30   470   590   60 

Mexico

  20   100   1,160   1,280   100 

Europe

  740   690   1,650   3,080   330 

Asia

  1,910   6,790   4,210   12,910   620 
                     

Consolidated Total

  6,310   9,320   25,730   41,360   3,300 

  

As of 12/31/2018

 
  

Retail

Customers

  

Preferred

Customers

  

Active

Distributors

  

Total Customers

and Distributors

  

Master

Affiliates and

Above

 
                     

United States

  4,190   1,470   18,340   24,000   2,340 

Australia/New Zealand

  50   240   720   1,010   90 

Canada

  100   30   530   660   80 

Mexico

  10   110   860   980   90 

Europe

  550   1,120   1,860   3,530   390 

Asia

  2,820   2,090   3,000   7,910   380 
                     

Consolidated Total

  7,720   5,060   25,310   38,090   3,370 

  

Change in %

 
  

Retail

Customers

  

Preferred

Customers

  

Active

Distributors

  

Total Customers

and Distributors

  

Master

Affiliates and

Above

 
                     

United States

  -16.5%  2.0%  -4.1%  -5.9%  -9.8%

Australia/New Zealand

  0.0%  -12.5%  -8.3%  -8.9%  -11.1%

Canada

  -10.0%  0.0%  -11.3%  -10.6%  -25.0%

Mexico

  100.0%  -9.1%  34.9%  30.6%  11.1%

Europe

  34.5%  -38.4%  -11.3%  -12.7%  -15.4%

Asia

  -32.3%  224.9%  40.3%  63.2%  63.2%
                     

Consolidated Total

  -18.3%  84.2%  1.7%  8.6%  -2.1%

8

 

Use of Non-GAAP Financial Information

 

Net sales expressed in local currency or net sales adjusted for the impact of foreign currency fluctuation are non-GAAP financial measures. We use these measurements to assess the level of business activity in a foreign market, absent the impact of foreign currency fluctuation relative to the U.S. dollar, which our local management has no ability to influence. This is a meaningful measurement to management, and we believe this is a useful measurement to provide to shareholders.

 

The following table provides key statistics related to distributor activity by market and should be read in conjunction with the following discussion.

 

Distributor Activity by Market

                         

International

 
  

United States

  

AUS/NZ

  

Canada

  

Mexico

  

Europe

  

Asia

  

-- Total

 

Sales in USD (in 000's):

                            

Year ended 12/31/2018

 $27,673  $732  $719  $474  $3,973  $2,545  $8,443 

Year ended 12/31/2017

 $32,475  $923  $915  $445  $4,578  $2,453  $9,314 
                             

% change in sales-2018 vs. 2017:

                            

Change in GAAP sales in USD

  -14.8%  -20.7%  -21.4%  6.5%  -13.2%  3.8%  -9.4%

Due to currency fluctuation

  -   -2.1%  0.1%  -2.1%  3.0%  -4.1%  0.0%

Sales in local currency (non-GAAP)

  -14.8%  -18.6%  -21.5%  8.6%  -16.2%  7.9%  -9.4%
                             

# of new distributors-2018(1)

  3,696   146   106   558   1,258   3,042   5,110 

# of new distributors-2017(1)

  4,667   168   145   271   1,646   2,632   4,862 

% change

  -20.8%  -13.1%  -26.9%  105.9%  -23.6%  15.6%  5.1%
                             

# of new Master Affiliates-2018

  330   9   14   50   86   171   330 

# of new Master Affiliates-2017

  534   8   15   15   108   215   361 

% change

  -38.2%  12.5%  -6.7%  233.3%  -20.4%  -20.5%  -8.6%
                             

# of Product orders-2018

  107,731   4,452   2,418   3,496   13,000   29,791   53,157 

# of Product orders-2017

  125,648   5,537   3,060   3,235   16,246   25,926   54,004 

% change

  -14.3%  -19.6%  -21.0%  8.1%  -20.0%  14.9%  -1.6%

(1)   The new distributor totals for 2018 and 2017 include 3,727 and 3,587, respectively, new worldwide preferred customers.

Distributor Activity by Market

                         

 

 
  

United States

  

AUS/NZ

  

Canada

  

Mexico

  

Europe

  

Asia

  

International-- Total

 

Sales in USD (in 000's):

                            

Year ended 12/31/2019

 $25,747  $595  $617  $577  $3,225  $4,294  $9,308 

Year ended 12/31/2018

 $27,673  $732  $719  $474  $3,973  $2,545  $8,443 
                             

% change in sales-2019 vs. 2018:

                            

Change in GAAP sales in USD

  -7.0%  -18.7%  -14.2%  21.7%  -18.8%  68.7%  10.3%

Due to currency fluctuation

  -   -5.7%  -2.1%  -0.3%  -3.7%  2.6%  -1.6%

Sales in local currency (non-GAAP)

  -7.0%  -13.0%  -12.1%  22.0%  -15.1%  66.1%  11.9%
                             

# of new Preferred customers-2019

  1,239   71   26   83   469   5,815   6,464 

# of new Preferred customers-2018

  1,352   97   25   112   682   1,459   2,375 

% change

  -8.4%  -26.8%  4.0%  -25.9%  -31.2%  298.6%  172.2%
                             

# of new distributors-2019

  2,849   52   49   707   455   2,420   3,683 

# of new distributors-2018

  2,344   49   81   446   576   1,583   2,735 

% change

  21.5%  6.1%  -39.5%  58.5%  -21.0%  52.9%  34.7%
                             

# of new Master Affiliates-2019

  448   11   7   39   67   428   552 

# of new Master Affiliates-2018

  330   9   14   50   86   171   330 

% change

  35.8%  22.2%  -50.0%  -22.0%  -22.1%  150.3%  67.3%
                             

# of Product orders-2019

  101,663   3,774   2,109   4,061   10,856   41,414   62,214 

# of Product orders-2018

  107,731   4,452   2,418   3,496   13,000   29,791   53,157 

% change

  -5.6%  -15.2%  -12.8%  16.2%  -16.5%  39.0%  17.0%

 


9

 

United States

 

Net sales in the United States declined by 14.8%7.0% in 20182019 compared to the prior year as all measurements of distributor activity declined. Netyear. Direct selling net sales in the United States in 2018 included2019 declined by 4.9% as the number of product orders dropped by 5.6%. Net sales in the U.S. in 2019 no longer include contract packaging sales as these operations were divested in January 2019. Contract manufacturing sales represented $1.44 million in contract manufacturing2018. These sales as we utilized our manufacturing facility for third-party production, beginning in mid-2018.

In May 2018, we launched Reliv Now® with Whey to provide our cornerstone Now product in an alternative protein source. In 2018, Now with Whey represented 2.0%were partially offset by leasing revenue from Nutracom of network marketing net sales in the United States.$783,000.

 

Products in the LunaRich line, including Reliv Now® and LunaRich X™, continued to perform well, constituting 15.9%14.6% and 12.4%11.6% of net sales in the United States, respectively, in 2018.2019. Reliv Now and LunaRich X represented 16.7%15.9% and 13.5%12.4%, respectively, of net sales in the United States in the prior year. Sales of the Fit3 product line represented 3.5% of net sales in the U.S. in 2018 compared to 6.1% of net sales in the prior year.

 

Distributor/Preferred Customer enrollments decreased by 20.8%In late June 2019, we introduced our RLV line of hemp-extract products. Initially, the RLV line includes three liquid tinctures and one balm. All of the RLV products are derived from organically-grown, non-GMO hemp. The RLV line represented 4.9% of net sales in 2018 compared to the prior year.

Distributor retention was 73.5% for the twelve month period ended December 31, 2018 compared to 71.5% for all of 2017. Distributor retention is determined by the percentage of active distributors from 2017 that renewed their distributorshipsUnited States in 2018.2019.

 

New Master Affiliate qualifications decreasedincreased by 38.2%35.8% in 20182019 compared to the prior year, and Master Affiliate retention improved toremained comparable at 71.2% in 2019 versus 71.3% in 2018 compared to 56.0% in 2017.2018. Master Affiliate retention is defined by the percentage of Master Affiliates as of end of 20172018 that requalified their distributorships as Master Affiliates during 2018. Our Master Affiliate count and new2019. New Master Affiliate qualifications have been negatively impacted sinceimproved in response to a cash bonus incentive in place beginning in Q1 2019 and an incentive trip promotion that took place in Q4 2019.

Distributor retention was 80.3% for the increased business volume requirementstwelve-month period ended December 31, 2019 compared to 73.5% for all of 2018. Distributor retention is determined by the percentage of active distributors from 2018 that renewed their distributorships in February 2016 to reach the Master Affiliate level.2019.

 

Our average order size in 2018 decreased2019 increased by 5.1%1.5% to $337$342 at suggested retail value compared to the prior year. Theyear; however, the number of product orders also decreased by 14.3%5.6% in 20182019 compared to the prior yearyear.

In March 2019, we introduced a feature in our compensation plan in the United States to pay the wholesale profit earned by distributors on a weekly basis. This feature does not alter the timing of the expense recognition of the commission earnings, but does speed up the timing of the wholesale commission payment.

In January 2019, we sold substantially all of the machinery, equipment, inventory, tools and other assets and materials used in our manufacturing operations to Nutracom. Nutracom is substantially owned and is controlled by former officers/employees of Reliv. Nutracom is leasing the manufacturing space in our facility for the same reasons as the overall decrease in sales.a period of seven years, with an option to renew for a five-year term. We also entered into agreements whereby Nutracom will continue to manufacture our core products on our premises for a period of seven years.

 

International Operations

 

 

The average foreign exchange rate for the U.S. dollar for 20182019 was stronger against most of the currencies in which we conduct business, except for the Canadian dollar, British pound and Euro,Philippine peso, when compared to the average foreign exchange rates for the year ended December 31, 2018. However, inIn the aggregate, foreign currency fluctuations in 20182019 had virtually noa negative impact of 1.6% on foreign sales reported in U.S. dollars.

We continue to review prices and margins in all of our international markets and plan to make adjustments as needed, as we increased prices in most of our markets in 2018. We are also reviewing sales by product to phase out products with lower sales levels and gross margins as strategically appropriate.

We closed our operations in Indonesia effective June 30, 2018 due to weak sales and minimal distributor activity.

 

Australia/New Zealand and Canadian net sales in 20182019 decreased by 18.6%13.0% and 21.5%12.1%, respectively, in local currency compared to 2017the prior year as the result of decreased distributor activity in the market. We terminated our sales manager in AUS/NZ during Q2 2018.

 

Net sales in Mexico increased by 8.6%22.0% in local currency in 20182019 compared to the prior year. SalesDistributor activity has increased in Mexico have begunrecent quarters subsequent to rebound as we have installed new promotions in the market and supported it with additional corporate-sponsored events. During Q3 2018, we retainedretaining a sales consultant with prior experience in another network marketing companydirect selling sales in Mexico. In Q4 2018, net sales in MexicoNew distributor enrollments increased by 35.1%58.5% in 2019 compared to the prior-year quarter.prior year. Product order count increased by 16.2% in 2019 as well.

 

Net sales in Europe decreased by 16.2%15.1% in local currency in 20182019 compared to the prior year. Distributor activity declinedcontinues to decline both in the form of new distributor and preferred customer enrollments and number of product orders placed in the region.

 

Sales in Asia increased by 7.9%66.1% in local currency in 20182019 compared to the prior year. Local currencyyear, driven primarily by sales growth in the Philippines, our largest market in the region,region. All measures of distributor and preferred customer activity have grown rapidly. New preferred customer and distributor enrollments increased by 10.3%299% and 53%, respectively, in 20182019 compared to the prior year. Distributor and customer activity continues to accelerate in the region asThe number of new distributor/preferred customer enrollmentsMaster Affiliate qualifications increased by 15.6% in 2018150% and the product orders in 2018order count increased by 14.9%.39.0% in 2019 compared to the prior year.

 


10

 

Costs and Expenses

 

The following table sets forth selected results of our operations expressed as a percentage of net sales for the years ended December 31, 20182019 and 2017.2018. Our results of operations for the periods described below are not necessarily indicative of results of operations for future periods.

 

Statement of Operations data

                                

(amounts in thousands)

 

2018

  

2017

  

2019

  

2018

 
 

Amount

  

% of net sales

  

Amount

  

% of net sales

  

Amount

  

% of net sales

  

Amount

  

% of net sales

 
                                

Net sales

 $36,116   100.0

%

 $41,789   100.0

%

 $35,055   100.0

%

 $36,116   100.0

%

                                

Costs and expenses:

                                

Cost of products sold

  9,710   26.9   9,401   22.5 

Cost of goods sold

  9,557   27.3   9,710   26.9 

Distributor royalties and commissions

  11,749   32.6   14,686   35.1   11,259   32.1   11,749   32.6 

Selling, general and adminstrative

  16,521   45.7   17,885   42.8 

Selling, general and administrative

  14,798   42.2   16,521   45.7 
                                

Loss from operations

  (1,864)  (5.2)  (183)  (0.4)  (559)  (1.6)  (1,864)  (5.2)

Interest income

  93   0.3   102   0.2   178   0.5   93   0.3 

Interest expense

  (96)  (0.3)  (109)  (0.3)  (47)  (0.1)  (96)  (0.3)

Other income

  62   0.2   38   0.1   17   0.1   63   0.2 

Gain (loss) of sale of fixed assets

  435   1.2   (1)  - 
                                

Loss before income taxes

  (1,805)  (5.0)  (152)  (0.4)

Income (loss) before income taxes

  24   0.1   (1,805)  (5.0)

Provision for income taxes

  98   0.3   545   1.3   468   1.4   98   0.3 
                                

Net loss

 $(1,903)  (5.3

)%

 $(697)  (1.7

)%

 $(444)  (1.3

)%

 $(1,903)  (5.3

)%

                                

Loss per common share-Basic

 $(1.03)     $(0.38)     $(0.25)     $(1.03)    

Loss per common share-Diluted

 $(1.03)     $(0.38)     $(0.25)     $(1.03)    

 

 

 

Cost of ProductsGoods Sold:

 

The cost of productsgoods sold as a percentage of net sales in 20182019 increased by 4.4%0.4% compared to the prior-year period. The cost of products soldgoods as a percentage of net sales in 2018 was negatively impacted by the contract manufacturing business, which has a lower margin than the network marketing sales. Cost of products sold as a percentage of net sales was also negatively impacted byseveral factors, including promotions in the United States that reduced our handlingfreight income and freight income.the lower gross margin percentage associated with our leasing revenue which began in 2019.

 

Distributor Royalties and Commissions:

 

Distributor royalties and commissions as a percentage of net sales for 20182019 decreased by 2.5%0.5% of net sales when compared to the prior-year period. OverThis decrease is primarily due to the courseinclusion of 2017, we increased the prices of our productsleasing revenue in most of our markets, with prices increased in the U.S. and Canada effective November 1, 2017. As part of the price increase, we did not increase the BV of the products. The BV represents the amount per commissionable product that is paid incurrent year net sales on which distributor royalties and commissions. This accounts for the slight decrease in royalties and commissions expense as a percentage of net sales. Net sales from contract manufacturing also slightly reduced this percentage as commissions are not paid on these sales.paid.

 


11

 

Selling, General and Administrative Expenses:

 

Selling, general and administrative (“SGA”) expenses declined by $1.36$1.72 million in 2018 compared to the prior-year period but increased2019 and decreased as a percentage of net sales duewhen compared to declining sales.the prior-year period.

 

SGA expenses, including salaries and other staffing expenses, related to the manufacturing/Nutracom operations represent a net decrease of $1.19 million of the SGA decrease in 2019, compared to the prior-year period

Other SGA Salaries, other staffing expenses, benefits, and incentive compensation decreased in the aggregate by $723,000$292,000 in YTD 20182019 compared to the prior-year period.

 

Sales and marketing expenses decreased by $801,000$118,000 in 20182019 compared to the prior-year period. Components of the decrease, with offsets in certain increases, include:

 

o

$368,000130,000 decrease in distributor conferences and meeting expenses as we held smaller regional events in the U.S. in 2019.

o

$61,000 increase in Star Director and other distributor bonuses, credit card fees, and other expenses related to the level of sales.

 

o

$73,000112,000 increase in promotion and incentive trip expenses in the United States and Philippines compared to prior year.

o

$37,000 decrease in video production and other sales development expense in 20182019 compared to the prior-year period. The decrease relates to Fit3 new product launch expenses incurred in Q1 2017.

 

o

$118,000110,000 decrease in distributor conferencesother sales and meetingmarketing expenses, including a $55,000 reduction in newsletter expenses as we held two smaller spring and fall conferencesdiscontinued most printed newsletters in the U.S. in 2018 versus one major conference.

o

$69,000 decrease in promotions expense as we have reduced such activities in 2018 relative to the level of sales.2019.

 

Other general and administrative expenses increaseddecreased by $160,000$244,000 in 20182019 versus the prior-year period. ComponentsSignificant components of the increasedecrease include:

 

o

$130,000 increase in consulting fees due to the conversion of a former R&D employee to a consulting arrangement, a consulting arrangement related to contact manufacturing business, and the addition of a sales consultant in Mexico in the latter half of 2018.

o

$107,000 increase180,000 decrease in legal fees

 

o

$60,000 increase68,000 decrease in accounting fees

o

An increase of $141,000 in the expense on a key-man life insurance policy that was redeemed during 2018.

Offsetting reductions include:

o

$95,000 reduction in depreciation expense.

o

$66,000 reduction in directors’ fees.

o

$47,000 reduction in corporate travel expenses.

General and administrative expenses in Indonesia for 2018 included $52,000 of severance and other expenses related to the closing of the office and operations in that country in June 2018.

 

Other Income/Expense:

 

The other income in 20182019 and 20172018 is primarily the result of foreign currency exchange gains on intercompany debt denominated in U.S. dollars in certain of our subsidiaries.

2019 includes $435,000 in income from the sale of our manufacturing equipment as part of the asset sale with Nutracom in Q1.

 

Income Taxes:

 

We reported income tax expense of $98,000$468,000 for 2018,2019, compared to income tax expense of $545,000$98,000 in 2017.2018.

 

During the fourth quarter of 2017, we determined that itOur income tax expense for 2019 was more likely than not that operating resultsrelated to income taxes on our earnings in our European subsidiary would not be sufficient to realize our net operating loss carryforwards. Accordingly, we placed a valuation allowance of $509,000Philippine entity, audit settlements for FY 2004 through 2006 and 2017 on our deferredPhilippine entity, and minimum U.S. state income tax asset in that subsidiary.

During 2016, we determined that it was more likely than not that Federal and various state net operating losses generated in 2016 and beyond will not be realized based on projections of future taxable income and other considerations. Accordingly, the tax provisions as of December 31, 2018 and 2017 include the impact of recording a valuation allowance of $265,000 and $198,000, respectively, against the losses generated from a U.S. tax perspective.expense.

 

See Note 1213 of the Consolidated Financial Statements for additional detail regarding income taxes, including a reconciliation of the income tax expense/benefit to the U.S. statutory rate for each period.

 

Net Loss:

 

For 2018,2019, we reported a net loss of $1.90 million$444,000 compared to a net loss of $697,000$1.90 million in 2017.2018. The increasedecrease in the net loss is primarily the result of the decrease in net sales inSGA expenses, coupled with the United States.gain on the sale of fixed assets as part of the asset sale with Nutracom.

 


12

 

Liquidity and Capital Resources

 

In 2018,2019, we used $1.17 million$943,000 of net cash in operating activities, $3.01 million$64,000 was provided by investing activities, and we used $3.05 million in$500,000 was provided by financing activities. This compares to $157,000$1.17 million used in operating activities, $377,000 used in$3.01 million provided by investing activities, and $136,000 generated$3.05 million used in financing activities in 2017.2018. Cash and cash equivalents decreased by $1.28$359,000 to $1.63 million as of December 31, 2019 compared to $1.99 million as of December 31, 2018 compared to $3.27 million as of December 31, 2017.2018.

 

Significant changes in working capital items consisted of an increase in trade/accounts receivable and deposits to related parties of $377,000,$645,000, a decrease in inventory of $844,000, a decrease in prepaid expenses and an increaseother current assets of $143,000, and a decrease in accounts payable, and accrued expenses, deferred revenue and non-current liabilities of $366,000$784,000 in 2018.2019. The increase in accounts receivable and deposits is primarily the result of deposits required on production purchase orders to Nutracom, in accordance with the supply agreement executed as of January 1, 2019. The decrease in inventory is the result of trade receivablesthe timing of the transfer of finished goods from contractNutracom to us under the terms of the supply agreement, partially offset by cash payments for finished goods. The decrease in prepaid expenses and other current assets is the result of the divestiture of manufacturing customers duringoperations to Nutracom, and the fourth quarter of 2018. The increasedecrease in accounts payable and accrued expensesother liabilities is the result of an increasedecrease in trade payables related to the contract manufacturing work as of December 31, 2018 compared to December 31, 2017.we no longer are responsible for stocking raw materials for production.

 

Investing activities during 20182019 consisted of $3.07 million$162,000 in proceeds provided by the redemption of a life insurance policy and payments received on a distributor and other related party note receivable, of $116,000, offset by a netan investment of $173,000$99,000 for capital expenditures. Financing activities during 20182019 consisted of principal paymentsborrowings of $3.05 million$500,000 on long-term borrowings.a revolving line of credit.

 

Stockholders’ equity decreased to $11.10 million at December 31, 2019 compared to $11.99 million at December 31, 2018 compared to $14.36 million at December 31, 2017.2018. The decrease is primarily due to our net loss during 20182019 of $1.90 million, an unfavorable$444,000 and $540,000 in treasury stock acquired under the purchase agreement with Nutracom, offset by a favorable adjustment in foreign currency translation of $124,000, and a reduction of $368,000 due to the recognition of deferred revenue under ASU No. 2014-09.$45,000. Our working capital balance was $1.88 million at December 31, 2019 compared to $4.17 million at December 31, 2018 compared to $2.14 million at December 31, 2017.2018. The current ratio at December 31, 20182019 was 2.071.47 compared to 1.342.07 at December 31, 2017.

In July 2018, management voluntarily elected to redeem the cash surrender value (CSV) of our whole life insurance policy maintained on the life of our Board of Directors’ Chairman and former Chief Executive Officer. Upon redemption and related receipt of the $3.07 million CSV proceeds, we simultaneously remitted to our lender $2.86 million of the CSV proceeds to be applied towards the full reduction of our outstanding term loan and revolver loan balances. Following this series of July 2018 transactions, the balances of our term loan, revolver loan, and life insurance policy balances were zero.2018.

 

In September 2018, the maximum borrowing amount on our revolving line of credit was reduced from $2.0 million to $750,000. As amended, the revolver’s maturity date remained April 29, 2019 and the revolver’s interest rate continued to be based on the 30-day LIBOR plus 2.25%. As of December 31, 2018, there were no outstanding borrowings on the revolving line of credit. In January 2019, we borrowed $500,000 under our revolving line of credit. In March 2019, the revolving line of credit’s maturity date was extended to April 28, 2020, and the interest rate was revised to the 30-day LIBOR plus 3.00%. As amended, the revolver’s maximum borrowing amount remains $750,000. As of December 31, 2019, we have borrowed $500,000 under our revolving line of credit. Borrowings under the lending agreement continue to be secured by all our tangible and intangible assets and by a mortgage on the real estate of our corporate headquarters.

 

We have experienced significant losses over the last several years and may experienceexperienced a loss in 2019. Our existing cash, cash equivalents, operating revenue and borrowing facilities may not be sufficient to fund our operating expenses through the next 12 months which would require us to obtain additional financing before that time. We hashave taken several steps which management believes will result in an improved financial position, operating results, and cash flows. Over the last several years, we have also taken other cost cutting measures including reductions in staff, freezing or lowering salaries, limiting promotional events all in an effort to reduce operating expenses.

 


As detailed in Note 2 of the accompanying consolidated financial statements, in January 2019, we entered into a Purchase Agreement with Nutracom LLC (Nutracom) pursuant to which Nutracom purchased the assets used by us in our manufacturing operations. Assets purchased by Nutracom from us were financed by us under payment terms scheduled to provide incoming funds to us of $200,000$100,000 or more per year. We have also entered into an agreement for Nutracom to lease a significant portion of our headquarters building. Management believes that these transactions with Nutracom will be favorable to our financial position, operating results, and cash flows; however, there are risks and uncertainties which arise with these Nutracom transactions and their impact to our operations.

 

Should the aforementioned changes to the company’s operations not provide sufficient cash flow improvement or should we be unable to obtain sufficient additional capital or borrowings, we may have to engage in any or all of the following activities: (i) monetize our headquarters building via traditional bank lending or a sale and leaseback-type transaction; (ii) seek to monetize a note receivable from athe related parties; (iii) modify our distributor (see Note 11 of the accompanying consolidated financial statements); (iii) restructure our core distributor business model including recruiting, promotions, incentives, and other activities; (iv) cease operations in certain geographic regions, and (v) reduce employee compensation and benefits.

13

 

We may not be able to obtain sufficient additional funding through monetizing certain of our existing assets, sourcing additional borrowings, and issuing additional equity, or any other means, and if we are able to do so, these available sources of funds may not be on satisfactory terms. Our ability to raise additional capital in the equity markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common stock, which itself is subject to a number of business risks and uncertainties, as well as the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us.

 

These actions may have a material adverse impact on our ability to achieve certain of our planned objectives. Even if we are able to source additional funding, we may be forced to significantly reduce our operations if our operating performance does not improve. If we are unable to source additional funding, we may be forced to significantly reduce or shut down our operations. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effect on our assets or liabilities should we not be able to continue as a going concern.

 

Critical Accounting PoliciesPolicies

 

Our financial statements are based on the selection and application of significant accounting policies, which require management to make significant estimates and assumptions. We believe that the following are some of the more critical judgment areas in the application of our accounting policies that currently affect our financial condition and results of operations.

 

Revenue

 

On January 1, 2018, we adopted Accounting Standards Update (ASU) No. 2014-09, RevenueWe recognize revenue from Contracts with Customers (including amendments), and applied the new revenue standard to all contracts using the modified retrospective method. Under this method, prior periods were not restated. Upon adoption, we recognized the cumulative effect of applying the new revenue standard as a reduction of $367,568 (with zero net tax effect) to the opening retained earnings (accumulated deficit) balance.

The new revenue standard definesproduct sales under a five step process to recognize revenues. We account for a contract with our independent distributors (including customers) when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. Product sales revenue (principally nutritional and dietary supplements) and commission expenses are recorded when control is transferred to the independent distributors, which occurs at the time of shipment. Generally, net sales reflect product sales less the distributor discount of 20 percent to 40 percent of the suggested retail price. We present distributor royalty and commission expense as an operating expense, rather than a reduction to net sales, as these payments are not made to the purchasing distributor. At point of sale, we receive payment by credit card, personal check, or guaranteed funds for contracts from independent distributors and make related commission payments inno later than the following month.

 


Under this new revenue standard, we determined thatWe recognize the timeframe for recognizing the revenue performance obligation for membership fees-type revenue would be lengthened to more closely correlate withover the distributor (including customer) membership termsterm of generally twelve months. Based upon all membership fees contracts still in existence as of December 31, 2017, the adoption of the new revenue standard resulted in the recognition of a deferred revenue liability balance of $367,568. We receive payment for membership fees at the beginning of the annual membership term and recognize membership fees revenue on a straight-line basis in correlation with the completion of our performance obligation under the membership term. At December 31, 2018, theOur remaining unearned membership fees obligations is reported as deferred revenue liability balance was $337,234.liability.

 

Actual and estimated sales returns are classified as a reduction of net sales. We estimate and accrue a reserve for product returns based on our return policy and historical experience. Our returnproduct returns policy allows for distributors to return product only upon termination of his or her distributorship. Allowable returns are limited to saleable product which was purchased within twelve months of the termination for a refund of 100% of the original purchase price less any distributor royalties and commission received relating to the original purchase of the returned products. For the years ended December 31, 20182019 and 2017,2018, total returns as a percent of net sales were approximately 0.17%0.08% and 0.25%0.17%, respectively.

 

We record handling and freight income as a component of net sales and record handling and freight costs as a component of cost of productsgoods sold. Total net sales do not include sales tax as we consider ourselves a pass-through conduit for collecting and remitting applicable sales taxes.

 

14

Other revenue consists of revenue derived from our leasing a portion of our headquarters building to Nutracom beginning January 1, 2019. The leased space encompasses manufacturing, warehouse, and certain office space. We do not anticipate thatrecognize lessor rent revenue on a straight-line basis over the adoptionterm of the newlease. As part of this straight-line methodology, the cumulative facility rental billings may be greater or less than the financial period’s recognized revenue; such timing differences are recognized on the balance sheet as an accrued other liability or an unbilled rent revenue standard will be materialreceivable. Also included in other revenue are billings to net salesthe tenant for its share of the facility’s common area costs such as real estate taxes, maintenance, and net income on an ongoing basis.utilities. These same common area costs plus the tenant’s share of the facilities’ depreciation are recorded as cost of goods sold.

 

Inventories

 

Inventories are valued at the lower of cost or market. Product cost includesmarket and are accounted for on a first-in, first-out basis. Effective January 1, 2019, finished goods inventories primarily consist of purchased products held for resale. Prior to 2019, finished goods inventories were primarily comprised of internally manufactured products consisting of the costs associated with raw material, labor and overhead costs and is accounted for using the first-in, first-out basis.overhead. On a periodic basis, we review our inventory levels in each country for estimated obsolescence or unmarketable items, as compared to future demand requirements and the shelf life of the various products. Based on this review, we record inventory write-downs when costs exceed expected net realizable value. Historically, our estimates of obsolete or unmarketable items have been materially accurate.

 

Sales aids and promotional materials inventories represent distributor kits, product brochures, and other sales and business development materials which are held for sale to distributors. Costs of the sales aids and promotional materials held for sale are capitalized as inventories and subsequently recorded to cost of goods sold upon recognition of revenue when sold to distributors. All other advertising and promotional costs are expensed when incurred.

 

Variable Interest Entities (VIE) - Unconsolidated

Effective January 1, 2019, we have a financial interest in Nutracom. If we are the primary beneficiary of a VIE, we are required to consolidate the VIE in our consolidated financial statements. To determine if we are the primary beneficiary, we evaluate whether we have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. Our VIE evaluation requires significant assumptions and judgments.

We do not have the power to direct the significant activities of Nutracom, primarily because we do not have governance rights. We also do not participate in the annual profits or losses of Nutracom. Therefore, we do not consolidate the financial results of Nutracom in our consolidated financial statements. We account for our financial interest in Nutracom as an equity investment measured at cost minus impairment, if any. A cost method equity investment is subject to periodic impairment review using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and our ability and intent to hold the investment for a sufficient period of time to allow for recovery.

Concentrations of Risk

Effective January 1, 2019, we have entered into outsourcing agreements with Nutracom to manufacture our nutritional and dietary supplements and for warehousing and fulfillment services for the U.S. distribution of our products. Nutracom has also issued promissory notes to us for the acquisition of our manufacturing and fulfillment operations. Any inability of Nutracom to deliver these contracted services or to repay the promissory notes could adversely impact our future operating results and valuation of our Nutracom equity investment.

15

Legal Proceedings

 

In the ordinary course of business, we are subject to various legal proceedings, including lawsuits and other claims related to labor, product and other matters. We are required to assess the likelihood of adverse judgments and outcomes to these matters as well as the range of potential loss. Such assessments are required to determine whether a loss contingency reserve is required under the provisions of FASB ASC Topic 450, “Contingencies,” and to determine the amount of required reserves, if any. These assessments are subjective in nature. Management makes these assessments for each individual matter based on consultation with outside counsel and based on prior experience with similar claims. To the extent additional information becomes available or our strategies or assessments change, our estimates of potential liability for a given matter may change. Changes to estimates of liability would result in a corresponding additional charge or benefit recognized in the statement of operations in the period in which such changes become known. We recognize the costs associated with legal defense in the periods incurred. Accordingly, the future costs of defending claims are not included in our estimated liability.

 


Income Tax Matters

 

We account for income taxes in accordance with FASB ASC Topic 740, “Income Taxes,” (ASC Topic 740) which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. ASC Topic 740 also requires that deferred tax assets be reduced by a valuation allowance if it is “more likely than not” that some portion or the entire deferred tax asset will not be realized. In our quarterly evaluation of the need for a valuation allowance, we consider and weigh both positive and negative factors, including the expected level of future taxable income and available tax planning strategies. If actual results differ from the assumptions made in our previous evaluation of our valuation allowance, we may record a change in valuation allowance through income tax expense in the period this determination is made.

 

The calculations of our tax liabilities involve dealing with uncertainties in the application of complex tax regulations. We recognize liabilities for uncertain tax positions based on the two-step process prescribed in the guidance under ASC Topic 740. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as we have to determine the probability of various possible outcomes. We re-evaluate these uncertain tax positions on a quarterly basis. This evaluation is based on factors including, but not limited to, changes in facts or circumstances, changes in tax law, effectively settled issues under audit, or new audit activity. Such a change in recognition or measurement would result in the recognition of a tax benefit or an additional charge to the tax provision.

 

During 2016 2017 and 2018,through 2019, we determined that it was more likely than not that U.S. federal and various state net operating losses primarily generated in these years will not be realized based on projections of future U.S. taxable income, estimated reversals of existing taxable timing differences, and other considerations. Accordingly, the 20182019 and 20172018 income tax provisions include the impact of recording a full deferred tax asset valuation allowance of approximately $265,000$91,000 and $198,000$186,000 against the annual losses generated from a U.S. tax perspective.

 

At December 31, 2018,2019, we had deferred tax assets related to net operating loss carryforwards and other income tax credits in our foreign operations with a tax value of $3.1$3.3 million. These net operating loss carryforwards principally do not expire, depending on the country and period in which they occurred. As of December 31, 2017, we assessed the realizability of the European subsidiary’s deferred tax assets and concluded that future realization failed to meet the threshold of more likely than not based upon the subsidiary’s recent tax operating losses. Accordingly, we recorded a full valuation allowance to the European subsidiary’s deferred tax assets and recorded a deferred income tax charge of $509,000 at December 31, 2017. We continue to have a full valuation allowance applied to all other net operating loss carryforwards in our foreign operations.

The Securities and Exchange Commission (“SEC”) issued Staff Accounting Bulletin (“SAB”) 118 to provide guidance to companies on the reporting of the impacts of The United States Tax Cuts and Jobs Act in their financial statements.  Under SAB 118, we recorded affected items in fiscal year 2017 as provisional to allow additional time for clarifying technical guidance from Treasury and analysis of the effect to our current tax positions.  In 2018, we completed our analysis and did not record any adjustments to our 2017 provisional income tax amounts.

Current-Year Adoption of Recent Accounting Pronouncements

 

Discussion regarding our adoption of accounting pronouncements is included in Note 1 to the Consolidated Financial Statements.

 


16

 

Item No. 8 - Financial Statements and Supplementary Data

 

Reference is made to the Consolidated Financial Statements contained in Part IV hereof.

 

Item No. 9 - Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 

 

None

 

Item No. 9A - Controls and Procedures 

Evaluation of Disclosure Controls and Procedures

 

Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, has reviewed and evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2018.2019. Based on such review and evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures were effective as of December 31, 2018,2019, to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, (a) is recorded, processed, summarized and reported within the time period specified in the SEC’s rules and forms and (b) is accumulated and communicated to our management, including the officers, as appropriate to allow timely decisions regarding required disclosure.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting. Our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the 2013 framework in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. This evaluation included review of the documentation of controls, evaluation of the design effectiveness of controls, testing of the operating effectiveness of controls and a conclusion on this evaluation. Although there are inherent limitations in the effectiveness of any system of internal control over financial reporting, based on our evaluation, management has concluded our internal controls over financial reporting were effective as of December 31, 2018.2019.

 

Attestation Report of the Registered Public Accounting Firm 

 

This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit us to provide only management’s report in this Annual Report on Form 10-K.

 

Changes in Internal Control over Financial Reporting

 

There were no material changes in our internal control over financial reporting during the fourth quarter of 20182019 that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.

 

 

 

Item No. 9B - Other Information

 

None

 


17

 

PART III

 

Item No. 10 - Directors, Executive Officers and Corporate Governance

 

Information calledBoard of Directors

Name

Age

Position

Robert L. Montgomery

77

Director, Chairman of the Board

Ryan A. Montgomery

46

Director, Chief Executive Officer

John M. Klimek

60

Director

Robert M. Henry

72

Director

Paul J. Adams

59

Director

Robert L. Montgomery is the Chairman of the Board of Directors and former Chief Executive Officer. Mr. Montgomery became Chairman of the Board of Directors and Chief Executive Officer on February 15, 1985 and served as the Chief Executive Officer until June 2018. Mr. Montgomery served as President of the Company from July 1985 until July 2012. Mr. Montgomery had been the principal executive officer of the Company since its founding in 1985. Prior to that time, he held positions for a number of years as an executive officer of several life insurance companies. Mr. Montgomery received a B.A. degree in Economics from the University of Missouri in Kansas City, Missouri in 1965. Mr. Montgomery is the father of Ryan A. Montgomery, the Company’s Chief Executive Officer, and R. Scott Montgomery, the President of Operations and International.

Ryan A. Montgomery was appointed Chief Executive Officer in June 2018 and has served as a member of the Board of Directors since May 2018. Previously he was President from July 2012 to June 2018, Executive Vice President, Worldwide Sales from April 2007 to July 2012 and Vice President, Sales from 2004 to 2007. Mr. Montgomery served as Corporate Counsel from September 1999 to October 2004. Mr. Montgomery received his B.A. degree in Economics from Vanderbilt University and graduated from Saint Louis University Law School.

John M. Klimek has been a member of the Board of Directors since May 2010. Mr. Klimek has been a practicing attorney in Illinois since 1984 specializing in corporate and securities law.  From August 2004 to July 2018, Mr. Klimek was employed by ItemHFR Asset Management, LLC, Chicago, Illinois, a hedge fund management company, most recently as President.    He holds a B.S. in Accountancy from the University of Illinois and Juris Doctor Degree from the University of Illinois School of Law.  Mr. Klimek serves as the Chairman of the Compensation Committee and is a member of the Audit and Nominating Committees.  He is also a director of CTI Industries Corporation (NASDAQ – CTIB).

Robert M. Henry has been a member of the Board of Directors of the Company since November 2013. He was previously a member of the Board of Directors of the Company from May 2004 through May 2011. Mr. Henry is currently a private investor and business consultant. From January 2011 until May 2013, Mr. Henry served as Chief Executive Officer and Chairman of the Board for Immunotec, Inc., a public Canadian direct selling company that sells nutritional supplements (TSX Venture Exchange – IMM). From December 2004 to 2008, Mr. Henry served as Chairman and Chief Executive Officer of Arbonne International, Inc., a personal care products company. Mr. Henry received a B.S. degree in Accounting from Hunter College in New York and a J.D. from Brooklyn Law School. Mr. Henry serves as Chairman of the Audit Committee and a member of the Compensation and Nominating Committees.

Paul J. Adams has been a member of the Board of Directors of the Company since May 2019. He is the President/CEO of the Adams Resource Group, a company he formed in 2017 that consults to direct selling companies in their marketing/communications and management strategies. Mr. Adams has been actively involved in the direct selling channel for over 32 years, serving as the head of marketing, sales and general management for one of the largest supplier/partners in the industry, SUCCESS Partners/VideoPlus, prior to forming Adams Resource Group. Mr. Adams attended the University of Texas at Arlington.

18

Executive Officers

Name

Age

Position

Ryan A. Montgomery

46

Chief Executive Officer and Director

R. Scott Montgomery

50

President of Operations and International

Thomas W. Pinnock

69

President of Sales and Marketing

Stephen M. Merrick

78

Secretary and General Counsel

Steven D. Albright

58

Sr. Vice President and Chief Financial Officer

Debra P. Bernardoni

48

Sr. Vice President and Chief Operating Officer

Kurt C. Wulff

55

Sr. Vice President of Marketing

R. Scott Montgomery was appointed President of Operations and International in July 2018. Mr. Montgomery joined the Company in 1993 and previously served as President of Reliv Asia Pacific from July 2012 to July 2018, Executive Vice President and Chief Operating Officer from April 2007 to July 2012, Senior Vice President – Worldwide Operations from 2004 to 2007 and Vice President of International Operations from 2001 to 2004. Mr. Montgomery graduated from Southwest Missouri State University with a B.S. degree in Finance and Investments.

Thomas W. Pinnock was named President of Sales and Marketing in July 2018. Previously, Mr. Pinnock served as Executive Vice President, Chief of Sales from December 2016 to July 2018. Mr. Pinnock has been an independent distributor of the Company since January 1990 and has served previously as Senior Vice President - U.S. Sales from May 1992 to June 1994. Mr. Pinnock is a former Army officer, journalist, and published author. Mr. Pinnock holds a B.A. degree from Valencia College, Orlando, Florida and studied journalism at the University of Florida and the Defense Department School of Journalism.

Stephen M. Merrick has been Secretary and General Counsel since July 1989 and served as a member of the Board of Directors from 1989 to May 2013 and from May 2014 to May 2016. Mr. Merrick has been engaged in the practice of law for more than 45 years and has represented the Company since the Company’s founding. Mr. Merrick received a Juris Doctor degree from Northwestern University School of Law in 1966. He is also an officer and director of CTI Industries Corporation (NASDAQ – CTIB).

Steven D. Albright has been Senior Vice President and Chief Financial Officer since March 2005. Mr. Albright was the Vice President, Finance/Controller from 2002 to 2005 and was the Controller since 1992. Prior to his employment with the Company, Mr. Albright was employed from 1987 to 1992 as Assistant Controller for Kangaroos USA, Inc., an athletic shoe importer and distributor. For the period from 1983 to 1987, he was employed by the public accounting firm of Ernst & Young LLP. Mr. Albright received a B.S. degree in Accountancy from the University of Illinois at Urbana-Champaign and is a CPA.

Debra P. Bernardoni was appointed as Senior Vice President and Chief Operating Officer in July 2018. Previously, Ms. Hellweg served as Vice President, Operations June 2008 to July 2018.   She has been employed by the Company since 2004 and served as Director of Internal Audit from 2004 to 2008.   Prior to her employment with the Company, Ms. Bernardoni was a Manager with Deloitte & Touche LLP and Vice President & Auditor of Southwest Bank of St. Louis.  Ms. Bernardoni has a B.S.B.A. degree in Accounting from the University of Missouri and an MBA from Webster University and is a CIA.

Kurt C. Wulff was appointed Vice President of Marketing in 2005 and Senior Vice President of Marketing in 2019. He has been employed by the Company in marketing positions since 1999. Previously, Mr. Wulff had over 10 years of Part IIIsales and marketing experience in a variety of industries. He graduated from the University of Missouri-Columbia with a Bachelor of Journalism degree.

19

CORPORATE GOVERNANCE AND

THE BOARD OF DIRECTORS

General

The business and affairs of the Company are managed under the direction of the Board of Directors in accordance with the General Corporation Law of the State of Delaware and the Company’s Second Amended and Restated Certificate of Incorporation and Bylaws, as amended. Members of the Board are kept informed of the Company’s business through discussions with the Chairman and Chief Executive Officer and other officers, by reviewing materials provided to them and by participating in meetings of the Board of Directors and its committees.

For the period from May 2013 to May 2014, the Board had five members. From May 2014 to May 2016 the Board had seven members, and in May 2016 the Board reverted back to five members. The Board met four times during 2019. During 2019, no director attended less than 75% of the combined Board of Directors and Committee meetings. The Board has determined that Messrs. Henry, Klimek, and Adams are independent based on the application of the rules and standards of the Nasdaq Stock Market.

Board Leadership Structure

Our Board of Directors has appointed the Company’s former Chief Executive Officer, Robert L. Montgomery, to continue to serve as Chairman of the Board. In his role as Chairman of the Board, he presides over the meetings of the Board of Directors and communicates the decisions and directives of the Board to management.

Our Board of Directors recognizes that depending on the circumstances, other leadership models might be appropriate. Accordingly, the Board of Directors periodically evaluates its leadership structure.

The Board of Directors has not appointed a lead independent director at this time. The Board has evaluated whether appointing a lead independent director facilitates the ability of the Company’s independent directors to carry out their duties. The independent directors of the Board attend at least one executive session, and may call such further sessions as they deem necessary, at which only independent directors are present and at which the independent directors are free to discuss any aspect of the Company’s business and risk management without the influence of interested directors or management. In addition, all members of the Company’s Audit, Nominating and Compensation Committees have been determined by the Board of Directors to be independent based on the application of the rules and standards of the NASDAQ Stock Market.

Board Role in Risk Oversight

The Board of Directors plays an active role, as a whole and at the committee level, in overseeing management of the Company’s risks. The Board regularly reviews information regarding our credit, liquidity and operations, as well as the risks associated with each. The Audit Committee oversees management of financial risks through regular meetings with the Company’s independent registered public accounting firm and the Company’s Chief Financial Officer and Manager of Internal Audit. The Company’s Compensation Committee evaluates and addresses risks relating to executive compensation, our incentive compensation plans and other compensatory arrangements. The Nominating Committee manages risks associated with the independence of the Board of Directors and potential conflicts of interest. While each committee is incorporated by referenceresponsible for evaluating certain risks and overseeing the management of those risks, the entire Board of Directors is regularly informed through committee reports and management presentations to the definitive Proxy Statementfull Board about these and other operational risks.

Committees of the Board of Directors

The Board of Directors has standing Audit, Nominating, and Compensation Committees.

Audit Committee

Since 2000, the Company has had a standing Audit Committee, which is presently composed of Messrs. Henry (Chairman), Klimek, and Adams. Mr. Henry has been designated and is the Company’s “Audit Committee Financial Expert” pursuant to Item 401 of Regulation S-K of the Securities Exchange Act of 1934. The Audit Committee held six meetings during fiscal year 2019, including quarterly meetings with management, the Manager of Internal Audit and the independent registered public accounting firm to discuss the Company’s financial statements and control systems. Mr. Henry and each appointed member of the Committee satisfies the definition of “independent” as that term is defined in the rules governing companies whose stock is traded on the Nasdaq Stock Market. The Board of Directors has adopted a written charter for the 2019Audit Committee. A copy of the Audit Committee Charter has been posted and can be viewed on the Company’s Internet website at www.reliv.com under the section entitled “Investor Relations.” In addition, the Audit Committee has adopted a complaint monitoring procedure to enable confidential and anonymous reporting to the Audit Committee of concerns regarding, among other things, questionable accounting or auditing matters.

20

Report of the Audit Committee

The Audit Committee oversees the Company’s financial reporting process on behalf of the Board of Directors. Management has the primary responsibility for the financial statements and the reporting process including the systems of internal controls. In fulfilling its oversight responsibilities, the Audit Committee reviewed the audited financial statements in the Annual MeetingReport with management and the Company’s independent registered public accounting firm, Ernst & Young LLP, including a discussion of Shareholdersthe quality, not just the acceptability, of the accounting principles, the reasonableness of significant judgments, the clarity of disclosures in the financial statements and internal controls.

The Audit Committee reviewed with the independent registered public accounting firm, which is responsible for expressing an opinion on the conformity of those audited financial statements with U.S. generally accepted accounting principles, their judgments as to the quality, not just the acceptability, of the Company’s application of accounting principles and such other matters as are required to be held on May 23, 2019, which is expecteddiscussed with the Audit Committee in accordance with the standards of the Public Company Accounting Oversight Board (U.S.) (“PCAOB”) including but not limited to those matters required to be fileddiscussed by PCAOB Auditing Standard No. 16. In addition, the Audit Committee has discussed with the Commission within 120 days afterindependent registered public accounting firm their independence from management and the Company including the matters in the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding its communications with the Audit Committee concerning independence.

The Audit Committee discussed with the Company’s independent registered public accounting firm the overall scope and plans for their audit of the Company’s financial statements. The Audit Committee meets with the internal auditor and independent registered public accounting firm, with and without management present, to discuss the results of their examinations, their evaluations of the Company’s internal controls and the overall quality of the Company’s financial reporting.

In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors (and the Board has approved) that the audited financial statements be included in the Annual Report on Form 10-K for the year ended December 31, 2018.2019 for filing with the Securities and Exchange Commission. The Audit Committee and the Board of Directors have also recommended, subject to stockholder approval, the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm.

Robert M. Henry, Audit Committee Chair

John M. Klimek, Member

Paul J. Adams, Member

Nominating Committee

The Nominating and Governance Committee consists of two directors, Messrs. Klimek (Chairman) and Henry. The Nominating Committee does not have a charter. The Board of Directors has determined that each of the members of the Nominating Committee is independent as defined in the listing standards for the Nasdaq StockMarket.

21

The Nominating Committee has not adopted a formal policy with regard to consideration of director candidates recommended by security holders. The Company believes that the continuing service of qualified incumbent members of the Board of Directors promotes stability and continuity at the Board level, contributes to the Board’s ability to work as a collective body and provides the benefit of familiarity and insight into the Company’s affairs. Accordingly, the process of the Nominating Committee for identifying nominees reflects the Company’s practice of re-nominating incumbent directors who continue to satisfy the criteria for membership on the Board. For vacancies which are anticipated on the Board of Directors, the Nominating Committee intends to seek out and evaluates potential candidates from a variety of sources that may include recommendations by security holders, members of management and the Board of Directors, consultants and others. The minimum qualifications for potential candidates for the Board of Directors include demonstrated business experience, decision-making abilities, personal integrity and a good reputation. While diversity is not a leading factor in the Nominating Committee’s evaluation of potential candidates and there is no formal policy for considering diversity when nominating a potential director, it is a consideration that is evaluated along with other qualifications of potential candidates. In light of the foregoing, it is believed that a formal policy and procedure with regard to consideration of director candidates recommended by security holders is not necessary in order for the Nominating Committee to perform its duties.

Compensation Committee

The Compensation Committee consists of three directors: Messrs. Klimek (Chairman), Henry, and Adams. The Board has determined that each of the members of the Compensation Committee is independent as defined in the listing standards for the Nasdaq Stock Market. The Compensation Committee reviews and acts on the Company’s executive compensation and employee benefit and retirement plans, including their establishment, modification and administration. It also determines the compensation of the Chief Executive Officer and certain other executive officers, including incentive compensation programs and stock options. The Compensation Committee has a charter which has been posted and can be viewed on the Company’s Internet website at www.reliv.com under the section entitled “Investor Relations.” The Compensation Committee met two times in 2019.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934 requires the Company’s officers and directors, and persons who own more than ten percent of a registered class of the Company’s equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission and with the Nasdaq Stock Market. Officers, directors and greater than ten percent stockholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file.

Based solely on a review of the copies of such forms furnished to the Company, or written representations that no Form 5’s were required, the Company believes that, for calendar year 2019, all of the officers, directors and ten percent beneficial owners of the Company complied with all applicable Section 16(a) filing requirements.

Code of Ethics

The Company has adopted a code of ethics that applies to senior executive and financial officers. The Company’s Code of Ethics seeks to promote (1) honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships, (2) full, fair, accurate, timely and understandable disclosure of information to the Commission, (3) compliance with applicable governmental laws, rules and regulations, (4) prompt internal reporting of violations of the Code of Ethics to predesignated persons, and (5) accountability for adherence to the Code of Ethics. A copy of the Company’s Code of Ethics has been posted to and can be viewed on the Company’s Internet website at http://www.reliv.com under the section entitled “Investor Relations.”

22

 

Item No. 11 - Executive Compensation

 

Information calledThe Company is a “smaller reporting company” under Item 10 of Regulation S-K promulgated under the Securities Exchange Act of 1934 and has elected to comply with certain of the requirements applicable to smaller reporting companies in connection with this proxy statement.

SUMMARY COMPENSATION TABLE

The following table sets forth the annual and long-term compensation for by Item 11the fiscal years ended December 31, 2019 and 2018, respectively, of Part IIIthe Company’s Principal Executive Officer and each of the two other most highly compensated executive officers. These individuals, including the Chief Executive Officer, are collectively referred to in this proxy statement as the Named Executive Officers.

Name and Principal Position

 

Year

 

Salary

  

Bonus

  

Option

Awards (1)

  

Non-Equity

Incentive Plan

Compensation (2)

  

All Other

Compensation

(3, 4, 5, 6, 7)

  

Total

 
                           

Robert L. Montgomery

 

2019

 $490,000  $-  $-  $-  $48,268  $538,268 

Chairman and former Chief

 

2018

 $559,516  $-  $-  $-  $43,745  $603,261 

Executive Officer

                          
                           

Ryan A. Montgomery

 

2019

 $211,366  $-  $-  $-  $7,528  $218,894 

Chief Executive Officer

 

2018

 $180,690  $-  $-  $-  $16,600  $197,290 
                           

Thomas W. Pinnock

 

2019

 $144,000  $-  $-  $-  $198,380  $342,380 

President of Sales and

 

2018

 $144,000  $-  $-  $-  $192,749  $336,749 

Marketing

                          


(1)

No option grants were made to any of the Named Executive Officers in 2019.

(2)

Amounts determined solely under the Company’s Incentive Compensation Plan. No amounts were earned under this plan in 2019.

(3)

Amounts for Thomas W. Pinnock for 2019 represent earnings from his Reliv distributorship.

(4)

Amounts for 2019 include matching 401(k) contributions as follows: Robert L. Montgomery, $2,450; and Ryan A. Montgomery, $959.

(5)

No Company contributions were made to the Employee Stock Ownership Plan in 2019.

(6)

Amounts for 2019 include life insurance allowance paid for Robert L. Montgomery of $39,000 and Ryan A. Montgomery of $2,000. A travel allowance of $4,569 for 2019 is also included for Ryan A. Montgomery.

(7)

Amounts for 2019 include value of automobile provided for Robert L. Montgomery of $6,818.

Narrative Disclosure for Summary Compensation Table

Employment Agreements with Our Named Executive Officers

In June 2007, the Company entered into an Employment Agreement with Robert L. Montgomery replacing a prior agreement. The agreement, as amended, is incorporated by referencefor a term of employment commencing on January 1, 2007 and expiring on December 31, 2009 with a provision for automatic one-year renewal terms, and provides for Mr. Montgomery to receive base annual compensation during the term of not less than $600,000. Mr. Montgomery is also to participate in the Company’s annual incentive compensation and the Company’s long-term equity incentive compensation plans and such other compensation plans as the Company may from time to time have for executives. In the event of Mr. Montgomery’s death during the term of the agreement, payments equal to the definitive Proxy Statementtotal compensation that would have been paid for a period of six months to Mr. Montgomery under the agreement, but for his death, will be made to his heirs. The agreement also allows Mr. Montgomery the option to reduce his level of service to the Company by approximately one-half with a corresponding decrease in base annual compensation and a reduction of 25% of his incentive compensation, after a requisite waiting period. Mr. Montgomery also has the option to terminate his active service and continue in a consulting capacity. The term of the consulting period will be 15 years and Mr. Montgomery will receive approximately 30% of his prior average annual cash compensation over the five years immediately preceding the earlier of (1) his election to terminate his employment and continue to serve the Company as a consultant or (2) his election to continue his employment at a reduced rate of service and compensation. The agreement includes the obligation of Mr. Montgomery to maintain the confidentiality of the Company’s confidential information and contains a covenant of Mr. Montgomery not to compete with the Company. In addition, for a period of at least 20 years following the termination of the agreement, the Company has the right to continue its use of Mr. Montgomery’s name and likeness in consideration of a $10,000 annual fee paid to Mr. Montgomery or his heirs.

23

In January 2008, the Company entered into an Employment Agreement with Ryan A. Montgomery. The agreement is for a term of employment commencing on January 1, 2008 and expiring on December 31, 2008 with a provision for automatic one-year renewal terms, and provides for Mr. Montgomery to receive base annual compensation during the term of not less than $170,000. Mr. Montgomery is also to participate in the Company’s annual incentive compensation and the Company’s long-term equity incentive compensation plans and such other compensation plans as the Company may from time to time have for executives. In the event of termination of this agreement and employment by the Company pursuant to the agreement, the Company shall be obligated to pay Mr. Montgomery an amount of severance equal to six months’ salary, payable by the Company over a 12-month period to commence on the date of termination.

Information Relating to Cash Incentives and Stock and Option Awards

Effective January 1, 2007, the Board of Directors, on the recommendation of the Compensation Committee, adopted an Incentive Compensation Plan providing for annual incentive compensation to be paid to executive and managerial employees of the Company. Under the Plan, designated Named Executive Officers and a number of other executive officers and managers receive incentive compensation payments, determined on a quarterly and annual basis, which are based upon the income from operations of the Company for the period if the profits exceed a threshold amount of quarterly income from operations in the amount of $500,000. The benefits under the Plan are divided into two Pools of compensation. Pool I (representing the largest pool of incentive compensation) covers senior executive officers who participate in the pool of incentive compensation based upon a percentage allocation made by the Compensation Committee each year. Pool II covers managers who are selected to participate in proportions determined by senior management. The Compensation Committee believes such incentive compensation motivates participants to achieve strong profitability which is viewed as the most significant element of corporate performance, provides rewards for strong corporate performance and aligns the incentive with the interests of the stockholders. Incentive compensation participation levels are generally determined during the first quarter of each fiscal year.

With respect to Pool I participants, the Compensation Committee, in consultation with management and the Chief Executive Officer, determines the participants and their relative level of participation during the first quarter of the year for a recommendation to the Board of Directors for formal approval. In determining participation and the level of participation each year, management and the Compensation Committee consider the executive’s responsibilities and individual performance during the prior year. For the fiscal year ended December 31, 2019, no amounts were earned under the Incentive Compensation Plan.

Long-Term Equity Incentives

At the Company’s Annual Meeting of ShareholdersStockholders held in May 2017, the Company’s 2017 Incentive Stock Plan was approved by the stockholders. The Plan provides for the issuance of stock options or incentive stock grants of up to be held200,000 shares of common stock of the Company. No option awards have been made from this Incentive Stock Plan as of December 31, 2019.

Stock option grants are determined from time to time by the Compensation Committee in consultation with management. The actual grant for each executive is determined taking into consideration (i) individual performance, (ii) corporate performance and (iii) prior grants to, or stock ownership of the Company by, the executive. Generally, stock options are granted with an exercise price equal to or greater than the closing price of the Company’s common stock on May 23,the NASDAQ Capital Market on the date of the grant.

24

In 2019, no grants of stock options were made to any Named Executive Officer.

We view participation by our executives in our Employee Stock Ownership Plan (the “ESOP”) as a component of long-term compensation. Shares purchased by the ESOP, or contributed to the ESOP, are allocated among participants based upon relative eligible compensation levels and subject to the vesting requirements of the ESOP.

Retirement Benefits

The Company maintains a 401(k) employee savings plan (the “401(k) Plan”) in which all salaried employees that have met the plan’s service requirements are eligible to participate. The Company also maintains the ESOP, which was adopted by the Company on September 1, 2006. Both plans are tax qualified retirement plans.

Under the 401(k) Plan, employees may contribute up to 15% of their eligible compensation to the 401(k) Plan and the Company will contribute a matching amount to the 401(k) Plan each year. The federal statutory limit for eligible compensation in 2019 was $280,000. Participating employees may direct the investment of individual and company contributions into one or more of the investment options offered by the 401(k) Plan, provided that, for new contributions, employees may not invest more than 15% in common stock of the Company. During 2019, the Company made matching contributions of 10% on employee contributions to the 401(k) Plan, subject to statutory limits and top-heavy plan rules. The Company’s contributions to the 401(k) Plan totaled approximately $24,000 in 2019, which is expectedsubject to the vesting requirements of the 401(k) Plan.

Under the ESOP, all employees of the Company are eligible to participate in the ESOP and interests in the ESOP are allocated to participants based on relative eligible compensation. All contributions to the ESOP are made by the Company in the form of cash or stock and are discretionary. The maximum amount of contribution which the Company can make is 25% of the annual eligible compensation of employees after taking into account contributions to the 401(k) Plan. Shares of stock purchased by, or contributed to the ESOP, are allocated to participants based on qualified compensation and subject to the vesting requirements of the ESOP. During 2019, the Company elected not to make a contribution to the ESOP.

Other Benefits

The Company provides certain general employee benefits and health insurance plans of the type commonly offered by other employers. These benefits form part of our compensation philosophy because the Company believes they are necessary in order to attract, motivate and retain talented executives.

Outstanding Equity Awards

As of March 23, 2020, the Company has no outstanding equity awards to any of the Named Executive Officers.

25

Payments upon Termination or Change of Control

The Company has no agreements with Named Executives or other executives of the Company under which payments are to be filedmade in the event of change of control of the Company.

Under the Employment Agreement between the Company and Robert L. Montgomery, Mr. Montgomery has the right, to reduce his level of service to the Company by approximately one-half with a corresponding decrease in position and base annual compensation and a 25% decrease in incentive compensation. Mr. Montgomery also has the Commission within 120 days after December 31, 2018.option to terminate his active service and continue in a consulting capacity. The term of the consulting period will be 15 years and Mr. Montgomery will receive approximately 30% of his prior average annual compensation over the previous five years or last five years of his full-time employment as a consulting fee. In the event of Mr. Montgomery’s death during the term of the agreement, payments equal to his total compensation under the agreement will be made to his heirs for a period of six months. In addition, for a period of 20 years following termination of the agreement, the Company has the right to continue its use of Mr. Montgomery’s name and likeness in consideration of a $10,000 annual fee payable to Mr. Montgomery or his heirs.

Under the Employment Agreement between the Company and Ryan A. Montgomery, Mr. Montgomery has the right to receive an amount of severance equal to six months’ salary, payable by the Company over a 12-month period to commence on the date of termination.     

DIRECTOR COMPENSATION

Name

 

Fees Earned or Paid in Cash ($)

  

Option Awards(1)

  

All Other Compensation ($)

  

Total ($)

 
                 

John M. Klimek

 $50,500  $-  $117,000  $167,500 

Robert M. Henry

  43,500   -   6,000   49,500 

Paul J. Adams

  25,000   -   -   25,000 


(1)

No stock option grants were awarded to these directors in 2019.

Narrative Description of Director Compensation

Members of the Board of Directors who are not employees receive a monthly fee of $2,000 and $1,500 per attendance at meetings in person of the Board of Directors or any committees of the Board of Directors, and $1,000 per attendance at meetings via conference call, up to a maximum of $3,000 per day. In 2018, Mr. Henry and Mr. Klimek were appointed as members of a special committee of the Board of Directors to evaluate the sale of substantially all of the machinery, equipment, inventory, tools and other assets and materials used in the Company’s manufacturing operations to Nutracom. (See “Part I - Item 2 – Properties”) The sale was completed on January 1, 2019. Amounts identified under “All Other Compensation” in the table above include amounts paid to Mr. Henry and Mr. Klimek for serving on the special committee as well as other amounts paid to Mr. Klimek for his work on other special projects for the Board of Directors.

26

 

Item No. 12 - Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

Information calledBENEFICIAL OWNERSHIP OF SHARES BY MANAGEMENT AND

SIGNIFICANT STOCKHOLDERS

The following table provides information concerning the beneficial ownership of the Company’s common stock by each director and nominee for by Item 12director, named executive officers, all of Part III is incorporated by referencethe Company’s directors and officers as a group, and the beneficial owners known to the definitive Proxy Statement forCompany to hold more than five percent of the 2019 Annual MeetingCompany’s outstanding common stock as of ShareholdersMarch 23, 2020.

The amounts and percentage of common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be held on May 23, 2019,a “beneficial owner” of a security if that person has or shares “voting power,” which includes the power to vote or to direct the voting of such security, or “investment power,” which includes the power to dispose of or to direct the disposition of such security. A person is expectedalso deemed to be filed with the Commissiona beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 12060 days after December 31, 2018.March 23, 2020. Under these rules, more than one person may be deemed a beneficial owner of the same securities and a person may be deemed a beneficial owner of securities as to which he has no economic interest. Percentage of class is based on 1,746,449 shares of common stock outstanding as of March 23, 2020.

 

Name of beneficial owner(1)

 

Amount of shares

beneficially owned

 

Percentage of Shares

Beneficially Owned

         

Directors and Named Executive Officers:

    
         

Robert L. Montgomery(2)

  313,559   17.95%

Ryan A. Montgomery

  112,033   6.41%

John M. Klimek

  ---   * 

Robert M. Henry

  143   * 

Paul J. Adams

  ---   * 

Thomas W. Pinnock

  5,000   * 

R. Scott Montgomery

  126,450   7. 24%
         

All Directors, nominees and officers as a group (7 persons)

  557,185   31. 90%
         

Other 5% or greater shareholders:

 
         

Renaissance Technologies LLC (3)

  106,880   6.12%

800 Third Avenue

        

New York, NY 10022

        


* less than one percent

(1)

Unless otherwise indicated below, the person named in the table has sole voting and investment power with respect to all shares beneficially owned, subject to community property laws where applicable. Unless otherwise indicated, the address for each person is c/o Reliv’ International, Inc., 136 Chesterfield Industrial Boulevard, Chesterfield, Missouri 63005.

(2)

Includes 5,932 shares held through the Montgomery Family Limited Partnership, and 69,129 shares held through Montgomery Enterprises, Ltd., for which Mr. Robert L. Montgomery has voting and investment power.

(3)

Information obtained from the Schedule 13G filed with the SEC by Renaissance Technologies LLC on February 13, 2020.

27

EQUITY COMPENSATION PLAN INFORMATION

The following table sets forth the common stock of the Company authorized for issuance under the Company’s equity compensation plans as of March 23, 2020.

Plan Category

Number of securities

to be issued upon

exercise of

outstanding options,

warrants and rights

Weighted-average

exercise price of

outstanding options,

warrants and rights

Number of securities

remaining available

for future issuance

under equity

compensation plans

Equity compensation plans approved by security holders

--200,000(1)

Equity compensation plans not approved by security holders

---

Total

--200,000


(1)

Represents 200,000 shares available for issuance under the Company’s 2017 Incentive Stock Plan.

 

Item No. 13 - Certain Relationships and Related Transactions, and Director Independence

 

Information called for by Item 13Certain Relationships and Related Transactions

Robert L. Montgomery, Chairman of Part IIIthe Board, is incorporated by reference to the definitive Proxy Statement forfather of Ryan A. Montgomery and R. Scott Montgomery. Ryan A. Montgomery is the current Chief Executive Officer and his compensation is listed in the Summary Compensation Table. R. Scott Montgomery is the President of Operations and International and as a result of serving in such capacity, the Company paid him cash compensation of $221,384 in 2019 Annual Meeting of Shareholders to be held on May 23, 2019, which is expected to be filed with the Commission within 120 days after December 31,and $207,200 in 2018.

 

Item No. 14 - Principal Accountant Fees and Services

 

Information calledFees Billed by Independent Registered Public Accounting Firm

The following table sets forth the amount of fees billed by Ernst & Young LLP for services rendered for the years ended December 31, 2019 and 2018:

  

2019

  

2018

 
         

Audit Fees (1)

 $297,000  $325,000 

Audit-Related Fees (2)

  40,000   --- 

Tax Fees (3)

  113,000   108,000 

Total Fees

 $450,000  $433,000 


(1)

Includes the annual consolidated financial statement audit, limited quarterly reviews, reviews of registration statements and comfort letters, and statutory audits required internationally.

(2)

Includes fees for services rendered in connection with accounting and reporting consultations.

(3)

Primarily represents the preparation of tax returns and other tax compliance and consulting services.

28

All audit, tax, and other services to be performed by Item 14Ernst & Young LLP for the Company must be pre-approved by the Audit Committee. The Audit Committee reviews the description of Part IIIthe services and an estimate of the anticipated costs of performing those services. Services not previously approved cannot commence until such approval has been granted. Pre-approval is incorporated by referencegranted usually at regularly scheduled meetings. If unanticipated items arise between meetings of the Audit Committee, the Audit Committee has delegated approval authority to the definitive Proxy Statement forchairman of the Audit Committee, in which case the chairman communicates such pre-approvals to the full committee at its next meeting. During 2019, Annual Meetingall services performed by Ernst & Young LLP were pre-approved by the Audit Committee in accordance with this policy.

The Audit Committee reviews all relationships with Ernst & Young LLP, including the provision of Shareholdersnon-audit services, which may relate to be held on May 23, 2019, which is expected to be filedthe independent registered public accounting firm’s independence. The Audit Committee considered the effect of Ernst & Young LLP’s non-audit services in assessing the independence of the independent registered public accounting firm and concluded that the provision of such services by Ernst & Young LLP was compatible with the Commission within 120 days after December 31, 2018.maintenance of that firm’s independence in the conduct of its auditing functions.

 

PART IV

 

Item No. 15 - Exhibits and Financial Statement Schedules

 

(a)

1.

The Consolidated Financial Statements filed as part of this report on Form 10-K are listed on the accompanying Index to Consolidated Financial Statements and Consolidated Financial Statement Schedules.

 

2.

Financial schedules required to be filed by Item 8 of this form, and by Item 15(d) below:

 

 

All other financial schedules are not required under the related instructions or are inapplicable and therefore have been omitted.

 

3.

Exhibits: See the Exhibit Index immediately before the signature page of this Annual Report on Form 10-K.

 

 

Item No. 16 – Form 10-K Summary

 

None

 


29

 

Exhibit Index

 

Exhibit

Number

Document

2.1

Purchase Agreement with Nutracom, LLC dated January 1, 2019 (filed herewith)(incorporated by reference to Exhibit 2.1 to the Form 10-K of the Registrant for the year ended December 31, 2018).

3.1

Second Amended and Restated Certificate of Incorporation (incorporated by reference to Appendix B of Schedule 14A of the Registrant filed on April 17, 2003).

3.2

Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.2 to the Form 10-K of the Registrant for the year ended December 31, 2016)

3.3

By-Laws (incorporated by reference to the Registration Statement on Form S-3 of the Registrant filed on February 21, 2006).

3.4

Amendment to By-Laws dated March 22, 2001 (incorporated by reference to the Registration Statement on Form S-3 of the Registrant filed on February 21, 2006).

3.5

Certificate of Designation to Create a Class of Series A Preferred Stock for Reliv’ International, Inc. (incorporated by reference to Exhibit 3.1 to the Form 10-Q of the Registrant for quarter ended March 31, 2003).

4.1

Form of Reliv International, Inc. common stock certificate (incorporated by reference to the Registration Statement on Form S-3 of the Registrant filed on February 21, 2006).

10.1

Amended Exclusive License Agreement with Theodore P. Kalogris dated December 1, 1991 (incorporated by reference to Exhibit 10.1 to the Form 10-K of the Registrant for the year ended December 31, 1992).

10.2*

Robert L. Montgomery Employment Agreement dated June 19, 2007 (incorporated by reference to Exhibit 10.1 to the Form 8-K of the Registrant filed June 25, 2007).

10.3*

Carl W. Hastings Employment Agreement dated January 1, 2019 (filed herewith).

10.4*

Reliv’ International, Inc. Supplemental Executive Retirement Plan dated June 1, 1998 (incorporated by reference to Exhibit 10.19 to the Form10-K of the Registrant for year ended December 31, 1998).

10.5*

Reliv International, Inc. Employee Stock Ownership Plan and Trust dated August 29, 2006 (incorporated by reference to Exhibit 10.1 to the Form 8-K of the Registrant filed August 30, 2006).

10.6*

2009 Distributor Stock Purchase Plan (incorporated by reference to Appendix 1 of Form S-3 Registration Statement the Registrant filed July 1, 2009).  

10.7*

2009 Incentive Stock Plan (incorporated by reference to Exhibit 10.1 to the Form S-8 Registration Statement the Registrant filed December 2, 2010).

10.8*10.4*

2014 Incentive Stock Plan (incorporated by reference to Exhibit 10.1 to the Form S-8 Registration Statement the Registrant filed November 19, 2014).

10.9*10.5*

Reliv International, Inc. Incentive Compensation Plan effective January 1, 2007 (incorporated by reference to Exhibit 10.1 to the Form 8-K of the Registrant filed May 31, 2007).

 


10.10*10.6*

R. Scott Montgomery Employment Agreement dated January 2, 2008 (incorporated by reference to Exhibit 10.1 to the Form 8-K of the Registrant filed January 4, 2008).

10.11*10.7*

Ryan A. Montgomery Employment Agreement dated January 2, 2008 (incorporated by reference to Exhibit 10.2 to the Form 8-K of the Registrant filed January 4, 2008).

10.12*10.8*

Steven D. Albright Employment Agreement dated January 2, 2008 (incorporated by reference to Exhibit 10.4 to the Form 8-K of the Registrant filed January 4, 2008).

10.1310.9

Loan Sale Agreement between 2010-1 RADC/CADC Venture, LLC and Reliv International, Inc. dated March 16, 2012 (incorporated by reference to Exhibit 10.1 to the Form 10-Q of the Registrant for the quarter ended March 31, 2012).

30

10.1410.10

Technology License Agreement by and between SL Technology, Inc. and Soy Labs, LLC dated July 23, 2013 (incorporated by reference to Exhibit 10.1 to the Form 8-K of the Registrant filed July 25, 2013).

10.1510.11

Agreement by and among Reliv International, Inc., SL Technology, Inc., Soy Labs, LLC and 1Soy, Inc. dated July 23, 2013 (incorporated by reference to Exhibit 10.2 to the Form 8-K of the Registrant filed July 25, 2013).

10.1610.12

Letter agreement between SL Technology, Inc. and Soy Labs, LLC dated September 2, 2016 (incorporated by reference to Exhibit 10.18 to the Form 10-K of the Registrant for the year ended December 31, 2016)

10.1710.13

Promissory Note (revolving credit facility) dated September 30, 2015 among Reliv International, Inc., Reliv, Inc., Reliv World Corporation, and SL Technology, Inc., as Borrowers and Enterprise Bank & Trust (incorporated by reference to Exhibit 10.2 to the Form 10-Q of the Registrant filed November 13, 2015).

10.1810.14

Business Loan Agreement dated September 30, 2015 among Reliv International, Inc., Reliv, Inc., Reliv World Corporation, and SL Technology, Inc., as Borrowers and Enterprise Bank & Trust (incorporated by reference to Exhibit 10.3 to the Form 10-Q of the Registrant filed November 13, 2015).

10.1910.15

Deed of Trust dated September 30, 2015 between Reliv International, Inc. as Grantor and Enterprise Bank & Trust (incorporated by reference to Exhibit 10.4 to the Form 10-Q of the Registrant filed November 13, 2015).

10.2010.16

First Amendment to Loan Agreement dated September 30, 2016 among Reliv International, Inc., Reliv, Inc., Reliv World Corporation, and SL Technology, Inc., as Borrowers and Enterprise Bank & Trust (incorporated by reference to Exhibit 10.1 to the Form 10-Q of the Registrant filed November 14, 2016).

10.2110.17

Change in Terms Agreement (revolving credit facility) dated September 30, 2016 among Reliv International, Inc., Reliv, Inc., Reliv World Corporation, and SL Technology, Inc., as Borrowers and Enterprise Bank & Trust (incorporated by reference to Exhibit 10.2 to the Form 10-Q of the Registrant filed November 14, 2016).

10.2210.18

Second Amendment to Loan Agreement dated April 11, 2018 among Reliv International, Inc., Reliv, Inc., Reliv World Corporation, and SL Technology, Inc., as Borrowers and Enterprise Bank & Trust (incorporated by reference to Exhibit 10.1 to the Form 10-Q of the Registrant filed May 15, 2018).

10.2310.19

Change in Terms Agreement (revolving credit facility) dated April 30, 2018 among Reliv International, Inc., Reliv, Inc., Reliv World Corporation, and SL Technology, Inc., as Borrowers and Enterprise Bank & Trust (incorporated by reference to Exhibit 10.3 to the Form 10-Q of the Registrant filed May 15, 2018).

 


10.2410.20

Third Amendment to Loan Agreement dated September 11, 2018 among Reliv International, Inc., Reliv, Inc., Reliv World Corporation, and SL Technology, Inc., as Borrowers and Enterprise Bank & Trust (incorporated by reference to Exhibit 10.1 to the Form 10-Q of the Registrant filed November 14, 2018).

10.2510.21

Change in Terms Agreement (revolving credit facility) dated September 11, 2018 among Reliv International, Inc., Reliv, Inc., Reliv World Corporation, and SL Technology, Inc., as Borrowers and Enterprise Bank & Trust (incorporated by reference to Exhibit 10.2 to the Form 10-Q of the Registrant filed November 14, 2018).

31

10.2610.22

Lease between Registrant (lessor) and Nutracom, LLC (lessee) dated January 1, 2019 (filed herewith)(incorporated by reference to Exhibit 10.26 to the Form 10-K of the Registrant for the year ended December 31, 2018).

10.2710.23

Secured Term Note issued by Nutracom, LLC to Registrant dated January 1, 2019 (filed herewith)(incorporated by reference to Exhibit 10.27 to the Form 10-K of the Registrant for the year ended December 31, 2018).

10.2810.24

Unsecured Term Note issued by Nutracom, LLC to Registrant dated January 1, 2019 (filed herewith)(incorporated by reference to Exhibit 10.28 to the Form 10-K of the Registrant for the year ended December 31, 2018).

10.2910.25

Fourth Amendment to Loan Agreement dated March 25, 2019 among Reliv International, Inc., Reliv, Inc., Reliv World Corporation, and SL Technology, Inc., as Borrowers and Enterprise Bank & Trust (filed herewith)(incorporated by reference to Exhibit 10.29 to the Form 10-K of the Registrant for the year ended December 31, 2018)

10.3010.26

Change in Terms Agreement (revolving credit facility) dated March 25, 2019 among Reliv International, Inc., Reliv, Inc., Reliv World Corporation, and SL Technology, Inc., as Borrowers and Enterprise Bank & Trust (filed herewith)(incorporated by reference to Exhibit 10.30 to the Form 10-K of the Registrant for the year ended December 31, 2018).

10.27

Agreement dated June 1, 2019 with Nutracom, LLC to modify Purchase Agreement and Secured Promissory Note dated January 1, 2019 (incorporated by reference to Exhibit 10.1 to the Form 10-Q of the Registrant filed August 14, 2019).

11

Statement re: computation of per share earnings (incorporated by reference to Note 911 of the Consolidated Financial Statements contained in Part IV).

21

Subsidiaries of the Registrant (filed herewith).

23

Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm (filed herewith).

31.1

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended (filed herewith).

31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended (filed herewith).

32

Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).

101

Interactive Data Files, including the following materials from the Company’s Annual Report on Form 10-K for the year ended December 31, 2018,2019, formatted in XBRL: (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Net Loss and Comprehensive Loss, (iii) the Consolidated Statements of Stockholders’ Equity, (iv) the Consolidated Statements of Cash Flows, and (v) the Notes to Consolidated Financial Statements.

 

 

*Indicates management compensation plan, contract or arrangement.

 


32

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

RELIV’ INTERNATIONAL, INC.

 

 

By:

/s/ Ryan A. Montgomery

 Ryan A. Montgomery, Chief Executive Officer

Date: March 27, 2020

Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Date: March 29, 2019

By:

Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
By:

/s/ Robert L. Montgomery

 Robert L. Montgomery, Chairman of the Board of Directors

Date: March 27, 2020

By:

Date: March 29, 2019
By:

/s/ Steven D. Albright

 Steven D. Albright, Chief Financial Officer (and accounting officer)

Date: March 27, 2020

By:

Date: March 29, 2019
By:

/s/ Ryan A. Montgomery

 Ryan A. Montgomery, Chief Executive Officer, Director

Date: March 27, 2020

By:

Date: March 29, 2019
By:/s/ Denis St. John  
Denis St. John, Director
Date: March 29, 2019
By:

/s/ Robert M. Henry

 Robert M. Henry, Director

Date: March 27, 2020

By:

Date: March 29, 2019
By:

/s/ John M. Klimek

 John M. Klimek, Director

Date: March 27, 2020

By:

/s/ Paul J. Adams

 
Date: March 29, 2019Paul J. Adams, Director

 

Date: March 27, 2020


33

 

Reliv’ International, Inc.

and Subsidiaries

 

Consolidated Financial Statements

 

 

Years ended December 31, 20182019 and 2017

2018

 

 

 

Contents

 

Consolidated Financial Statements:

 

Report of Independent Registered Public Accounting Firm

F-1

Consolidated Balance Sheets as of December 31, 20182019 and 20172018

F-2

Consolidated Statements of Net Loss and Comprehensive  Loss for the years ended December 31, 20182019 and 20172018

F-4

Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2019 and 2018 and 2017

F-5

Consolidated Statements of Cash Flows for the years ended December 31, 20182019 and 20172018

F-6

Notes to Consolidated Financial Statements – December 31, 20182019

F-8

 


 

Report of Independent Registered Public Accounting Firm

To the Stockholders and the Board of Directors

Reliv’ International, Inc.

 

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Reliv’ International, Inc. and Subsidiaries (the Company) as of December 31, 20182019 and 2017,2018, and the related consolidated statements of net loss and comprehensive loss, stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2018,2019, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 20182019 and 2017,2018, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2018,2019, in conformity with U.S. generally accepted accounting principles.

 

The Company’s Ability to Continue as a Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations, and has stated that substantial doubt exists about the Company’s ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for OpinionOpinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

 

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 1991.

 

 

St. Louis, Missouri

March 29, 201927, 2020

 


F-1

 

 

Reliv’ International, Inc. and Subsidiaries

 

Consolidated Balance Sheets

 

 

December 31

  

December 31

 
 

2018

  

2017

  

2019

  

2018

 

Assets

                

Current assets:

                

Cash and cash equivalents

 $1,989,974  $3,272,788  $1,630,779  $1,989,974 

Accounts receivable, less allowances of $5,000 in 2018 and $26,300 in 2017

  400,759   29,760 

Accounts due from employees and distributors

  151,222   138,497 

Accounts receivable, less allowances of $5,000 in 2019 and 2018

  107,369   400,759 

Notes & accounts receivables and deposits - related parties

  1,099,228   151,222 

Inventories:

                

Finished goods

  2,460,563   2,762,249   2,275,306   2,460,563 

Raw materials

  372,865   1,653,466   305,571   372,865 

Sales aids and promotional materials

  121,519   139,770   120,811   121,519 

Total inventories

  2,954,947   4,555,485   2,701,688   2,954,947 
                

Refundable income taxes

  22,712   26,552   22,406   22,712 

Assets held for sale

  2,124,939   -   -   2,124,939 

Prepaid expenses and other current assets

  441,453   372,602   304,048   441,453 

Total current assets

  8,086,006   8,395,684   5,865,518   8,086,006 
                

Other assets

  338,974   337,190   -   338,974 

Cash surrender value of life insurance

  -   3,086,522 

Note receivable due from distributor

  1,282,072   1,405,113 

Notes and accounts receivables - related parties

  2,418,921   1,282,072 

Operating lease right-to-use assets

  354,440   - 

Intangible assets, net

  1,948,263   2,174,248   1,722,277   1,948,263 

Equity investment

  505,000   - 
                

Property, plant, and equipment

  14,420,559   19,055,260   14,527,400   14,420,559 

Less accumulated depreciation

  9,722,009   13,378,021   10,086,560   9,722,009 

Property, plant, and equipment, net

  4,698,550   5,677,239   4,440,840   4,698,550 
                
                
                
        

Total assets

 $16,353,865  $21,075,996  $15,306,996  $16,353,865 

 


F-2

 

Reliv’ International, Inc. and Subsidiaries

 

Consolidated Balance Sheets (continued)

 

 

December 31

  

December 31

 
 

2018

  

2017

  

2019

  

2018

 
                

Liabilities and stockholders’ equity

                

Current liabilities:

                

Accounts payable and accrued expenses

 $3,880,086  $3,200,018  $3,131,209  $3,880,086 

Income taxes payable

  35,304   12,616   121,177   35,304 

Operating lease liabilities

  236,771   - 

Revolving line of credit

  -   500,000   500,000   - 

Current maturities of long-term debt

  -   2,545,421 

Total current liabilities

  3,915,390   6,258,055   3,989,157   3,915,390 
                

Noncurrent liabilities:

                

Operating lease liabilities

  103,580   - 

Other noncurrent liabilities

  445,611   453,354   112,616   445,611 

Total noncurrent liabilities

  445,611   453,354   216,196   445,611 
                

Stockholders’ equity:

                

Preferred stock, par value $0.001 per share; 500,000 shares authorized; -0- shares issued and outstanding in 2018 and 2017

  -   - 

Common stock, par value $0.001 per share; 5,000,000 shares authorized, 2,110,013 shares issued and 1,845,160 shares outstanding in 2018; 2,110,013 shares issued and 1,845,160 shares outstanding in 2017

  2,110   2,110 

Preferred stock, par value $0.001 per share; 500,000 shares authorized; -0- shares issued and outstanding in 2019 and 2018

  -   - 

Common stock, par value $0.001 per share; 5,000,000 shares authorized, 2,110,013 shares issued and 1,746,449 shares outstanding in 2019; 2,110,013 shares issued and 1,845,160 shares outstanding in 2018

  2,110   2,110 

Additional paid-in capital

  30,622,547   30,598,920   30,643,771   30,622,547 

Accumulated deficit

  (12,311,138)  (10,040,229)  (12,755,495)  (12,311,138)

Accumulated other comprehensive loss:

                

Foreign currency translation adjustment

  (982,095)  (857,654)  (937,320)  (982,095)

Treasury stock

  (5,338,560)  (5,338,560)  (5,851,423)  (5,338,560)

Total stockholders’ equity

  11,992,864   14,364,587   11,101,643   11,992,864 
                

Total liabilities and stockholders’ equity

 $16,353,865  $21,075,996  $15,306,996  $16,353,865 

 

 

See accompanying notes.

 


F-3

 

Reliv’ International, Inc. and Subsidiaries

 

Consolidated Statements of Net Loss

and Comprehensive Loss

 

 

Year ended December 31

  

Year ended December 31

 
 

2018

  

2017

  

2019

  

2018

 
                

Product sales

 $33,918,169  $38,751,357  $32,298,533  $33,918,169 

Handling & freight income

  2,197,572   3,037,425 

Freight income

  1,973,320   2,197,572 

Other revenue

  783,462   - 

Net sales

  36,115,741   41,788,782   35,055,315   36,115,741 
                

Costs and expenses:

                

Cost of products sold

  9,709,743   9,401,406 

Cost of goods sold

  9,557,116   9,709,743 

Distributor royalties and commissions

  11,749,604   14,685,553   11,259,071   11,749,604 

Selling, general, and administrative

  16,520,885   17,885,226   14,798,586   16,520,885 

Loss from operations

  (1,864,491)  (183,403)  (559,458)  (1,864,491)
                

Other income (expense):

                

Interest income

  93,054   101,901   177,810   93,054 

Interest expense

  (95,556)  (109,254)  (47,180)  (95,556)

Other income

  61,652   38,844   17,922   62,347 

Loss before income taxes

  (1,805,341)  (151,912)

Gain (loss) on sale of fixed assets

  434,549   (695)

Income (loss) before income taxes

  23,643   (1,805,341)

Provision for income taxes

  98,000   545,000   468,000   98,000 
                

Net loss available to common shareholders

 $(1,903,341) $(696,912) $(444,357) $(1,903,341)
                

Other comprehensive income (loss):

                

Foreign currency translation adjustment

  (124,441)  113,551   44,775   (124,441)
                

Comprehensive loss

 $(2,027,782) $(583,361) $(399,582) $(2,027,782)
                
        

Loss per common share - Basic

 $(1.03) $(0.38) $(0.25) $(1.03)

Weighted average shares

  1,845,000   1,845,000   1,746,000   1,845,000 
                

Loss per common share - Diluted

 $(1.03) $(0.38) $(0.25) $(1.03)

Weighted average shares

  1,845,000   1,845,000   1,746,000   1,845,000 

 

 

See accompanying notes.

 


F-4

 

Reliv’ International, Inc. and Subsidiaries

 

Consolidated Statements of Stockholders’ Equity

 

                 

Accumulated

                              

Accumulated

             
         

Additional

      

Other

                      

Additional

      

Other

             
 

Common Stock

  

Paid-In

  

Accumulated

  

Comprehensive

  

Treasury Stock

      

Common Stock

  

Paid-In

  

Accumulated

  

Comprehensive

  

Treasury Stock

     
 

Shares

  

Amount

  

Capital

  

Deficit

  

Loss

  

Shares

  

Amount

  

Total

  

Shares

  

Amount

  

Capital

  

Deficit

  

Loss

  

Shares

  

Amount

  

Total

 

Balance at December 31, 2016

  2,110,013  $2,110  $30,565,144  $(9,284,317) $(1,030,205)  264,853  $(5,338,560) $14,914,172 

Net loss

  -   -   -   (696,912)  -   -   -   (696,912)

Other comprehensive income (loss):

                                

Foreign currency translation adjustment

  -   -   -   -   113,551   -   -   113,551 

Income tax effects of Tax Cuts & Jobs Act

  -   -   -   (59,000)  59,000   -   -   - 

Total comprehensive loss

                              (583,361)

Stock-based compensation

  -   -   33,776   -   -   -   -   33,776 

Balance at December 31, 2017

  2,110,013   2,110   30,598,920   (10,040,229)  (857,654)  264,853   (5,338,560)  14,364,587   2,110,013  $2,110  $30,598,920  $(10,040,229) $(857,654)  264,853  $(5,338,560) $14,364,587 

Net loss

  -   -   -   (1,903,341)  -   -   -   (1,903,341)  -   -   -   (1,903,341)  -   -   -   (1,903,341)

Other comprehensive income (loss):

                                                                

Foreign currency translation adjustment

  -   -   -   -   (124,441)  -   -   (124,441)  -   -   -   -   (124,441)  -   -   (124,441)

Total comprehensive loss

                              (2,027,782)                              (2,027,782)

Adoption of Accounting Standards Update 2014-09

  -   -   -   (367,568)  -   -   -   (367,568)  -   -   -   (367,568)  -   -   -   (367,568)

Stock-based compensation

  -   -   23,627   -   -   -   -   23,627   -   -   23,627   -   -   -   -   23,627 

Balance at December 31, 2018

  2,110,013  $2,110  $30,622,547  $(12,311,138) $(982,095)  264,853  $(5,338,560) $11,992,864   2,110,013   2,110   30,622,547   (12,311,138)  (982,095)  264,853   (5,338,560)  11,992,864 

Net loss

  -   -   -   (444,357)  -   -   -   (444,357)

Other comprehensive income (loss):

                                

Foreign currency translation adjustment

  -   -   -   -   44,775   -   -   44,775 

Total comprehensive loss

                              (399,582)

Treasury stock acquired

  -   -   -   -   -   99,200   (540,144)  (540,144)

Other

  -   -   -   -   -   (489)  27,281   27,281 

Stock-based compensation

  -   -   21,224   -   -   -   -   21,224 

Balance at December 31, 2019

  2,110,013  $2,110  $30,643,771  $(12,755,495) $(937,320)  363,564  $(5,851,423) $11,101,643 

 

See accompanying notes.

 


F-5

 

Reliv’ International, Inc. and Subsidiaries

 

Consolidated Statements of Cash Flows

 

 

 

Year ended December 31

  

Year ended December 31

 
 

2018

  

2017

  

2019

  

2018

 

Operating activities

                

Net loss

 $(1,903,341) $(696,912) $(444,357) $(1,903,341)

Adjustments to reconcile net loss to net cash used in operating activities:

                

Depreciation and amortization

  810,442   900,126   583,824   810,442 

Stock-based compensation

  23,627   33,776   21,224   23,627 

Non-cash life insurance policy reduction (accretion)

  20,329   (120,540)  -   20,329 

Non-cash other revenue

  (345,732)  - 

Non-cash miscellaneous loss

  24,618   - 

(Gain) loss on sale of property, plant and equipment

  (684)  (8,844)  (434,549)  695 

Deferred income taxes

  -   508,000 

Foreign currency transaction (gain)/loss

  (32,577)  (20,659)  11,450   (32,577)

(Increase) decrease in accounts receivable and accounts due from employees and distributors

  (377,466)  104,671 

(Increase) decrease in trade, accounts & notes receivable, and deposits - related parties

  (644,823)  (377,466)

(Increase) decrease in inventories

  (26,036)  15,472   843,881   (26,036)

(Increase) decrease in refundable income taxes

  (3,840)  70,612   306   (3,840)

(Increase) decrease in prepaid expenses and other current assets

  (75,941)  107,051   142,614   (75,941)

(Increase) decrease in other assets

  (1,783)  (32,102)

Increase (decrease) in income taxes payable

  30,909   12,616   82,833   30,909 

Increase (decrease) in accounts payable & accrued expenses and other non-current liabilities

  366,437   (1,030,062)

Increase (decrease) in accounts payable & accrued expenses, deferred revenue, and non-current liabilities

  (783,880)  363,275 

Net cash used in operating activities

  (1,169,924)  (156,795)  (942,591)  (1,169,924)
                

Investing activities

                

Proceeds from sale of property, plant, and equipment

  8,522   13,143   -   8,522 

Purchase of property, plant, and equipment

  (181,343)  (499,409)  (98,773)  (181,343)

Proceeds from redemption of life insurance policy

  3,066,193   -   -   3,066,193 

Payments received on distributor note receivable

  115,892   109,160 

Net cash provided by (used in) investing activities

  3,009,264   (377,106)

Payments received on notes receivables - related parties

  162,457   115,892 

Net cash provided by investing activities

  63,684   3,009,264 
                

Financing activities

                

Proceeds from revolving line of credit borrowings

  -   500,000   500,000   - 

Principal payments on long-term borrowings

  (3,045,421)  (363,736)  -   (3,045,421)

Net cash provided by (used in) financing activities

  (3,045,421)  136,264   500,000   (3,045,421)

Effect of exchange rate changes on cash and cash equivalents

  (76,733)  63,608   19,712   (76,733)

Increase (decrease) in cash and cash equivalents

  (1,282,814)  (334,029)  (359,195)  (1,282,814)

Cash and cash equivalents at beginning of year

  3,272,788   3,606,817   1,989,974   3,272,788 

Cash and cash equivalents at end of year

 $1,989,974  $3,272,788  $1,630,779  $1,989,974 

 


F-6

 

Reliv’ International, Inc. and Subsidiaries

 

Consolidated Statements of Cash Flows (continued)

 

 

Year ended December 31

  

Year ended December 31

 
 

2018

  

2017

  

2019

  

2018

 
                

Supplemental disclosures of cash flow information:

                

Cash paid during the year for:

                

Interest

 $99,000  $99,800  $47,700  $99,000 
                

Income taxes paid (received), net

 $66,600  $(52,500)

Income taxes paid

 $355,000  $66,600 
        

Non-cash investing & financing transactions (Note 3):

        

 

 

See accompanying notes.

 


F-7

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

December 31, 20182019

 

 

1. Nature of Business and Significant Accounting Policies

 

Nature of Business

 

Reliv’ International, Inc. (the Company) produces a proprietary line of nutritional supplements addressing basic nutrition, specific wellness needs, weight management, and sports nutrition. These products are sold by subsidiaries of the Company to a sales force of independent distributors of the Company that sell products directly to consumers. The Company and its subsidiaries sell products to distributors throughout the United States and in Australia, Austria, Canada, France, Germany, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, Singapore, and the United Kingdom.

 

Basis of Presentation

 

The consolidated financial statements include the accounts of the Company and its foreign and domestic subsidiaries. All significant intercompany accounts and transactions have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

 

Reclassifications

Certain previously reported 2018 amounts have been reclassified to conform to the current year presentation.

Cash Equivalents

 

The Company'sOur policy is to consider the following as cash and cash equivalents: demand deposits and short-term investments with a maturity of three months or less when purchased.

 

Property, Plant, and Equipment

Property, plant, and equipment are stated on the cost basis. Depreciation is computed using the straight-line or an accelerated method over the useful life of the related assets. Generally, computer equipment and software are depreciated over 3 to 5 years, office and other equipment over 7 years, and real property over 39 years.  

F-8

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

1.Nature of Business and Significant Accounting Policies (continued)

Inventories

 

Inventories are valued at the lower of cost or market. Product cost includes raw materials, labor,market and overhead costs and isare accounted for on a first-in, first-out basis. Effective January 1, 2019, finished goods inventories primarily consist of purchased products held for resale. Prior to 2019, finished goods inventories were primarily comprised of internally manufactured products consisting of the costs associated with raw materials, labor, and overhead. On a periodic basis, the Company reviews itswe review inventory levels, as compared to future demand requirements and the shelf life of the various products. Based on this review, the Company recordswe record inventory write-downs when necessary.

 

Sales aids and promotional materials inventories represent distributor kits, product brochures, and other sales and business development materials which are held for sale to distributors. Cost of the sales aids and promotional materials held for sale are capitalized as inventories and subsequently recorded to cost of goods sold upon recognition of revenue when sold to distributors. All other advertising and promotional costs are expensed when incurred.

 

Amortizable Intangible Assets

Intangible assets are recorded based on management’s determination of the fair value of the respective assets at the time of acquisition. Determining the fair value of intangible assets is judgmental and involves the use of significant estimates and assumptions of future company operations. Our fair value estimates and related asset lives are based on assumptions we believe to be reasonable but that are unpredictable and inherently uncertain. Actual future results may differ from these estimates.

Intangible assets estimated to have finite lives are amortized over their estimated economic life under the straight-line method; such method correlates to management’s estimate of the assets’ economic benefit. Based on management’s estimates at origination, these lives range from two to seventeen years. Related amortization expense is presented within Selling, General, and Administrative in the accompanying consolidated statements of net loss and comprehensive loss. As of December 31, 2019, remaining lives of intangible assets range from five to ten years.

Concentrations of Risk

Effective January 1, 2019, we have entered into outsourcing agreements with Nutracom LLC (“Nutracom”) to manufacture our nutritional and dietary supplements and for warehousing and fulfillment services for the U.S. distribution of our products. Nutracom has also issued promissory notes to us for the acquisition of our manufacturing and fulfillment operations. Any inability of Nutracom to deliver these contracted services or to repay the promissory notes could adversely impact our future operating results and valuation of our Nutracom equity investment. See Note 2 and Note 3 for further discussion of our relationship with Nutracom.


F-9

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

1. Nature of Business and Significant Accounting Policies (continued)

 

Property, Plant, and EquipmentVariable Interest Entities (VIE) - Unconsolidated

 

Property, plant,Effective January 1, 2019, we have a financial interest in Nutracom. If we are the primary beneficiary of a VIE, we are required to consolidate the VIE in our consolidated financial statements. To determine if we are the primary beneficiary, we evaluate whether we have the power to direct the activities that most significantly impact the VIE’s economic performance and equipmentthe obligation to absorb losses or the right to receive benefits of the VIE that could potentially be significant to the VIE. Our VIE evaluation requires significant assumptions and judgments.

We do not have the power to direct the significant activities of Nutracom, primarily because we do not have governance rights. We also do not participate in the annual profits or losses of Nutracom. Therefore, we do not consolidate the financial results of Nutracom in our consolidated financial statements. We account for our financial interest in Nutracom as an equity investment measured at cost minus impairment, if any. A cost method equity investment is subject to periodic impairment review using the other-than-temporary impairment model, which considers the severity and duration of a decline in fair value below cost and our ability and intent to hold the investment for a sufficient period of time to allow for recovery.

See Note 2 and Note 3 for further information on our financial relationship with Nutracom.

Revenue Recognition

We recognize revenue from product sales under a five step process with our independent distributors (including customers) when there is a legally enforceable contract, the rights of the parties are statedidentified, the contract has commercial substance, and collectability of the contract consideration is probable. Product sales revenue (principally nutritional and dietary supplements) and commission expenses are recorded when control is transferred to the independent distributors, which occurs at the time of shipment. Generally, net sales reflect product sales less the distributor discount of 20 percent to 40 percent of the suggested retail price. We present distributor royalty and commission expense as an operating expense, rather than a reduction to net sales, as these payments are not made to the purchasing distributor. At point of sale, we receive payment by credit card, personal check, or guaranteed funds for contracts from independent distributors and make related commission payments no later than the following month.

We recognize the performance obligation for membership fees-type revenue over the membership term of generally twelve months. We receive payment for membership fees revenue at the beginning of the membership term and recognize membership fees revenue on a straight-line basis in correlation with the completion of our performance obligation under the membership term. Our remaining unearned membership fees obligation is reported as a deferred revenue liability.

F-10

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

1.Nature of Business and Significant Accounting Policies (continued)

Revenue Recognition (continued)

We record freight income as a component of net sales and record freight costs as a component of cost basis. Depreciationof goods sold. Total sales do not include sales tax as we consider ourselves a pass-through conduit for collecting and remitting applicable sales taxes.

Other revenue is defined in the lessor accounting sections within this Note 1 and in Note 9.

Actual and estimated sales returns are classified as a reduction of net sales. We estimate and accrue a reserve for product returns based on our return policy and historical experience. Our product returns policy allows for distributors to return product only upon termination of his or her distributorship. Allowable returns are limited to saleable product which was purchased within twelve months of the termination for a refund of 100% of the original purchase price less any distributor royalties and commissions received relating to the original purchase of the returned products. For the year to date periods ending December 31, 2019 and 2018, total returns as a percent of net sales were approximately 0.08% and 0.17%, respectively.

Basic and Diluted Earnings (Loss) per Share

Basic earnings (loss) per common share are computed using the straight-line or an accelerated method overweighted average number of common shares outstanding during the useful lifeyear. Diluted earnings (loss) per common share are computed using the weighted average number of common shares and potential dilutive common shares that were outstanding during the related assets. Generally, computer equipmentperiod. Potential dilutive common shares consist of outstanding stock options, outstanding stock warrants, and software are depreciated over 3 to 5 years, office equipment and machinery over 7 years, and real property over 39 years.  convertible preferred stock. See Note 11 for additional information regarding earnings (loss) per share.

 

Foreign Currency Translation and Transaction Gains or Losses

 

All balance sheet accounts have been translated using the exchange rates in effect at the balance sheet date. Statements of net income (loss) amounts have been translated using the average exchange rate for the year. The gains and losses resulting from the changes in exchange rates from year to year have been reported in other comprehensive income (loss). The foreign currency translation adjustment is the only component of accumulated other comprehensive loss. If applicable, foreign currency translation adjustments exclude income tax expense (benefit) as certain of the Company’sour investments in non-U.S. subsidiaries are deemed to be reinvested for an indefinite period of time. Foreign currency transaction gains (losses) were $(11,450) and $32,577 for 2019 and $20,659 for 2018, and 2017, respectively.

 

Basic and Diluted Earnings (Loss) per ShareFair Value Measurements

 

Basic earnings (loss) per common share are computed using the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per common share are computed using the weighted average number of common sharesFASB ASC Topic 820, “Fair Value Measurements and potential dilutive common shares that were outstanding during the period. Potential dilutive common shares consist of outstanding stock options, outstanding stock warrants,Disclosures,” defines fair value, establishes a framework for measuring fair value, and convertible preferred stock.requires disclosures about fair value measurements required under other accounting pronouncements. See Note 97 for additional information regarding earnings (loss) per share.further discussion.

F-11

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

1.Nature of Business and Significant Accounting Policies (continued)

 

Stock-Based Compensation

 

The Company hasWe have stock-based incentive plans under which itwe may grant stock option, restricted stock, and unrestricted stock awards. The Company recognizesWe recognize stock-based compensation expense based on the grant date fair value of the award and the related vesting terms. Depending upon the characteristics of the option, the fair value of stock-based awards is primarily determined using the Black-Scholes model, which incorporates assumptions and management estimates including the risk-free interest rate, expected volatility, expected option life, and dividend yield. The Company recognizesWe recognize forfeitures when incurred. See Note 810 for additional information.

The Company accounts for options granted to non-employees and warrants granted to distributors under the fair value approach required by FASB ASC Topic 505-50, “Equity Based Payments to Non-Employees.”


Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

1.Nature of Business and Significant Accounting Policies (continued)

Fair Value Measurements

FASB ASC Topic 820, “Fair Value Measurements and Disclosures,” defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements required under other accounting pronouncements. See Note 6 for further discussion.

 

Income Taxes

 

The provision for income taxes is computed using the liability method. The primary differences between financial statement and taxable income result from financial statement accruals and reserves and differences between depreciation and amortization for book and tax purposes.

 

Unrecognized tax benefits are accounted for as required by FASB ASC Topic 740 which prescribes a more likely than not threshold for financial statement presentation and measurement of a tax position taken or expected to be taken in a tax return. See Note 1213 for further discussion.

 

Advertising

 

Costs of sales aids and promotional materials are capitalized as inventories. All other advertising and promotional costs are expensed when incurred. The Company recordedAdvertising expenses were $16,800 and $19,300 in 2019 and $22,300 of advertising expense in 2018, and 2017, respectively.

 

Research and Development Expenses

 

Research and development expenses, which are charged to selling, general, and administrative expenses as incurred, were $185,000 and $473,000 in 2019 and $488,000 in 2018, and 2017, respectively.

 

Amortizable Intangible AssetsNew Accounting Pronouncement – Leases Adopted in 2019

 

On January 1, 2019, we adopted Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842) (including subsequent issued lease-related ASU’s).

Lessee Accounting

We applied the new lease accounting standard to all lessee operating leases using the prospective transition method. Under this method, prior financial reporting periods are not restated. The Company records intangible assets based on management’s determinationadoption of the fair value of the respective assets at the time of acquisition. Determining the fair value of intangible assets is judgmental and involves the use of significant estimates and assumptions of future company operations. The Company bases its fair value estimates and related asset lives on assumptions it believes to be reasonable but that are unpredictable and inherently uncertain. Actual future results may differ from these estimates.

Intangible assets estimated to have finite lives are amortized over their estimated economic life under the straight-line method; such method correlates to management’s estimate of the assets’ economic benefit. Based on management’s estimates at origination, these lives range from two to seventeen years. Related amortization expense is presented within Selling, General, and Administrativenew lease accounting standard resulted in the accompanyingrecording of assets and obligations of our operating leases of approximately $451,000 and $457,000, respectively, on our consolidated statements of net lossbalance sheets. Certain amounts previously recorded for prepaid and comprehensive loss. As of December 31, 2018, remaining lives of intangible assets range from sixaccrued rent associated with historical operating leases were reclassified to eleven years.the newly captioned Operating lease right-to-use assets.

 


F-12

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

1. Nature of Business and Significant Accounting Policies (continued)

 

Revenue RecognitionNew Accounting Pronouncement – Leases Adopted in 2019 (continued)

 

On January 1, 2018, the Company adopted Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (including amendments), and appliedAt adoption, we used the new revenue standardlease accounting standard’s package of practical expedients permitted under the transition guidance that allowed us to allnot reassess: (a) whether any expired or existing contracts usingare or contain leases, (b) lease classification for any expired or existing leases, and (c) initial direct costs for any expired or existing leases. We also used the modified retrospective method. Under this method, prior periods are not restated. Upon adoption,lease standard’s practical expedient that allows lessees to treat the Company recognized the cumulative effectlease and implicit non-lease components of applying the new revenue standardour leases as a reductionsingle lease component and we do not record on the balance sheet leases with an initial term of $367,568 (with zero net tax effect) totwelve months or less. Fixed lease expense on all of our operating leases is recognized on a straight-line basis over the opening retained earnings (accumulated deficit) balance.contractual lease term, including our estimate of any renewal or early termination lease terms. Operating lease expense is presented within Selling, General and Administrative expense in our operating results.

 

The new revenue standard defines a five step process to recognize revenues. The Company accounts for a contract with its independent distributors (including customers) when there is a legally enforceable contract, the rightsOperating lease liabilities and related operating lease right-to-use assets are recognized at commencement date of the parties are identified,lease based on the contract has commercial substance, and collectabilitypresent value of lease payments over the contract consideration is probable. Product sales revenue (principally nutritional and dietary supplements) and commission expenses are recorded when control is transferred to independent distributors, which occurs atlease term. When leases do not provide an implicit discount rate, we use a country specific incremental borrowing rate based upon the time of shipment. Generally, net sales reflect product sales less the distributor discount of 20 percent to 40 percent of the suggested retail price. The Company presents distributor royalty and commission expense as an operating expense, rather than a reduction to net sales, as these payments are not made to the purchasing distributor. At point of sale, the Company receives payment by credit card, personal check, or guaranteed funds for contracts from independent distributors and makes related commission payments in the following month.lease term.

 

Under this newSee Note 9 for additional lease disclosures.

Lessor Accounting – Other Revenue

Other revenue standard, the Company determined that the timeframe for recognizing theconsists of revenue performance obligation for membership fees-type revenue would be lengthenedderived from our leasing a portion of our headquarters building to more closely correlate with the distributor (including customer) membership terms of generally twelve months. Based upon all membership fees contracts still in existence as of December 31, 2017, the adoption of the new revenue standard resulted in the recognition of a deferred revenue liability balance of $367,568. The Company receives payment for membership fees at the beginning of the annual membership term and recognizes membership feesNutracom. We recognize lessor rent revenue on a straight-line basis in correlation withover the completionterm of its performance obligation under the membership term. At December 31, 2018,lease. As part of this straight-line methodology, the deferredcumulative rental billings may be greater or less than the financial period’s recognized revenue; such timing differences are recognized on the balance sheet as an accrued other liability or an unbilled rent revenue liability balance was $337,234.receivable.

 

Actual and estimated sales returnsAlso included in other revenue are classified as a reduction of net sales. The Company estimates and accrues a reservebillings to the tenant for product returns based on the Company’s return policy and historical experience. The Company’s return policy allows for distributors to return product only upon termination of his or her distributorship. Allowable returns are limited to saleable product which was purchased within twelve monthsits share of the termination for a refund of 100%facility’s common area costs such as real estate taxes, maintenance, and utilities. These same common area costs plus the tenant’s share of the original purchase price less any distributor royaltiesfacilities’ depreciation are recorded as cost of goods sold.

See Note 2 and commission received relating to the original purchase of the returned products. For the years ended December 31, 2018 and 2017, total returns as a percent of net sales were approximately 0.17% and 0.25%, respectively.Note 3 for further information on our financial relationship with Nutracom. See Note 9 for further information on our leases.

 


F-13

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

1. Nature of Business and Significant Accounting Policies (continued)

Revenue Recognition (continued)

The Company records handling and freight income as a component of net sales and records handling and freight costs as a component of cost of products sold. Total net sales do not include sales tax as the Company considers itself a pass-through conduit for collecting and remitting applicable sales taxes.

In accordance with the new revenue standard requirements, the disclosure of the impact of adoption to the Company’s results from operations are as follows:

  

Year Ended December 31, 2018

 
      

Without

  

Effect of

 
      

Adoption of

  

Change

 
  

As Reported

  

ASU 2014-09

  

Higher/(Lower)

 

Operating results

            

Net sales

 $36,115,741  $36,086,633  $29,108 

Net loss

  (1,903,341)  (1,932,449)  29,108 

The Company does not anticipate that the adoption of the new revenue standard will be material to net sales and net income on an ongoing basis.

New Accounting Pronouncements – Not Yet Adopted

 

In FebruaryJune 2016, the Financial Accounting Standards Board (FASB) issued ASUAccounting Standards Update (ASU) No. 2016-02, Leases2016-13, Credit Losses (Topic 842)326): Measurement of Credit Losses on Financial Instruments which supersedesrequires entities to use a current lifetime expected credit loss methodology to measure impairments of certain financial assets. Using this methodology may result in earlier recognition of losses than under the existing lease guidance. This updatecurrent incurred loss approach, which requires lesseeswaiting to recognize a lease liabilityloss until it is probable of having been incurred. There are other provisions within the standard that affect how impairments of other financial assets may be recorded and presented, and that expand disclosures. This standard will be effective for our interim and annual financial periods beginning January 1, 2023, with early adoption permitted. Adoption of this standard must be applied on a lease asset for all leases, including operating leases,modified retrospective basis. We are evaluating the potential impact of this standard on its balance sheet. The update also expands the required quantitativeour consolidated financial statements and qualitative disclosures surrounding leases. Subsequent to its issuance of ASU No. 2016-02,related disclosures.

In December 2019, the FASB issued related ASU’s, including ASU No. 2018-11,2019-12, LeasesIncome Taxes (Topic 842)740): Targeted Improvements,Simplifying the Accounting for Income Taxes which providesadds new guidance for another transition methodaccounting for tax law changes, year-to-date losses in addition to the modified retrospective approach originally required by ASU No. 2016-02. This transition method option under ASU No. 2018-11 allows entities to initially apply the new leases standard at the adoption dateinterim periods, and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.

As required, the Company will adopt ASU 2016-02 on January 1, 2019. The Company anticipates applying certain practical expedients permitted in the standard,franchise-type taxes, as well as other changes to simplify accounting for income taxes. This standard will be effective for our interim and annual financial periods beginning January 1, 2021, with early adoption permitted. The adoption methodologies for this standard vary; subject to the prospective transition method. The Company’s adoptionspecific provision(s) within the standard being adopted. We are evaluating the potential impact of this new lease standard will result in the January 1, 2019 recognition of right-of-use assets and lease liabilities of approximately $460,000 in the Company’son our consolidated financial statements. The Company leases certain office facilities, storage,statements and equipment.


Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statementsrelated disclosures.

 

1.Nature of Business and Significant Accounting Policies (continued)

Going Concern

 

The Company hasWe have incurred operating losses, declining net sales, and negative net cash flows over itsour most recent five years. ManagementOur management estimates that these unfavorable trends are more likely than not to continue for the foreseeable future, and as a result, the Companywe will require additional financial support to fund itsour operations and execute itsour business plan. As of December 31, 2018, the Company2019, we had $1,989,974$1,630,779 in cash and cash equivalents which may not be sufficient to fund the Company’sour planned operations through one year aftersubsequent to the date of the consolidatedissuance of these financial statements, are issued, and accordingly, there is substantial doubt about the Company’sour ability to continue as a going concern. The analysis used to determine the Company’sour ability to continue as a going concern does not include cash sources outside of the Company’sour direct control that our management expects to be available within the next twelve months.

 

The Company may not be able to obtain sufficient additional funding through monetizing certain of its existing assets, sourcing additional borrowings, and issuing additional equity, or any other means, and if it is able to do so, these available sources of funds may not be on satisfactory terms. The Company’s ability to raise additional capital in the equity markets, should the Company choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for the Company’s common stock, which itself is subject to a number of business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company

The Company has taken several steps which management believes will result in an improved financial position, operating results, and cash flows. As detailed in Note 7 of these consolidated financial statements, in January 2019, the Company has borrowed $500,000 of its available $750,000 revolving line of credit balance. In March 2019, the Company and its lender have agreed to extend its available $750,000 revolving line of credit agreement to April 28, 2020.

As detailed in Note 2 of these consolidated financial statements, in January 2019, the Company entered into a Purchase Agreement with Nutracom, LLC (Nutracom) pursuant to which Nutracom purchased the assets used by the Company in its manufacturing operations. Assets purchased by Nutracom from the Company were financed by the Company under payment terms scheduled to provide incoming funds to the Company of $200,000 or more per year. The Company has also entered into an agreement for Nutracom to lease a significant portion of the Company’s headquarters building. Management believes that these transactions with Nutracom will be favorable to its financial position, operating results, and cash flows; however, there are risks and uncertainties which arise with these Nutracom transactions and their impact to the Company’s operations.


F-14

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

1. Nature of Business and Significant Accounting Policies (continued)

 

Going Concern (continued)

We may not be able to obtain sufficient additional funding through monetizing certain of our existing assets, sourcing additional borrowings, and issuing additional equity, or any other means, and if we are able to do so, these available sources of funds may not be on satisfactory terms. Our ability to raise additional capital in the equity markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common stock, which itself is subject to a number of business risks and uncertainties, as well as the uncertainty that we would be able to raise such additional capital at a price or on terms that we believe are favorable.

We have taken several steps in 2019 which we believe will result in improvement to our financial position, operating results, and cash flows. We have borrowed $500,000 of our available $750,000 revolving line of credit balance. In addition, our lender has agreed to extend the available $750,000 revolving line of credit agreement to April 28, 2020.

As detailed in Note 2 of these consolidated financial statements, on January 1, 2019, we sold the assets previously used by us in our manufacturing operations to Nutracom. We financed the assets purchased by Nutracom from us under payment terms scheduled to provide incoming funds to us of $100,000 or more per year. We have also entered into an agreement for Nutracom to lease a significant portion of our headquarters building. Our management believes that these transactions with Nutracom will be favorable to our financial position, operating results, and cash flows; however, there are risks and uncertainties which arise from these Nutracom transactions and their impact to our operations.

 

Should the aforementioned changes to the company’sour operations not provide sufficient cash flow improvement or should the Companywe be unable to obtain sufficient additional capital or borrowings, the Companywe may have to engage in any or all of the following activities: (i) seek to monetize itsour headquarters building via traditional bank lending or a sale and leaseback-type transaction; (ii) monetizing itsseek to monetize the note receivable from a distributor (see Note 11);distributor; (iii) restructure its coremodify our distributor business model including recruiting, promotions, incentives, and other activities; (iv) cease operations in certain geographic regions, and (v) reduce employee compensation and benefits.

 

These actions may have a material adverse impact on the Company’sour ability to achieve certain of itsour planned objectives. Even if the Company iswe are able to source additional funding, itwe may be forced to significantly reduce itsour operations or shut down our operations if itsour business operating performance does not improve. If the Company is unable to source additional funding, it may be forced to significantly reduce or shut down its operations. These consolidated financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event the Companywe can no longer continue as a going concern.

F-15

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

 

 

2. Sale of Manufacturing Operations’ Assets Held For Sale

 

On January 1, 2019, the Companywe entered into a Purchase Agreement with Nutracom LLC (Nutracom) pursuant to which Nutracom purchased the following assets used by the Companyus in itsour manufacturing operations:

 

Inventories (sold at cost of $1.56 million) and,

 

Machinery and other equipment with a net book value of $565,000 (sold for $1 million; gain on disposal of $435,000).

 

Nutracom was formed by the Company’sour manufacturing operations management which included former officers of the Company. Employees of the Company’sour manufacturing operations were offered employment by Nutracom.

 

Prior to its approval of the transaction, the Company’sour Board of Directors formed a special committee consisting of the Company’sBoard’s independent directors to review the transaction. To assist in its review, the special committee engaged a qualified third-party expert to opine a fairness opinion on the transaction and related agreements as detailed below.

 


Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

2. Assets Held For Sale (continued)

Concurrently with the execution of the Purchase Agreement, the Companywe entered into several agreements with Nutracom including a product supply agreement for a term of seven years, a fulfillment agreement, and a facility lease agreement whereby Nutracom will lease manufacturing, warehouse, and certain office space of the Company’sour headquarters building from the Companyus for a term of seven years, with a Nutracom option for an additional five-year term. Annual lease amounts range from $193,000 to $410,000 per year over the seven-year term.

 

Nutracom provided the following consideration to the Companyus for the manufacturing operations and related identified assets and agreements:

 

$1 million secured promissory note, seven yearseven-year term, fixed interest rate of 5.5%, principal and interest payable monthly;monthly. (See June 1, 2019 note modification within this Note 2).

 

$764,344 unsecured promissory note, seven yearseven-year term, fixed interest rate of 7.0%, interest only payable for the first two years with monthly payment of principal and interest thereafter under a ten-year amortization schedule. The face value of the unsecured note includes the first year’s rent due the Companyus under the facility lease agreement. (See October 1, 2019 note modification within this Note 2).

 

Nutracom management transferred to the Companyus its ownership of 99,200 shares of the Company’sour common stock valued at $540,144.

 

Nutracom issued to the Companyus a non-voting Class B 15% equity membership interest in Nutracom, LLC. The Class B interest does not share in any profits or losses from operations of Nutracom. As defined within the Nutracom Operating Agreement, upon any merger, consolidation, disposition, or liquidation of Nutracom, the Class B equity membership interest converts to a Class A equity membership interest.

 

Commencing January 1, 2020, the Company’sour Class B interest will be entitled to receive a percentage, (ranging from 1.0% to 1.25%) of Nutracom’s annual revenues (excluding Nutracom’s revenues from sales to the Company)us).

 

F-16

The Company’s

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

2. Sale of Manufacturing Operations’ Assets (continued)

Our non-voting Class B 15% equity membership interest in Nutracom was valued by the aforementioned third-party expert at $505,000. As the Company’sour non-voting membership interest does not participate in the management of Nutracom, nor does the Companydo we share in any Nutracom operating profits or losses, the Company anticipateswe are accounting for itsour Nutracom equity investment under the cost method.

 

As ofAt December 31, 2018, the Company haswe presented inventories and machinery and other equipment sold to Nutracom as a current asset under the caption of “Assets held for sale” in the accompanying consolidated balance sheets. The Company will accountWe have accounted for the Nutracom aforementioned transactions in itsour first quarter 2019 financial results.

 

Promissory Note Modification – June 1, 2019

On June 1, 2019, we entered into an Agreement with Nutracom to modify the Secured Promissory Note originally issued to us by Nutracom on January 1, 2019, as follows:

Effective June 1, 2019, the outstanding balance of the Secured Promissory Note was reduced by $500,000 to $460,583 with a corresponding reduction of $500,000 to our outstanding vendor obligation due Nutracom under our ongoing product supply agreement.

The $460,583 remaining Secured Promissory Note was exchanged with Nutracom for a newly issued June 1, 2019 Nutracom Unsecured Promissory Note for the same amount under the following terms: fixed interest rate of 6.0% with interest only payable monthly through December 2020. Beginning January 1, 2021, principal and interest of $8,904 will be payable monthly for 60 months.

Promissory Note Modification – October 1, 2019

In December 2019, we entered into an Agreement with Nutracom to modify the Unsecured Promissory Note originally issued to us by Nutracom on January 1, 2019, as follows:

Effective October 1, 2019, the outstanding balance of the January 1, 2019 Unsecured Promissory Note of $764,344 was reduced to $711,163. The reduction of $53,181 in the Note’s balance represents Nutracom’s return to us of now-expired inventories originally acquired by Nutracom from us on January 1, 2019.

The $711,163 remaining balance of the January 1, 2019 Unsecured Promissory Note was exchanged with Nutracom for a newly issued October 1, 2019 Nutracom Unsecured Promissory Note for the same amount under the following terms: fixed interest rate of 7.0% with interest only payable monthly through December 2020. Beginning January 1, 2021, principal and interest of $8,257, under a ten-year amortization schedule, will be payable monthly for 60 months, with a balloon payment of all remaining principal and interest due January 1, 2026.


F-17

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

3. Related Parties

The following summarizes our related party activities with Nutracom and a significant distributor of the Company.

  

December 31

  

December 31

 

Assets and liabilities - related parties

 

2019

  

2018

 
         

Notes & accounts receivables and deposits - current

        

Deposits with Nutracom for inventory

 $941,154  $- 

Note receivable - distributor (Note 12)

  130,629   123,040 

Other miscellaneous receivables

  27,445   28,182 
  $1,099,228  $151,222 
         
         

Notes & accounts receivables - non-current

        

Note receivable - distributor (Note 12)

 $1,151,443  $1,282,072 

Note receivable - Nutracom unsecured DTD 6/1/2019

  460,583   - 

Note receivable - Nutracom unsecured DTD 10/1/2019

  711,163   - 

Unbilled receivables: Straight line rent revenue greater than rental billings

  95,732   - 
  $2,418,921  $1,282,072 
         
         

Equity investment in Nutracom

 $505,000   - 
         

Liability captions with Nutracom balances included therein

        

Trade accounts payable and other accrued expenses

 $430,907   - 

The following table presents scheduled principal payments to be received on the distributor and Nutracom promissory notes receivable:

2020

 $130,629 

2021

  271,037 

2022

  288,294 

2023

  306,655 

2024

  326,190 

Thereafter

  1,131,013 
  $2,453,818 

F-18

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

3. Related Parties (continued)

  

Year ended December 31

 

Revenue and expense - related parties

 

2019

  

2018

 
         

Other revenue

 $783,462  $- 
         

Selling, general and administrative expense:

        

Fullfillment & professional fees

  622,169   - 
         

Interest income on promissory notes

  171,812   66,519 

Gain on sale of fixed assets

  434,549   - 
         

Finished goods inventory purchased from Nutracom

 $5,756,000   - 

At December 31, 2019, we had $1.41 million in commitments (net of deposits) to purchase finished goods inventory from Nutracom.

Supplementary Disclosure of Cash Flows Information:

We incurred the following 2019 year noncash investing and financing transactions relating to our transactions with Nutracom:

  

2019

 
     

January 1, 2019

    

Sale of fixed assets

 $1,000,000 

Sale of inventories

  1,559,488 

First year building rental received in advance

  250,000 

Acquire company common stock for treasury

  540,144 

Acquire equity investment in Nutracom

  505,000 

Secured promissory note received

  1,000,000 

Unsecured promissory note received

  764,344 
     

June 1, 2019

    

Secured promissory note receivable balance decreased; applied as reduction to outstanding trade accounts payable

  500,000 

Unsecured promissory note received in exchange for remaining secured promissory note balance and other considerations

  460,583 
     

October 1, 2019

    

Unsecured promissory note receivable balance decreased; applied to return of inventories previously sold under January 1, 2019 Purchase Agreement

  53,181 

Unsecured promissory note received in exchange for balance remaining on unsecured promissory note issued January 1, 2019

  711,163 

F-19

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

 

3.4. Property, Plant, and Equipment

 

Property, plant, and equipment at December 31, 20182019 and 2017,2018, consist of the following:

 

  

2018

  

2017

  

2019

  

2018

 
                 

Land and land improvements

Land and land improvements

 $905,190  $905,190  $905,190  $905,190 

Building

Building

  9,964,523   9,950,190   10,145,005   9,964,523 

Machinery and equipment

  180,519   4,755,727 

Office equipment

  1,157,392   1,183,115 

Office and other equipment

  1,237,142   1,337,911 

Computer equipment and software

Computer equipment and software

  2,212,935   2,261,038   2,240,063   2,212,935 
   14,420,559   19,055,260   14,527,400   14,420,559 

Less accumulated depreciation

Less accumulated depreciation

  9,722,009   13,378,021   10,086,560   9,722,009 
  $4,698,550  $5,677,239  $4,440,840  $4,698,550 

 

At December 31, 2018, approximately $0.56 million of net property, plant, and equipment (cost $4.70 million; $4.14 million accumulated depreciation) is presented as “Assets held for sale” in the accompanying consolidated balance sheets. See Note 2 for further discussion.

 

For the years ended December 31, 20182019 and 2017,2018, depreciation expense was $584,457$357,839 and $674,141,$584,457, respectively.

 

 

4.5. Accounts Payable and Accrued Expenses

 

Accounts payable and accrued expenses at December 31, 20182019 and 2017,2018, consist of the following:

 

  

2018

  

2017

  

2019

  

2018

 
                 

Trade payables

Trade payables

 $2,105,814  $1,667,495  $1,565,198  $2,105,814 

Distributors' commissions

Distributors' commissions

  1,030,948   1,115,649   891,492   1,030,948 

Sales taxes

Sales taxes

  195,802   154,958   139,542   195,802 

Deferred revenue

Deferred revenue

  337,234   -   322,261   337,234 

Payroll and payroll taxes

Payroll and payroll taxes

  210,288   261,916   212,716   210,288 
  $3,880,086  $3,200,018  $3,131,209  $3,880,086 

 


F-20

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

 

5.6. Amortizable Intangible Assets

 

The Company had amortizableAmortizable intangible assets as follows as of December 31, 2019 and 2018 and 2017:were as follows:

 

         

Accumulated

          

Accumulated

 
 

Gross Carrying Amount

  

Amortization

  

Gross Carrying Amount

  

Amortization

 
 

2018

  

2017

  

2018

  

2017

  

2019

  

2018

  

2019

  

2018

 
                                

Distributorship and related agreements

 $2,060,000  $2,060,000  $1,437,423  $1,327,556  $2,060,000  $2,060,000  $1,547,290  $1,437,423 

Lunasin technology license

  1,954,661   1,954,661   628,975   512,857   1,954,661   1,954,661   745,094   628,975 
 $4,014,661  $4,014,661  $2,066,398  $1,840,413  $4,014,661  $4,014,661  $2,292,384  $2,066,398 

 

Amortization expense for intangible assets totaled $225,985 in each of 20182019 and 2017,2018, respectively. Amortization expense for amortizable intangible assets over the next five years is estimated to be:

 

 

Intangible

  

Intangible

 
 

Amortization

  

Amortization

 
        

2019

 $226,000 

2020

  226,000  $226,000 

2021

  226,000   226,000 

2022

  226,000   226,000 

2023

  226,000   226,000 

2024

  189,000 

 

 

6.7. Fair Value of Financial Instruments

 

The carrying amount and fair value of financial instruments at December 31, 20182019 and 20172018 were approximately as follows:

 

 

Carrying

  

Fair

              

Carrying

  

Fair

             

Description

 

Amount

  

Value

  

Level 1

  

Level 2

  

Level 3

  

Amount

  

Value

  

Level 1

  

Level 2

  

Level 3

 
                                        

December 31, 2019

                    

Revolving line of credit

 $500,000  $500,000   -  $500,000   - 

Note receivable - distributor

  1,282,072   1,400,000   -   1,400,000   - 

Notes receivable - Nutracom

  1,171,746   1,169,000   -   -  $1,169,000 
                    
                    

December 31, 2018

                                        

Note receivable

 $1,405,112  $1,529,000   -  $1,529,000   - 

Note receivable - distributor

 $1,405,112  $1,529,000   -  $1,529,000   - 

Marketable securities

  339,000   339,000  $339,000   -   -   339,000   339,000  $339,000   -   - 
                    

December 31, 2017

                    

Long-term debt

 $3,045,421  $3,045,421   -  $3,045,421   - 

Note receivable

  1,521,005   1,684,000   -   1,684,000   - 

Marketable securities

  330,000   330,000  $330,000   -   - 

 


F-21

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

6.7. Fair Value of Financial Instruments (continued)

 

Fair value can be measured using valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). Accounting standards utilize a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those levels:

 

Level 1:

Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2:Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets or similar assets or liabilities in markets that are not active.
Level 3:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

 

Long-term debt: The fair value of the Company’s term andour revolver loansloan approximated carrying value as these loans hadthis loan has a variable market-based interest ratesrate that resetresets every thirty days. (Fair value is only disclosed).

 

Note receivable - distributor: The Company’s note receivable - distributor is a variable rate residential mortgage-based financial instrument. An average of published interest rate quotes for a fifteen-year residential jumbo mortgage, a comparable financial instrument, was used to estimate fair value of this note receivable under a discounted cash flow model. (Fair value is only disclosed).

Notes receivable - Nutracom: The notes receivable - Nutracom represent two fixed rate promissory notes issued by a privately-held entity (PHE). We developed an estimated market discount rate based upon the PHE’s third party incremental variable borrowing rate plus a risk-adjustment factor to estimate the fair value of these notes receivable under a discounted cash flow model. (Fair value is only disclosed).

 

Marketable securities: The assets (trading securities) of the Company’sour Supplemental Executive Retirement Plan are recorded at fair value on a recurring basis, and are presented within Other Assets in the consolidated balance sheets.

 

The carrying value of other financial instruments, including cash, accounts receivable and accounts payable, and accrued liabilities approximate fair value due to their short maturities or variable-rate nature of the respective balances.

7. Debt

Debt at December 31, 2018 and 2017 consists of the following:

  

2018

  

2017

 
         

Term loan

 $-  $2,545,421 

Revolving line of credit

  -   500,000 
   -   3,045,421 

Less current maturities

  -   3,045,421 

Long-term portion

 $-  $- 

 


F-22

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

7. 8. Debt (continued)

 

EffectiveOn September 30, 2015, the Companywe entered into a series of lending agreements with a newour primary lender which included agreements for a $3.25 million term loan and $3.5 milliona revolving credit facility. These lending agreements replaced similar borrowings under agreements withAs detailed below, the Company’s former primary lender.

The $3.25 million term loan was for a period of three yearsrepaid in 2018 and required monthly term loan payments, under a ten-year amortization, consisting of principal of $27,080 plus interest with a balloon payment for the outstanding balance due and payable on September 30, 2018. The term loan’s interest rate was based on the 30-day LIBOR plus 2.25%.

The $3.5 million revolving line of credit agreement, originally dated September 30, 2015, and subsequentlyrevolver has been periodically amended and extended, accrues interest at a floating interest rate based on the 30-day LIBOR plus 2.25% and had an original term of one year.

At June 30, 2018, the Company was current on all principal and interest due to its lender. In July 2018, management voluntarily elected to redeem the cash surrender value (CSV) of the Company’s whole life insurance policy maintained on the life of the Company’s Board of Directors’ Chairman and former Chief Executive Officer. Upon redemption and related receipt of the $3.07 million CSV proceeds, the Company simultaneously remitted to its lender $2.86 million of the CSV proceeds to be applied towards the full reduction of its outstanding term loan and revolver balances. Following this series of July 2018 transactions, the balances of the Company’s term loan, revolver loan, and life insurance policy balances were zero.extended.

 

Effective with a September 11, 2018 amendment, the revolving line of credit’s maximum borrowing amount was reduced from $2.0 million to $750,000. As amended, theThe revolver’s maturity date remainedwas April 29, 2019 and the revolver’s interest rate continued to bewas based on the 30-day LIBOR plus 2.25%. As of December 31, 2018, there were no outstanding borrowings on the revolving line of credit. In January 2019, the Companywe borrowed $500,000 under itsthe revolving line of credit.

 

Effective with a March 25, 2019 amendment, the revolving line of credit’s maturity date was extended to April 28, 2020 and the interest rate was revised to the 30-day LIBOR plus 3.00%. As amended, the revolver’s maximum borrowing amount remains $750,000. At December 31, 2019, outstanding borrowings under the revolving line of credit were $500,000 at an interest rate of 4.69%.

 

Borrowings under the lending agreement arecontinue to be secured by all of our tangible and intangible assets of the Company and by a mortgage on the real estate of the Company’s headquarters.our headquarters facility. At December 31, 2018, the Company was2019, we were in compliance with itsour loan covenant requirements.

 

2018 Loan Payoff

At June 30, 2018, we were current on all principal and interest due to our lender. In July 2018, management voluntarily elected to redeem the cash surrender value (CSV) of our whole life insurance policy maintained on the life of our Board of Directors’ Chairman and former Chief Executive Officer. Upon redemption and related receipt of the $3.07 million CSV proceeds, we simultaneously remitted to our lender $2.86 million of the CSV proceeds to be applied towards the full reduction of our outstanding term loan and revolver balances. Upon completion of this series of July 2018 transactions, our term loan, revolver loan, and life insurance policy balances were zero.

9. Leases

Lessee

We lease certain office facilities, storage, and equipment. These leases have varying terms, are generally one to five years in length, and certain real estate leases have options to extend or early terminate. Several of our operating leases are subject to annual changes in the Consumer Price or similar indexes (CPI). The changes to the lease payment due to CPI changes are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.


F-23

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

9. Leases (continued)

The following represents the maturity of our operating lease liabilities as of December 31, 2019:

2020

 $248,425 

2021

  74,550 

2022

  27,013 

2023

  5,768 

2024

  - 

Thereafter

  - 

Total operating lease payments

  355,756 

Less: imputed interest

  (15,405)

Total operating lease liabilities

 $340,351 

Operating lease expense:

 

Year ended

 
  

December 31

 
  

2019

 

Fixed

 $264,131 

Variable

  17,361 

Short-term

  24,500 

Total

 $305,992 

Rental expense under operating leases, including short-term operating leases was $305,992 and $326,724 for the years ended December 31, 2019 and 2018, respectively.

As of December 31, 2019, our operating leases have a weighted-average remaining lease term of 1.75 years and a weighted-average discount rate of 5.2%. Cash paid for amounts included in the measurement of operating lease liabilities was approximately $263,700 for the year ended December 31, 2019.

Lessor – Other Revenue

Other revenue consists of revenue derived from our leasing a portion of our headquarters building to Nutracom effective January 1, 2019. The leased space, encompassing manufacturing, warehouse, and certain office space, is for a term of seven years, with a tenant option for an additional five-year term. Annual lease amounts range from $193,000 to $410,000 over the seven-year term.

We recognize lessor rent revenue on a straight-line basis over the term of the lease. As part of this straight-line methodology, the cumulative rental billings may be greater or less than the financial period’s recognized revenue; such timing differences are recognized on the balance sheet as an accrued other liability or an unbilled rent revenue receivable.

F-24

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

9. Leases (continued)

Also included in other revenue are billings to the tenant for its share of the facility’s common area costs such as real estate taxes, maintenance, and utilities; totaling approximately $437,700 for the year ended December 31, 2019. These same common area costs plus the tenant’s share of the facilities’ depreciation are recorded as cost of goods sold.

The following table details lessor’s estimated straight-line rent revenue over the remaining six-year lease term as compared with fixed rent amounts under the lease agreement.

  

Estimated

     
  

Straight-line

  

Lease Agreement

 
  

Rent Revenue

  

Fixed Rent

 
         

2020

 $345,732  $192,900 

2021

  345,732   385,800 

2022

  345,732   385,800 

2023

  345,732   385,800 

2024

  345,732   409,913 

Thereafter

  345,733   409,912 

Total

 $2,074,393  $2,170,125 

 

 

8.10. Stockholders’ Equity

 

Stock Options – Incentive Stock Plans

 

The Company sponsorsWe sponsor an incentive stock plan (the “2014 Plan”) allowing for a maximum of 142,857 shares to be granted in the form of either incentive stock options, non-qualified stock options, restricted stock awards, or unrestricted stock awards. Employees,Our employees, directors, advisors, and consultants of the Company are eligible to receive the grants. This plan has been approved by the stockholders of the Company. The Compensation Committee of the Board of Directors administers the plan.

 

The 2014 Plan provides that options may be issued under the Plan at an option price not less than fair market value of the stock at the time the option is granted. Under the plan, restricted stock of the Company may be granted at no cost to the grantee. The grantees are entitled to dividends and voting rights for their respective shares. Restrictions limit the sale or transfer of these shares during the requisite service period. In addition, the committee may grant or sell unrestricted stock at a purchase price to be determined by the committee. Vesting terms and restrictions, if applicable, under the plan, are set by the committee and will be 10 years or less. The 2014 Plan expires in 2024.

 

In May 2017, the Company’s shareholders voted to approve a 2017 Incentive Stock Plan (2017 Plan) which authorizes the issuance of up to 200,000 shares of the Company’sour common stock in various forms of stock options and/or stock awards. The 2017 Plan will not become effective until registered with the Securities and Exchange Commission.

 

A summary of the Company’s stock option activity and related information for the years ended December 31 follows:

  

2018

  

2017

 
  

Options

  

Weighted

Avg.

Exercise

Price

  

Options

  

Weighted

Avg.

Exercise

Price

 

Outstanding beginning of the year

  140,424  $7.85   236,844  $$8.14 

Granted

  -       -     

Exercised

  -       -     

Expired and forfeited

  (58,998)  7.96   (96,420)  8.57 

Outstanding at end of year

  81,426  $7.77   140,424  $7.85 
                 

Exercisable at end of year

  14,655  $7.77   13,713  $7.77 

Compensation cost for the stock option plan was approximately $21,000 ($21,000 net of tax) and $27,000 ($27,000 net of tax) for the years ended December 31, 2018 and 2017, respectively, and has been recorded in selling, general, and administrative expense. As of December 31, 2018, the total remaining unrecognized compensation cost related to the non-vested portion of time vesting stock options totaled $19,000 ($19,000 net of tax), which will be amortized over the weighted remaining requisite service period of 1.17 years. The aggregate intrinsic value of stock options outstanding and currently exercisable at December 31, 2018 was $-0-.


F-25

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

8.10. Stockholders’ Equity (continued)

 

A summary of our stock option activity and related information for the years ended December 31 follows:

  

2019

  

2018

 
  

Options

  

Weighted

Avg.

Exercise

Price

  

Options

  

Weighted

Avg.

Exercise

Price

 

Outstanding beginning of the year

  81,426  $7.77   140,424  $7.85 

Granted

  -       -     

Exercised

  -       -     

Expired and forfeited

  -       (58,998)  7.96 

Outstanding at end of year

  81,426  $7.77   81,426  $7.77 
                 

Exercisable at end of year

  24,426  $7.77   14,655  $7.77 

Compensation cost for the stock option plan was approximately $19,000 ($19,000 net of tax) and $21,000 ($21,000 net of tax) for the years ended December 31, 2019 and 2018, respectively, and has been recorded in selling, general, and administrative expense. All stock options issued and outstanding as of December 31, 2019 will expire in March 2020. At December 31, 2019, the estimated total remaining unrecognized compensation cost related to the non-vested portion of time vesting stock options was zero and the aggregate intrinsic value of stock options outstanding and currently exercisable was zero.

Distributor Stock Purchase Plan

 

In July 2009, the Companywe established a Distributor Stock Purchase Plan (2009 Plan) which replaced a similar plan which had expired.

The plan allows distributors who have reached the “Ambassador” status the opportunity to allocate up to 10% of their monthly compensation into the plan to be used to purchase the Company’s common stock at the current market value. The plan also states that at the end of each year, the Company will grant warrants to purchase additional shares of the Company’s common stock based on the number of shares purchased by the distributors under the plan during the year. The warrant exercise price will equal the market price for the Company’s common stock at the date of issuance. The warrants issued shall be in the amount of 25% of the total shares purchased under the plan during the year and the warrants are fully vested upon grant.

The Company records expense under the fair value method for warrants granted to distributors. Total expense for the warrants was $3,000 and $6,600 in 2018 and 2017, respectively.

A summary of the Company’s warrant activity for the years ended December 31 follows:

  

2018

  

2017

 
  

Warrants

  

Weighted

Avg.

Exercise

Price

  

Warrants

  

Weighted

Avg.

Exercise

Price

 
                 

Outstanding beginning of the year

  5,960  $4.46   6,291  $5.34 

Granted

  1,113   4.24   1,258   4.77 

Exercised

  -       -     

Expired

  (2,183)  4.06   (1,589)  8.19 

Outstanding at end of year

  4,890  $4.58   5,960  $4.46 
                 

Exercisable at end of year

  4,890       5,960     

     

As of December 31, 2018

 
     

Warrants Outstanding and Exercisable

 

Range of

Exercise Prices

  

Warrants

  

Weighted

Avg. Exercise

Price

  

Weighted

Avg. Remaining

Life

 
 $4.24    1,113  $4.24   3.00 
 $4.64    2,519   4.64   1.00 
 $4.77    1,258   4.77   2.00 
$4.24-$4.77   4,890  $4.58   1.71 


Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

8. Stockholders’ Equity (continued)

Distributor Stock Purchase Plan (continued)

The fair value of the warrants was estimated at the date of grant using a Black-Scholes option pricing model with the following assumptions:

  

Year ended December 31

 
  

2018

  

2017

 
         

Expected warrant life (years)

  3.0   3.0 

Risk-free weighted average interest rate

  2.46%  1.98%

Stock price volatility

  55.8%  73.8%

Dividend yield

  0.0%  0.0%

The intrinsic value for stock warrants outstanding at December 31, 2018 was $-0-.

 

The 2009 Distributor Stock Purchase Plan was established with a ten-year life. As a result, there will be no further grants from this Plan. Upon exercise, forfeiture or expiration of all outstanding warrants, the Plan will terminate. At December 31, 2019, there were 2,371 warrants outstanding at exercise prices ranging from $4.24 to $4.77. Remaining warrants will expire no later than December 31, 2021.

We record expense for warrants granted to distributors under the fair value method. Total expense for the warrants was $2,000 and $3,600 in 2019 and 2018, respectively. The intrinsic value for stock warrants outstanding at December 31, 2019 was zero.

F-26

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

 

 

9.11. Loss per Share

 

The following table sets forth the computation of basic and diluted loss per share:

 

 

Year ended December 31

  

Year ended December 31

 
 

2018

  

2017

  

2019

  

2018

 

Numerator:

                

Net loss

 $(1,903,341) $(696,912) $(444,357) $(1,903,341)

Denominator:

                

Denominator for basic loss per share – weighted average shares

  1,845,000   1,845,000   1,746,000   1,845,000 
                

Dilutive effect of employee stock options and other warrants

  -   -   -   - 
                

Denominator for diluted loss per share – adjusted weighted average shares

  1,845,000   1,845,000   1,746,000   1,845,000 
                

Basic loss per share

 $(1.03) $(0.38) $(0.25) $(1.03)

Diluted loss per share

 $(1.03) $(0.38) $(0.25) $(1.03)

 

For the years ended December 31, 20182019 and 2017,2018, options and warrants totaling 86,31683,797 and 146,384,86,316, respectively, shares of common stock were not included in the denominator for diluted loss per share because their effect would be anti-dilutive or because the shares were deemed contingently issuable.


Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

 

 

10. Leases

The Company leases certain office facilities, storage, and equipment. These leases have varying terms, and certain leases have renewal and/or purchase options. Future minimum payments under non-cancelable leases with initial or remaining terms in excess of one year consist of the following at December 31, 2018:

2019

 $268,652 

2020

  186,168 

2021

  16,479 

2022

  16,479 

2023

  6,681 

Thereafter

  - 
  $494,459 

Rent expense for operating leases was $326,724 and $338,734 for the years ended December 31, 2018 and 2017, respectively.

11.12. Note Receivable Due From Distributor

 

In March 2012, the Companywe purchased a note and mortgage (“Note”) from a real estate investment management firm on certain properties in Wyoming and Idaho for $2 million. In May 2012, the Companywe entered into a Loan Modification Agreement (“LMA”) with the Note’s original and present borrower (“Borrower”) to restructure the Note’s principal amount due and related terms. The LMA terms are for a principal balance due of $2 million with interest only payments made monthly in 2012. The LMA’s interest rate is the greater of 6% or prime and there is no prepayment penalty for voluntary principal payments. Concurrently, with the execution of the LMA, the Company and the Borrower alsowe entered into a Security Agreement with the Borrower in which repayment of the LMA is secured by the Borrower’s Reliv distributorship business.

 

As originally structured, beginning in 2013, the LMA was to require monthly payment of principal and interest under a five-year amortization period. In February 2013, while retaining the Company’sour right to require Borrower’s compliance with the LMA’s terms, the Company and the Borrowerwe agreed to a verbal modification in the payment schedule in which the Company agreed to acceptBorrower makes monthly payments of principal and interest under a fifteen-year amortization period. The outstanding balance of the note receivable was $1,405,112$1,282,072 and $1,521,005$1,405,112 as of December 31, 20182019 and 2017,2018, respectively.

 


F-27

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

 

12.13. Income Taxes

 

Compenents of loss before income taxes:

 

Year ended December 31

 

Compenents of income (loss) before income taxes:

 

Year ended December 31

 
 

2018

  

2017

  

2019

  

2018

 
                

United States

 $(1,694,301) $(30,606) $(332,929) $(1,694,301)

Foreign

  (111,040)  (121,306)  356,572   (111,040)
 $(1,805,341) $(151,912) $23,643  $(1,805,341)

 

Compenents of provision (benefit) for income taxes:

 

Year ended December 31

  

Year ended December 31

 
 

2018

  

2017

  

2019

  

2018

 

Current:

                

Federal

 $(3,000) $(2,000) $(2,000) $(3,000)

State

  4,000   5,000   5,000   4,000 

Foreign

  97,000   33,000   465,000   97,000 

Total current

  98,000   36,000   468,000   98,000 
                

Deferred:

                

Federal

  -   -   -   - 

State

  -   -   -   - 

Foreign

  -   509,000   -   - 

Total deferred

  -   509,000   -   - 
 $98,000  $545,000  $468,000  $98,000 

During the fiscal years of 2016 through 2019, we determined that it was more likely than not that losses generated in the U.S. and certain foreign jurisdictions will not be realized. As a result, we recorded a valuation allowance on all of our domestic and foreign deferred tax assets. Accordingly, the 2019 and 2018 income tax provisions include the impact of recording a full deferred tax asset valuation allowance, net, of approximately $91,000 and $186,000, respectively, against the annual losses generated from a U.S. tax perspective

The effective income tax rate percentage was not meaningful for the year ended December 31, 2019 and was (5.4)% for the year ended December 31, 2018. The income tax provision amounts primarily represent estimated income taxes for one of our foreign subsidiaries and certain U.S. states, plus the current year settlement of several foreign tax audits.

 


F-28

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

12.13. Income Taxes (continued)

 

The provision (benefit) for income taxes is different from the amounts computed by applying the United States federal statutory income tax rate of 21% and 34% for the years ended December 31, 20182019 and 2017,2018, respectively. The reasons for these differences are as follows:

 

 

Year ended December 31

  

Year ended December 31

 
 

2018

  

2017

  

2019

  

2018

 
                

Income taxes at U.S. statutory rate

 $(379,000) $(52,000) $5,000  $(379,000)

State income taxes, net of federal benefit

  7,000   11,000   8,000   7,000 

Higher/(lower) effective taxes on earnings/losses in foreign countries

  38,000   (65,000)

Higher effective taxes on earnings in foreign countries

  77,000   38,000 

Foreign corporate income taxes

  97,000   33,000   51,000   97,000 

Foreign tax credit carryover

  -   (66,000)

Foreign income tax audit settlements

  154,000   - 

Life insurance settlement

  118,000   -   -   118,000 

GILTI

  34,000   -   71,000   34,000 

Nondeductible meals and entertainment expense

  9,000   13,000   7,000   9,000 

Valuation allowance, net

  186,000   707,000   91,000   186,000 

Other

  (12,000)  (36,000)  4,000   (12,000)
 $98,000  $545,000  $468,000  $98,000 

 

The Company has determined that it was more likely than not that its U.S. federal and various state net operating losses will not be realized based on projectionscomponents of future U.S. taxable income, estimated reversals of existing taxable timing differences, and other considerations. Accordingly, the 2018 and 2017 income tax provisions include the impact of recording a full deferred tax asset valuation allowanceassets and liabilities, and the related tax effects of approximately $186,000each temporary difference at December 31, 2019 and $198,000, respectively, against the annual losses generated from a U.S. tax perspective. The Company has2018, are as follows:

  

2019

  

2018

 

Deferred tax assets:

        

Inventory obsolescence reserve

 $41,000  $53,000 

Deferred revenue

  54,000   91,000 

Organization costs

  117,000   117,000 

Deferred compensation

  -   97,000 

Depreciation and amortization

  33,000   2,000 

Operating lease liabilities

  76,000   - 

Miscellaneous accrued expenses

  20,000   23,000 

Domestic net operating loss carryforwards

  649,000   451,000 

Foreign net operating loss carryforwards

  3,311,000   3,118,000 

Valuation allowance

  (4,117,000)  (3,845,000)
   184,000   107,000 

Deferred tax liabilities:

        

Operating lease right-to-use assets

  77,000   - 

Foreign currency exchange

  107,000   107,000 
   184,000   107,000 

Net deferred tax assets (liabilities)

 $-  $- 

F-29

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

13. Income Taxes (continued)

We have a deferred tax asset relating to domestic federal net operating loss carryforwards of approximately $451,000$649,000 at December 31, 20182019 of which approximately $188,000$464,000 will expire between 2036 and 2037. The Company has2038. We have a deferred tax asset of $3,118,000$3,311,000 at December 31, 20182019 relating to foreign net operating loss carryforwards in various jurisdictions which principally do not expire. At December 31, 2018, the Company has2019, we have recorded a full valuation allowance against all domestic and foreign net operating loss carryforward balances as it is more likely than not that this asset will not be realized.

As of December 31, 2017, management’s assessment of the realizability of its Europe’s subsidiary’s deferred tax assets concluded that it no longer meets the threshold of more likely than not based upon the subsidiary’s recent declining operating results. Accordingly, the Company recorded a full valuation allowance against the Europe subsidiary’s deferred tax assets with a corresponding deferred income tax charge of $509,000 in 2017.


Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

12. Income Taxes (continued)

The components of the deferred tax assets and liabilities, and the related tax effects of each temporary difference at December 31, 2018 and 2017, are as follows:

  

2018

  

2017

 

Deferred tax assets:

        

Inventory obsolescence reserve

 $53,000  $62,000 

Product refund reserve

  -   7,000 

Deferred revenue

  91,000   - 

Organization costs

  117,000   127,000 

Deferred compensation

  97,000   94,000 

Depreciation and amortization

  2,000   - 

Miscellaneous accrued expenses

  23,000   13,000 

Domestic net operating loss carryforwards

  451,000   186,000 

Foreign net operating loss carryforwards

  3,118,000   3,413,000 

Valuation allowance

  (3,845,000)  (3,767,000)
   107,000   135,000 

Deferred tax liabilities:

        

Depreciation and amortization

  -   28,000 

Foreign currency exchange

  107,000   107,000 
   107,000   135,000 

Net deferred tax assets (liabilities)

 $-  $- 

 

The United States Tax Cuts and Jobs Act (TCJA) was enacted in December 2017, which significantly changed U.S. tax law, principally by permanently reducing the U.S. federal statutory rate to 21% effective January 1, 2018, implementing a territorial tax system, and imposing a repatriation tax on deemed repatriated earnings of foreign subsidiaries. The effect of the federal tax rate reduction to 21% was reflected as a reduction in the December 31, 2017 U.S. deferred tax asset balances with a corresponding reduction in the valuation allowance. Under the TCJA’s repatriation tax, the Company’sour cumulative amount of unremitted foreign earnings and related tax was immaterial.

Securities and Exchange Commission (“SEC”) issued Staff Accounting Bulletin (“SAB”) 118 to provide guidance to companies on the reporting of the impacts of TCJA in their financial statements. Under SAB 118, the Company recorded affected items in fiscal year 2017 as provisional to allow additional time for clarifying technical guidance from Treasury and analysis of the effect to the Company’s current tax positions. In 2018, the Company has completed its analysis and did not record any adjustments to its 2017 provisional income tax amounts.

 

The TCJA introduced a new tax on global intangible low-taxed income (“GILTI”) effective as of January 1, 2018. The Company’sOur policy is to treat GILTI as a period cost when incurred.

 


Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

12. Income Taxes (continued)

At December 31, 2019 and 2018, we had $30,000 and 2017, the Company had $32,000, and $36,000, respectively, of cumulative unrecognized tax benefits, of which only the net amount of $22,000$19,000 would impact the effective income tax rate if recognized.

 

The aggregate changes in the balance of net unrecognized tax benefits were as follows:

 

 

2018

  

2017

  

2019

  

2018

 
                

Beginning of year

 $26,000  $32,000  $22,000  $26,000 

Settlements and effective settlements with tax authorities

  -   -   -   - 

Lapse of statute of limitations

  (7,000)  (6,000)  (5,000)  (7,000)

Decrease to tax positions taken during prior periods

  (3,000)  (6,000)  (3,000)  (3,000)

Increase to tax positions taken during current period

  6,000   6,000   5,000   6,000 

End of year

 $22,000  $26,000  $19,000  $22,000 

 

The CompanyWe have applied applicable accounting guidance relating to accounting for uncertainty in income taxes. Reserves for uncertainty in income taxes are adjusted quarterly in light of changing facts and circumstances, such as the progress of tax audits, case law, and emerging legislation. The primary difference between gross unrecognized tax benefits and net unrecognized tax benefits is the U.S. federal tax benefit from state tax deductions. It is the Company’sour practice to recognize interest and / or penalties related to income tax matters in income tax expense.

 

At December 31, 2019 and 2018, and 2017, the Companywe had $10,000 and $11,000, respectively, accrued for interest and penalties within the balance of unrecognized tax benefits. The Company’sOur unrecognized tax benefits balance is included within other noncurrent liabilities on the consolidated balance sheets.

 

F-30

The Company, including its

Reliv’ International, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

13. Income Taxes (continued)

Our domestic and foreign subsidiaries isare subject to U.S. federal income tax as well as income tax of multiple state and foreign jurisdictions. The Company hasWe have concluded all U.S. federal income tax matters for years through 20142015 and concluded years through 20142015 with itsour primary state jurisdiction. During the third quarter of 2019, the U.S. Internal Revenue Service (IRS) commenced an examination of our 2017 U.S. federal income tax return.

Foreign Tax Audit Settlements

For the year ended December 31, 2019, our operating results include $154,000 and $25,000 for income tax expense and various net general administrative and interest expenses, respectively, in settlement of the following foreign tax audits.

Tax Year 2017 Settlement

In mid-2019, one of our foreign subsidiaries received a local country tax year 2017 audit assessment alleging deficiencies of approximately $217,000 plus interest. In the third quarter of 2019, we paid the local taxing authority approximately $96,000 in final settlement of the 2017 tax year audit.

Tax Years 2004 – 2006 Settlements

 

One of the Company’sour foreign subsidiaries is presentlyhas been under local country audit for greater than ten years for alleged deficiencies (totaling approximately $800,000 plus interest at 20% per annum) in value-added tax (VAT) and withholding tax for the years 2004 through 2006. The Company, in consultation with its legal counsel, believes that there are strong legal grounds that it should not be liable to pay the majority of the alleged tax deficiencies. As of December 31, 2010, management estimated and reserved approximately $185,000 for resolution of this matter and recorded this amount within Selling, General, and Administrative expense in the 2010 Consolidated Statement of Income. In 2011, the Companywe made good faith deposits of approximately $173,000 to the local tax authority under the tax agency’s administrative judicial resolution process.

In May 2018, we received a formal notice of denial of one of our appeals under the tax agency’s administrative judicial resolution process; however, we continued to pursue other available legal processes as we continued to maintain our position that we were not liable for the majority of the alleged tax deficiencies. As of December 31, 2018, management’sour estimated reserve (net of deposits) for this matter isthese matters was approximately $172,500. In November 2019, under a tax amnesty program, we paid the local taxing authority approximately $164,000 in final settlement of tax years 2005 and 2006.

In December 2019, we have an agreement in principle with the local taxing authority to settle the tax year 2004 audit. At December 31, 2019, we have an estimated full reserve of approximately $84,000 for resolution of this matter.

 


F-31

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

 

13. Employee Benefit Plans

The Company sponsors a 401(k) employee savings plan which covers substantially all employees. Employees can contribute up to 15% of their gross income to the plan. The Company matched a percentage of the employee’s contribution at a rate of 10% for the years ended December 31, 2018, and 2017, respectively. Company contributions under the 401(k) plan totaled $36,800 and $35,400 in 2018 and 2017, respectively.

The Company sponsors an employee stock ownership plan ("ESOP") which covers substantially all U.S. employees. Contributions to the ESOP are funded by the Company on a discretionary basis. In 2018 and 2017, the Company did not make any contributions to the ESOP.

14.14. Incentive Compensation Plans

 

Under a Board of Directors approved incentive compensation plan, bonuses are payable quarterly in an amount not to exceed 18% of the Company’s Income from Operations for any period, subject to the Company achieving a minimum quarterly Income from Operations of at least $500,000. For fiscal years 20182019 and 2017,2018, the Board determined that the aggregate amount of incentive compensation available under the Plan shall be equal to 18% of the Company’s Income from Operations. The bonus pool is allocated to executives according to a specified formula, with a portion allocated to a middle management group determined by the Executive Committee of the Board of Directors. The Company expensed a total of $-0-Our expense for this incentive compensation plan was zero for 2019 and $109,500 to the participants of the bonus pool for 2018, and 2017, respectively.

 

The Company sponsorsWe sponsored a Supplemental Executive Retirement Plan (SERP) to allow certain executives to defer a portion of their annual salary and bonus into a grantor trust. A grantor trust was established to hold theIn December 2019, a final participant distribution of SERP assets in satisfaction of the SERP. The Company funds the grantor trust by paying the amount deferred by the participant into the trust at the time of deferral. Investment earningsSERP’s liability was made and losses accrue to the benefit or detriment of the participants. The SERP also provides for a discretionary matching contribution by the Company not to exceed 100% of the participant’s annual contribution. In 2018 and 2017, the Company did not provide a match. The participants fully vest in the deferred compensation three years from the date they enter the SERP. The participants are not eligible to receive distribution under the SERP until retirement, death, or disability of the participant.was terminated. At December 31, 20182019 and 2017,2018, SERP assets were $339,000$-0- and $330,000,$339,000, respectively, and are included in “Other Assets” in the accompanying consolidated balance sheets. At December 31, 20182019 and 2017,2018, SERP liabilities were $341,000$-0- and $332,000,$341,000, respectively, and are included in “Other Non-Current Liabilities” in the accompanying consolidated balance sheets. The changes

15. Employee Benefit Plans

We sponsor a 401(k) employee savings plan which covers substantially all U.S. employees. Employees can contribute up to 15% of their gross income to the plan. We matched a percentage of the employee’s contribution at a rate of 10% for the years ended December 31, 2019, and 2018, respectively. Our matching contributions under the 401(k) plan totaled $24,000 and $36,800 in 2019 and 2018, respectively.

We sponsor an employee stock ownership plan ("ESOP") which covers substantially all U.S. employees. We fund contributions to the balances of SERP assetsESOP on a discretionary basis. In 2019 and SERP liabilities during 2018, and 2017 were duewe did not make any contributions to net realized and unrealized investment gains/losses incurred by the plan.ESOP.

 


F-32

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

 

15.16. Segment Information

 

Description of Products and Services by Segment

 

The Company operatesWe operate in one reportable segment, a network marketingdirect selling segment consisting of six operating units that sell nutritional and dietary products to a sales force of independent distributors that sell the products directly to customers. These operating units are based on geographic regions. Geographic area data for the yearsyear ended December 31 2018 and 2017 follow:

 

2018

  

2017

  

2019

  

2018

 
                

Net sales to external customers

                

United States

 $27,673,352  $32,474,797  $25,747,158  $27,673,352 

Australia/New Zealand

  732,227   922,594   595,349   732,227 

Canada

  718,560   914,775   616,556   718,560 

Mexico

  474,372   445,299   577,488   474,372 

Europe (1)

  3,972,381   4,578,095   3,224,971   3,972,381 

Asia (2)

  2,544,849   2,453,222   4,293,793   2,544,849 

Total net sales

 $36,115,741  $41,788,782  $35,055,315  $36,115,741 
                

Assets by area

                

United States

 $13,584,424  $18,100,872  $12,340,835  $13,584,424 

Australia/New Zealand

  540,591   572,368   502,812   540,591 

Canada

  166,533   265,629   154,825   166,533 

Mexico

  179,713   219,501   223,238   179,713 

Europe (1)

  867,008   1,032,641   971,159   867,008 

Asia (2)

  1,015,596   884,985   1,114,127   1,015,596 

Total consolidated assets

 $16,353,865  $21,075,996  $15,306,996  $16,353,865 

 

(1)

Europe consists of United Kingdom, Ireland, France, Germany, Austria, and the Netherlands.

(2)

Asia consists of Philippines Malaysia, and Singapore.Malaysia.

 

The Company classifies its sales into two categories of sales products plus handling & freight income. Net sales by product category data for the years ended December 31, 2018 and 2017, follow:

  

2018

  

2017

 
         

Net sales by product category

        

Nutritional and dietary supplements

 $32,670,362  $37,326,863 

Sales aids, membership fees, and other

  1,247,807   1,424,494 

Handling & freight income

  2,197,572   3,037,425 

Total net sales

 $36,115,741  $41,788,782 


F-33

 

Reliv’ International, Inc. and Subsidiaries

 

Notes to Consolidated Financial Statements

 

16. Restructuring ActivitiesSegment Information (continued)

 

In April 2018, the Company announced the June 30, 2018 closingWe classify sales into three categories of the operations of its Reliv Indonesia subsidiary. The total cost of this program, primarily representing employee severance costs, facility exit costs,sales products plus freight income and a write-down of inventory to its net realizable value, was approximately $77,000, and was included in the company’s operating resultsother revenue. Net sales by product category data for the second quarteryears ended June 30, 2018. At December 31 2018, this program has been substantially completed.follow:

  

2019

  

2018

 
         

Net sales by product category

        

Nutritional and dietary supplements

 $29,822,879  $32,670,362 

Other supplements

  1,223,977   - 

Sales aids, membership fees, and other

  1,251,677   1,247,807 

Freight income

  1,973,320   2,197,572 

Other revenue

  783,462   - 

Total net sales

 $35,055,315  $36,115,741 

F-34

 

17. Subsequent Events

On January 1, 2019, the Company entered into a Purchase Agreement with Nutracom, LLC (Nutracom) pursuant to which Nutracom purchased the assets used by the Company in its manufacturing operations. See Note 2 for further information.

In January 2019, the Company borrowed $500,000 under its revolving line of credit. In March 2019, the Company and its primary lender amended the terms of the Company’s revolving line of credit agreement. See Note 7 for further information.

F-30